# WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, December 05, 2005

| Hide? | Set Name | Query | Hit Count |
|---|---|---|---|
| | | *DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ* | |
| ☐ | L4 | (Gal?3 \|galectin?3\|LGALS3 \|galactose speific lectin 3 \|LEG3) same (diabet$2 \|hypertens$3 \| symptom? \|disorder\|disease?) | 58 |
| ☐ | L3 | Gal?3 \|galectin?3 | 316 |
| ☐ | L2 | 6610508.pn. | 1 |
| ☐ | L1 | 6043092.pn. | 1 |

END OF SEARCH HISTORY

```
FILE 'HOME' ENTERED AT 13:40:21 ON 05 DEC 2005

=> Index medicine bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS,
       CEN, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE,
       ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET,
       LIFESCI, MEDLINE, NAPRALERT, ...' ENTERED AT 13:40:39 ON 05 DEC 2005

77 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (Gal?3 or galectin?3 or LGALS3  or galactose speific lectin 3 |LEG3) (P)  (diabet? or
symptom or disorder or disease?)
          0*  FILE ADISCTI

=> s (Gal?3 or galectin?3 or LGALS3  or galactose speific lectin 3 |LEG3) and  (diabet? or
symptom or disorder or disease# or condition#)
          0*  FILE ADISCTI

=> s (Gal?3 or galectin?3 or LGALS3  or galactose speific lectin 3  or LEG3) (P)   (diabet? or
symptom or disorder or disease# or condition#)
          0*  FILE ADISCTI

=> s (Gal?3 or galectin?3 or LGALS3  or galactose speific lectin 3  or LEG3) and  (diabet? or
symptom or disorder or disease# or condition#)
          0*  FILE ADISCTI

=> s Gal?3 or galectin?3 or LGALS3  or galactose speific lectin 3  or LEG3
          0*  FILE ADISCTI

=> SET DETAIL on
SET COMMAND COMPLETED

=> s (Gal?3 or galectin?3 or LGALS3  or galactose speific lectin 3  or LEG3) (P)   (diabet? or
symptom or disorder or disease# or condition#)
FILE 'ADISCTI'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'GAL?3'
The truncation symbol ?  may be used only at the end of a search
term.  To specify a variable character within a word use '!', e.g.,
'wom!n' to search for both 'woman' and 'women'.  Enter "HELP
TRUNCATION" at an arrow prompt (=>) for more information.

=> s (Gal 3 or Gal-3  or galectin 3 or galectin-3 or LGALS3  or galactose speific lectin 3  or
LEG3) (P)   (diabet? or symptom or disorder or disease# or condition#)
FILE 'ADISCTI'
            65 GAL
        103481 3
             1 GAL 3
                 (GAL(W)3)
            65 GAL
        103481 3
             1 GAL-3
                 (GAL(W)3)
             5 GALECTIN
        103481 3
             2 GALECTIN 3
                 (GALECTIN(W)3)
             5 GALECTIN
        103481 3
             2 GALECTIN-3
                 (GALECTIN(W)3)
             0 LGALS3
```

```
            69 GALACTOSE
             0 SPEIFIC
           104 LECTIN
            30 LECTINS
           127 LECTIN
                 (LECTIN OR LECTINS)
        103481 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             0 LEG3
         42188 DIABET?
          8090 SYMPTOM
         48077 SYMPTOMS
         51239 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
         64768 DISORDER
        504087 DISORDERS
        518967 DISORDER
                 (DISORDER OR DISORDERS)
        589824 DISEASE#
         40141 CONDITION#
             0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
               TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
               DISORDER OR DISEASE# OR CONDITION#)

FILE 'ADISINSIGHT'
            15 "GAL"
         11244 "3"
             0 GAL 3
                 ("GAL"(W)"3")
            15 "GAL"
         11244 "3"
             0 GAL-3
                 ("GAL"(W)"3")
             1 "GALECTIN"
         11244 "3"
             1 GALECTIN 3
                 ("GALECTIN"(W)"3")
             1 "GALECTIN"
         11244 "3"
             1 GALECTIN-3
                 ("GALECTIN"(W)"3")
             0 LGALS3
            18 "GALACTOSE"
             0 "SPEIFIC"
            23 "LECTIN"
             7 "LECTINS"
            25 "LECTIN"
                 ("LECTIN" OR "LECTINS")
         11244 "3"
             0 GALACTOSE SPEIFIC LECTIN 3
                 ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
             0 LEG3
          1387 DIABET?
           312 SYMPTOM
          1327 SYMPTOMS
          1422 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
           431 DISORDER
          6493 DISORDERS
          6576 DISORDER
                 (DISORDER OR DISORDERS)
          6952 DISEASE#
          1029 CONDITION#
             1 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
               TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
               DISORDER OR DISEASE# OR CONDITION#)

FILE 'ADISNEWS'
```

```
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
           13 GAL
        36807 3
            0 GAL 3
                (GAL(W)3)
           13 GAL
        36807 3
            0 GAL-3
                (GAL(W)3)
            0 GALECTIN
        36807 3
            0 GALECTIN 3
                (GALECTIN(W)3)
            0 GALECTIN
        36807 3
            0 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
            5 GALACTOSE
            0 SPEIFIC
            8 LECTIN
            3 LECTINS
            9 LECTIN
                (LECTIN OR LECTINS)
        36807 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
         4274 DIABET?
         1935 SYMPTOM
        13198 SYMPTOMS
        14117 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         3466 DISORDER
         5995 DISORDERS
         8684 DISORDER
                (DISORDER OR DISORDERS)
        17330 DISEASE#
         5796 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'BIOSIS'
        11580 GAL
           58 GALS
        11619 GAL
                (GAL OR GALS)
      2577076 3
          138 GAL 3
                (GAL(W)3)
        11580 GAL
           58 GALS
        11619 GAL
                (GAL OR GALS)
      2577076 3
          138 GAL-3
                (GAL(W)3)
         1531 GALECTIN
          375 GALECTINS
         1593 GALECTIN
                (GALECTIN OR GALECTINS)
      2577076 3
          789 GALECTIN 3
                (GALECTIN(W)3)
         1531 GALECTIN
          375 GALECTINS
         1593 GALECTIN
```

```
              (GALECTIN OR GALECTINS)
      2577076 3
          789 GALECTIN-3
              (GALECTIN(W)3)
           18 LGALS3
        26599 GALACTOSE
           67 GALACTOSES
        26630 GALACTOSE
              (GALACTOSE OR GALACTOSES)
           42 SPEIFIC
        29253 LECTIN
        12409 LECTINS
        34652 LECTIN
              (LECTIN OR LECTINS)
      2577076 3
            0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            2 LEG3
       224777 DIABET?
        87370 SYMPTOM
       215117 SYMPTOMS
       271724 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
       165294 DISORDER
       349544 DISORDERS
       440744 DISORDER
              (DISORDER OR DISORDERS)
      2848236 DISEASE#
       798917 CONDITION#
          135 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'BIOTECHNO'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
            5467 GAL
              24 GALS
            5479 GAL
                 (GAL OR GALS)
          485790 3
              43 GAL 3
                 (GAL(W)3)
            5467 GAL
              24 GALS
            5479 GAL
                 (GAL OR GALS)
          485790 3
              43 GAL-3
                 (GAL(W)3)
             505 GALECTIN
             128 GALECTINS
             509 GALECTIN
                 (GALECTIN OR GALECTINS)
          485790 3
             238 GALECTIN 3
                 (GALECTIN(W)3)
             505 GALECTIN
             128 GALECTINS
             509 GALECTIN
                 (GALECTIN OR GALECTINS)
          485790 3
             238 GALECTIN-3
                 (GALECTIN(W)3)
               9 LGALS3
            7047 GALACTOSE
              16 GALACTOSES
            7055 GALACTOSE
                 (GALACTOSE OR GALACTOSES)
```

```
      1 SPEIFIC
   8950 LECTIN
   2979 LECTINS
   9780 LECTIN
          (LECTIN OR LECTINS)
 485790 3
      0 GALACTOSE SPEIFIC LECTIN 3
          (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
      1 LEG3
  18109 DIABET?
   4745 SYMPTOM
  15478 SYMPTOMS
  18436 SYMPTOM
          (SYMPTOM OR SYMPTOMS)
  35405 DISORDER
  20670 DISORDERS
  51333 DISORDER
          (DISORDER OR DISORDERS)
 217011 DISEASE#
 130059 CONDITION#
     50 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
        TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
        DISORDER OR DISEASE# OR CONDITION#)

FILE 'CANCERLIT'
   2142 GAL
      3 GALS
   2145 GAL
          (GAL OR GALS)
 508438 3
     14 GAL 3
          (GAL(W)3)
   2142 GAL
      3 GALS
   2145 GAL
          (GAL OR GALS)
 508438 3
     14 GAL-3
          (GAL(W)3)
    306 GALECTIN
     83 GALECTINS
    315 GALECTIN
          (GALECTIN OR GALECTINS)
 508438 3
    190 GALECTIN 3
          (GALECTIN(W)3)
    306 GALECTIN
     83 GALECTINS
    315 GALECTIN
          (GALECTIN OR GALECTINS)
 508438 3
    190 GALECTIN-3
          (GALECTIN(W)3)
      1 LGALS3
   2797 GALACTOSE
      6 GALACTOSES
   2798 GALACTOSE
          (GALACTOSE OR GALACTOSES)
      0 SPEIFIC
   6023 LECTIN
   4835 LECTINS
   8090 LECTIN
          (LECTIN OR LECTINS)
 508438 3
      0 GALACTOSE SPEIFIC LECTIN 3
          (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
      0 LEG3
  12854 DIABET?
   9527 SYMPTOM
```

```
        51416 SYMPTOMS
        57843 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
        16218 DISORDER
        54993 DISORDERS
        67220 DISORDER
                (DISORDER OR DISORDERS)
       435031 DISEASE#
        98194 CONDITION#
           28 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'CAPLUS'
        33957 GAL
         2460 GALS
        35876 GAL
                (GAL OR GALS)
      6440362 3
          193 GAL 3
                (GAL(W)3)
        33957 GAL
         2460 GALS
        35876 GAL
                (GAL OR GALS)
      6440362 3
          193 GAL-3
                (GAL(W)3)
         1551 GALECTIN
          430 GALECTINS
         1607 GALECTIN
                (GALECTIN OR GALECTINS)
      6440362 3
          723 GALECTIN 3
                (GALECTIN(W)3)
         1551 GALECTIN
          430 GALECTINS
         1607 GALECTIN
                (GALECTIN OR GALECTINS)
      6440362 3
          723 GALECTIN-3
                (GALECTIN(W)3)
           33 LGALS3
        54327 GALACTOSE
          192 GALACTOSES
        54388 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            1 SPEIFIC
        26760 LECTIN
        27892 LECTINS
        39179 LECTIN
                (LECTIN OR LECTINS)
      6440362 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            2 LEG3
       119163 DIABET?
        10877 SYMPTOM
        77867 SYMPTOMS
        83816 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
       248854 DISORDER
       166416 DISORDERS
       370696 DISORDER
                (DISORDER OR DISORDERS)
       921353 DISEASE#
      1840233 CONDITION#
          191 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
```

```
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'CEN'
           389 "GAL"
             1 "GALS"
           390 "GAL"
                 ("GAL" OR "GALS")
          4359 "3"
             0 GAL 3
                 ("GAL"(W)"3")
           389 "GAL"
             1 "GALS"
           390 "GAL"
                 ("GAL" OR "GALS")
          4359 "3"
             0 GAL-3
                 ("GAL"(W)"3")
             0 "GALECTIN"
          4359 "3"
             0 GALECTIN 3
                 ("GALECTIN"(W)"3")
             0 "GALECTIN"
          4359 "3"
             0 GALECTIN-3
                 ("GALECTIN"(W)"3")
             0 LGALS3
            25 "GALACTOSE"
             0 "SPEIFIC"
            14 "LECTIN"
            12 "LECTINS"
            19 "LECTIN"
                 ("LECTIN" OR "LECTINS")
          4359 "3"
             0 GALACTOSE SPEIFIC LECTIN 3
                 ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
             0 LEG3
           228 DIABET?
            20 SYMPTOM
           254 SYMPTOMS
           263 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
           129 DISORDER
           286 DISORDERS
           384 DISORDER
                 (DISORDER OR DISORDERS)
          1829 DISEASE#
          2474 CONDITION#
             0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
               TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
               DISORDER OR DISEASE# OR CONDITION#)

FILE 'DDFB'
            18 GAL
         85734 3
             0 GAL 3
                 (GAL(W)3)
            18 GAL
         85734 3
             0 GAL-3
                 (GAL(W)3)
             0 GALECTIN
         85734 3
             0 GALECTIN 3
                 (GALECTIN(W)3)
             0 GALECTIN
         85734 3
             0 GALECTIN-3
                 (GALECTIN(W)3)
             0 LGALS3
```

```
         1012 GALACTOSE
            0 SPEIFIC
          118 LECTIN
           37 LECTINS
          137 LECTIN
                (LECTIN OR LECTINS)
        85734 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
        13217 DIABET?
          992 SYMPTOM
          871 SYMPTOMS
         1801 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
        19889 DISORDER
         1919 DISORDERS
        21208 DISORDER
                (DISORDER OR DISORDERS)
        68881 DISEASE#
         2743 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'DDFU'
          587 GAL
       198153 3
            5 GAL 3
                (GAL(W)3)
          587 GAL
       198153 3
            5 GAL-3
                (GAL(W)3)
           47 GALECTIN
            2 GALECTINS
           47 GALECTIN
                (GALECTIN OR GALECTINS)
       198153 3
           21 GALECTIN 3
                (GALECTIN(W)3)
           47 GALECTIN
            2 GALECTINS
           47 GALECTIN
                (GALECTIN OR GALECTINS)
       198153 3
           21 GALECTIN-3
                (GALECTIN(W)3)
            1 LGALS3
          882 GALACTOSE
            2 SPEIFIC
          658 LECTIN
          207 LECTINS
          753 LECTIN
                (LECTIN OR LECTINS)
       198153 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
        29542 DIABET?
         4177 SYMPTOM
        35489 SYMPTOMS
        38220 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
       101682 DISORDER
        13261 DISORDERS
       110556 DISORDER
                (DISORDER OR DISORDERS)
       363420 DISEASE#
```

```
        25799 CONDITION#
            5 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'DGENE'
         2312 GAL
      1042416 3
           13 GAL 3
                (GAL(W)3)
         2312 GAL
      1042416 3
           13 GAL-3
                (GAL(W)3)
         1502 GALECTIN
           78 GALECTINS
         1502 GALECTIN
                (GALECTIN OR GALECTINS)
      1042416 3
          614 GALECTIN 3
                (GALECTIN(W)3)
         1502 GALECTIN
           78 GALECTINS
         1502 GALECTIN
                (GALECTIN OR GALECTINS)
      1042416 3
          614 GALECTIN-3
                (GALECTIN(W)3)
            1 LGALS3
         3680 GALACTOSE
            3 SPEIFIC
         6998 LECTIN
         1569 LECTINS
         7633 LECTIN
                (LECTIN OR LECTINS)
      1042416 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
       769687 DIABET?
         7612 SYMPTOM
        60350 SYMPTOMS
        65685 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
      1534959 DISORDER
      2077800 DISORDERS
      2381136 DISORDER
                (DISORDER OR DISORDERS)
      3346576 DISEASE#
      1793213 CONDITION#
          402 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'DISSABS'
           954 GAL
            25 GALS
           972 GAL
                (GAL OR GALS)
        287467 3
            30 GAL 3
                (GAL(W)3)
           954 GAL
            25 GALS
           972 GAL
                (GAL OR GALS)
        287467 3
            30 GAL-3
                (GAL(W)3)
```

```
        55 GALECTIN
        19 GALECTINS
        56 GALECTIN
             (GALECTIN OR GALECTINS)
    287467 3
        31 GALECTIN 3
             (GALECTIN(W)3)
        55 GALECTIN
        19 GALECTINS
        56 GALECTIN
             (GALECTIN OR GALECTINS)
    287467 3
        31 GALECTIN-3
             (GALECTIN(W)3)
         1 LGALS3
      1368 GALACTOSE
         1 GALACTOSES
      1369 GALACTOSE
             (GALACTOSE OR GALACTOSES)
         0 SPEIFIC
      1170 LECTIN
       545 LECTINS
      1416 LECTIN
             (LECTIN OR LECTINS)
    287467 3
         0 GALACTOSE SPEIFIC LECTIN 3
             (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         0 LEG3
      5275 DIABET?
      5770 SYMPTOM
     15533 SYMPTOMS
     18626 SYMPTOM
             (SYMPTOM OR SYMPTOMS)
     14668 DISORDER
     11092 DISORDERS
     22405 DISORDER
             (DISORDER OR DISORDERS)
     38063 DISEASE#
    179899 CONDITION#
        11 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
           TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
           DISORDER OR DISEASE# OR CONDITION#)

FILE 'DRUGB'
        18 GAL
     85734 3
         0 GAL 3
             (GAL(W)3)
        18 GAL
     85734 3
         0 GAL-3
             (GAL(W)3)
         0 GALECTIN
     85734 3
         0 GALECTIN 3
             (GALECTIN(W)3)
         0 GALECTIN
     85734 3
         0 GALECTIN-3
             (GALECTIN(W)3)
         0 LGALS3
      1012 GALACTOSE
         0 SPEIFIC
       118 LECTIN
        37 LECTINS
       137 LECTIN
             (LECTIN OR LECTINS)
     85734 3
         0 GALACTOSE SPEIFIC LECTIN 3
```

```
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
           0 LEG3
       13217 DIABET?
         992 SYMPTOM
         871 SYMPTOMS
        1801 SYMPTOM
               (SYMPTOM OR SYMPTOMS)
       19889 DISORDER
        1919 DISORDERS
       21208 DISORDER
               (DISORDER OR DISORDERS)
       68881 DISEASE#
        2743 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'DRUGMONOG2'
         134 GAL
       69529 3
           0 GAL 3
               (GAL(W)3)
         134 GAL
       69529 3
           0 GAL-3
               (GAL(W)3)
           0 GALECTIN
       69529 3
           0 GALECTIN 3
               (GALECTIN(W)3)
           0 GALECTIN
       69529 3
           0 GALECTIN-3
               (GALECTIN(W)3)
           0 LGALS3
          57 GALACTOSE
           0 SPEIFIC
           0 LECTIN
       69529 3
           0 GALACTOSE SPEIFIC LECTIN 3
               (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
           0 LEG3
         280 DIABET?
           3 SYMPTOM
           0 DISORDER
           3 DISEASE#
           6 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'DRUGU'
         995 GAL
      687518 3
          13 GAL 3
               (GAL(W)3)
         995 GAL
      687518 3
          13 GAL-3
               (GAL(W)3)
          63 GALECTIN
           5 GALECTINS
          64 GALECTIN
               (GALECTIN OR GALECTINS)
      687518 3
          28 GALECTIN 3
               (GALECTIN(W)3)
          63 GALECTIN
           5 GALECTINS
```

```
      64 GALECTIN
           (GALECTIN OR GALECTINS)
  687518 3
      28 GALECTIN-3
           (GALECTIN(W)3)
       1 LGALS3
    1332 GALACTOSE
       2 GALACTOSES
    1332 GALACTOSE
           (GALACTOSE OR GALACTOSES)
       4 SPEIFIC
     968 LECTIN
     323 LECTINS
    1121 LECTIN
           (LECTIN OR LECTINS)
  687518 3
       0 GALACTOSE SPEIFIC LECTIN 3
           (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
       0 LEG3
   35385 DIABET?
   12377 SYMPTOM
   69838 SYMPTOMS
   75320 SYMPTOM
           (SYMPTOM OR SYMPTOMS)
  103603 DISORDER
   18922 DISORDERS
  116049 DISORDER
           (DISORDER OR DISORDERS)
  382314 DISEASE#
   59823 CONDITION#
       9 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
         TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
         DISORDER OR DISEASE# OR CONDITION#)

FILE 'EMBAL'
     100 GAL
   23809 3
       3 GAL 3
           (GAL(W)3)
     100 GAL
   23809 3
       3 GAL-3
           (GAL(W)3)
      30 GALECTIN
       9 GALECTINS
      32 GALECTIN
           (GALECTIN OR GALECTINS)
   23809 3
      16 GALECTIN 3
           (GALECTIN(W)3)
      30 GALECTIN
       9 GALECTINS
      32 GALECTIN
           (GALECTIN OR GALECTINS)
   23809 3
      16 GALECTIN-3
           (GALECTIN(W)3)
       0 LGALS3
      92 GALACTOSE
       2 GALACTOSES
      94 GALACTOSE
           (GALACTOSE OR GALACTOSES)
       0 SPEIFIC
     148 LECTIN
      53 LECTINS
     165 LECTIN
           (LECTIN OR LECTINS)
   23809 3
       0 GALACTOSE SPEIFIC LECTIN 3
```

```
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
           0 LEG3
        2617 DIABET?
        1019 SYMPTOM
        3905 SYMPTOMS
        4412 SYMPTOM
               (SYMPTOM OR SYMPTOMS)
        2550 DISORDER
        3002 DISORDERS
        4869 DISORDER
               (DISORDER OR DISORDERS)
       15057 DISEASE#
        7059 CONDITION#
           4 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'EMBASE'
           9659 "GAL"
             41 "GALS"
           9682 "GAL"
                  ("GAL" OR "GALS")
        1763017 "3"
             98 GAL 3
                  ("GAL"(W)"3")
           9659 "GAL"
             41 "GALS"
           9682 "GAL"
                  ("GAL" OR "GALS")
        1763017 "3"
             98 GAL-3
                  ("GAL"(W)"3")
           1245 "GALECTIN"
            308 "GALECTINS"
           1259 "GALECTIN"
                  ("GALECTIN" OR "GALECTINS")
        1763017 "3"
            617 GALECTIN 3
                  ("GALECTIN"(W)"3")
           1245 "GALECTIN"
            308 "GALECTINS"
           1259 "GALECTIN"
                  ("GALECTIN" OR "GALECTINS")
        1763017 "3"
            617 GALECTIN-3
                  ("GALECTIN"(W)"3")
             13 LGALS3
          18013 "GALACTOSE"
             43 "GALACTOSES"
          18033 "GALACTOSE"
                  ("GALACTOSE" OR "GALACTOSES")
              5 "SPEIFIC"
          22701 "LECTIN"
           8160 "LECTINS"
          24761 "LECTIN"
                  ("LECTIN" OR "LECTINS")
        1763017 "3"
              0 GALACTOSE SPEIFIC LECTIN 3
                  ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
              0 LEG3
         221957 DIABET?
         127806 SYMPTOM
         303221 SYMPTOMS
         380608 SYMPTOM
                  (SYMPTOM OR SYMPTOMS)
         489775 DISORDER
         215022 DISORDERS
         633323 DISORDER
                  (DISORDER OR DISORDERS)
```

```
      1967989 DISEASE#
       630174 CONDITION#
          107 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'ESBIOBASE'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
           5522 GAL
             27 GALS
           5539 GAL
                  (GAL OR GALS)
         829781 3
             71 GAL 3
                  (GAL(W)3)
           5522 GAL
             27 GALS
           5539 GAL
                  (GAL OR GALS)
         829781 3
             71 GAL-3
                  (GAL(W)3)
            902 GALECTIN
            280 GALECTINS
            938 GALECTIN
                  (GALECTIN OR GALECTINS)
         829781 3
            439 GALECTIN 3
                  (GALECTIN(W)3)
            902 GALECTIN
            280 GALECTINS
            938 GALECTIN
                  (GALECTIN OR GALECTINS)
         829781 3
            439 GALECTIN-3
                  (GALECTIN(W)3)
             12 LGALS3
           5804 GALACTOSE
             18 GALACTOSES
           5815 GALACTOSE
                  (GALACTOSE OR GALACTOSES)
              2 SPEIFIC
           8489 LECTIN
           3794 LECTINS
           9693 LECTIN
                  (LECTIN OR LECTINS)
         829781 3
              0 GALACTOSE SPEIFIC LECTIN 3
                  (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
              1 LEG3
          51349 DIABET?
          12602 SYMPTOM
          59426 SYMPTOMS
          65570 SYMPTOM
                  (SYMPTOM OR SYMPTOMS)
          37571 DISORDER
         145317 DISORDERS
         170419 DISORDER
                  (DISORDER OR DISORDERS)
         678943 DISEASE#
         255374 CONDITION#
            142 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
                TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
                DISORDER OR DISEASE# OR CONDITION#)

FILE 'IFIPAT'
           2548 GAL
             49 GALS
```

```
      2588 GAL
             (GAL OR GALS)
   4499320 3
        23 GAL 3
             (GAL(W)3)
      2548 GAL
        49 GALS
      2588 GAL
             (GAL OR GALS)
   4499320 3
        23 GAL-3
             (GAL(W)3)
        94 GALECTIN
        24 GALECTINS
        98 GALECTIN
             (GALECTIN OR GALECTINS)
   4499320 3
        43 GALECTIN 3
             (GALECTIN(W)3)
        94 GALECTIN
        24 GALECTINS
        98 GALECTIN
             (GALECTIN OR GALECTINS)
   4499320 3
        43 GALECTIN-3
             (GALECTIN(W)3)
         0 LGALS3
      3393 GALACTOSE
         1 GALACTOSES
      3394 GALACTOSE
             (GALACTOSE OR GALACTOSES)
         3 SPEIFIC
      1632 LECTIN
       835 LECTINS
      2229 LECTIN
             (LECTIN OR LECTINS)
   4499320 3
         0 GALACTOSE SPEIFIC LECTIN 3
             (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         0 LEG3
     14963 DIABET?
      1948 SYMPTOM
      7892 SYMPTOMS
      9029 SYMPTOM
             (SYMPTOM OR SYMPTOMS)
     20331 DISORDER
     36445 DISORDERS
     44997 DISORDER
             (DISORDER OR DISORDERS)
     75146 DISEASE#
    510092 CONDITION#
        29 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
           TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
           DISORDER OR DISEASE# OR CONDITION#)

FILE 'IMSDRUGNEWS'
         3 "GAL"
      2297 "3"
         0 GAL 3
             ("GAL"(W)"3")
         3 "GAL"
      2297 "3"
         0 GAL-3
             ("GAL"(W)"3")
         3 "GALECTIN"
      2297 "3"
         2 GALECTIN 3
             ("GALECTIN"(W)"3")
         3 "GALECTIN"
```

```
        2297 "3"
           2 GALECTIN-3
               ("GALECTIN"(W)"3")
           0 LGALS3
           6 "GALACTOSE"
           0 "SPEIFIC"
          18 "LECTIN"
           7 "LECTINS"
          25 "LECTIN"
               ("LECTIN" OR "LECTINS")
        2297 "3"
           0 GALACTOSE SPEIFIC LECTIN 3
               ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
           0 LEG3
        2539 DIABET?
         142 SYMPTOM
        1094 SYMPTOMS
        1197 SYMPTOM
               (SYMPTOM OR SYMPTOMS)
         777 DISORDER
        2025 DISORDERS
        2666 DISORDER
               (DISORDER OR DISORDERS)
        9590 DISEASE#
         688 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'IMSPRODUCT'
          93 "GAL"
        8867 "3"
           0 GAL 3
               ("GAL"(W)"3")
          93 "GAL"
        8867 "3"
           0 GAL-3
               ("GAL"(W)"3")
           0 "GALECTIN"
        8867 "3"
           0 GALECTIN 3
               ("GALECTIN"(W)"3")
           0 "GALECTIN"
        8867 "3"
           0 GALECTIN-3
               ("GALECTIN"(W)"3")
           0 LGALS3
          48 "GALACTOSE"
           0 "SPEIFIC"
           0 "LECTIN"
        8867 "3"
           0 GALACTOSE SPEIFIC LECTIN 3
               ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
           0 LEG3
        3782 DIABET?
          58 SYMPTOM
        3439 SYMPTOMS
        3491 SYMPTOM
               (SYMPTOM OR SYMPTOMS)
        1209 DISORDER
        5696 DISORDERS
        6775 DISORDER
               (DISORDER OR DISORDERS)
        5303 DISEASE#
        4427 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)
```

```
FILE 'IPA'
           59 GAL
        81567 3
            0 GAL 3
                (GAL(W)3)
           59 GAL
        81567 3
            0 GAL-3
                (GAL(W)3)
            0 GALECTIN
            2 GALECTINS
            2 GALECTIN
                (GALECTIN OR GALECTINS)
        81567 3
            0 GALECTIN 3
                (GALECTIN(W)3)
            0 GALECTIN
            2 GALECTINS
            2 GALECTIN
                (GALECTIN OR GALECTINS)
        81567 3
            0 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
          159 GALACTOSE
            0 SPEIFIC
          137 LECTIN
          121 LECTINS
          179 LECTIN
                (LECTIN OR LECTINS)
        81567 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
         8144 DIABET?
         1814 SYMPTOM
        14495 SYMPTOMS
        15499 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         3465 DISORDER
         7890 DISORDERS
        10269 DISORDER
                (DISORDER OR DISORDERS)
        38306 DISEASE#
        14381 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'JICST-EPLUS'
          949 GAL
           74 GALS
         1018 GAL
                (GAL OR GALS)
       515970 3
            8 GAL 3
                (GAL(W)3)
          949 GAL
           74 GALS
         1018 GAL
                (GAL OR GALS)
       515970 3
            8 GAL-3
                (GAL(W)3)
          163 GALECTIN
           47 GALECTINS
          188 GALECTIN
                (GALECTIN OR GALECTINS)
       515970 3
```

```
        34 GALECTIN 3
             (GALECTIN(W)3)
       163 GALECTIN
        47 GALECTINS
       188 GALECTIN
             (GALECTIN OR GALECTINS)
    515970 3
        34 GALECTIN-3
             (GALECTIN(W)3)
         0 LGALS3
      1873 GALACTOSE
         5 GALACTOSES
      1876 GALACTOSE
             (GALACTOSE OR GALACTOSES)
         9 SPEIFIC
      6380 LECTIN
       914 LECTINS
      6516 LECTIN
             (LECTIN OR LECTINS)
    515970 3
         0 GALACTOSE SPEIFIC LECTIN 3
             (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         6 LEG3
     47637 DIABET?
    311073 SYMPTOM
     47537 SYMPTOMS
    336662 SYMPTOM
             (SYMPTOM OR SYMPTOMS)
    299567 DISORDER
     28781 DISORDERS
    313344 DISORDER
             (DISORDER OR DISORDERS)
   1301634 DISEASE#
    311666 CONDITION#
         1 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
           TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
           DISORDER OR DISEASE# OR CONDITION#)

FILE 'KOSMET'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
        10 GAL
      4797 3
         0 GAL 3
             (GAL(W)3)
        10 GAL
      4797 3
         0 GAL-3
             (GAL(W)3)
         0 GALECTIN
      4797 3
         0 GALECTIN 3
             (GALECTIN(W)3)
         0 GALECTIN
      4797 3
         0 GALECTIN-3
             (GALECTIN(W)3)
         0 LGALS3
        18 GALACTOSE
         0 SPEIFIC
        20 LECTIN
        22 LECTINS
        28 LECTIN
             (LECTIN OR LECTINS)
      4797 3
         0 GALACTOSE SPEIFIC LECTIN 3
             (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         0 LEG3
        72 DIABET?
```

```
          43 SYMPTOM
         252 SYMPTOMS
         282 SYMPTOM
               (SYMPTOM OR SYMPTOMS)
         148 DISORDER
         523 DISORDERS
         637 DISORDER
               (DISORDER OR DISORDERS)
        1606 DISEASE#
        2997 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'LIFESCI'
        4162 "GAL"
          26 "GALS"
        4174 "GAL"
               ("GAL" OR "GALS")
      447770 "3"
          33 GAL 3
               ("GAL"(W)"3")
        4162 "GAL"
          26 "GALS"
        4174 "GAL"
               ("GAL" OR "GALS")
      447770 "3"
          33 GAL-3
               ("GAL"(W)"3")
         248 "GALECTIN"
          64 "GALECTINS"
         258 "GALECTIN"
               ("GALECTIN" OR "GALECTINS")
      447770 "3"
          96 GALECTIN 3
               ("GALECTIN"(W)"3")
         248 "GALECTIN"
          64 "GALECTINS"
         258 "GALECTIN"
               ("GALECTIN" OR "GALECTINS")
      447770 "3"
          96 GALECTIN-3
               ("GALECTIN"(W)"3")
           7 LGALS3
        6390 "GALACTOSE"
          12 "GALACTOSES"
        6397 "GALACTOSE"
               ("GALACTOSE" OR "GALACTOSES")
           1 "SPEIFIC"
        7872 "LECTIN"
        5112 "LECTINS"
        9504 "LECTIN"
               ("LECTIN" OR "LECTINS")
      447770 "3"
           0 GALACTOSE SPEIFIC LECTIN 3
               ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
           0 LEG3
       13598 DIABET?
        4297 SYMPTOM
       32691 SYMPTOMS
       34989 SYMPTOM
               (SYMPTOM OR SYMPTOMS)
       15022 DISORDER
       25743 DISORDERS
       37837 DISORDER
               (DISORDER OR DISORDERS)
      252140 DISEASE#
      204808 CONDITION#
          21 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
```

```
            TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
            DISORDER OR DISEASE# OR CONDITION#)

FILE 'MEDLINE'
         10170 GAL
            44 GALS
         10195 GAL
                 (GAL OR GALS)
       2888534 3
           113 GAL 3
                 (GAL(W)3)
         10170 GAL
            44 GALS
         10195 GAL
                 (GAL OR GALS)
       2888534 3
           113 GAL-3
                 (GAL(W)3)
          1274 GALECTIN
           711 GALECTINS
          1608 GALECTIN
                 (GALECTIN OR GALECTINS)
       2888534 3
           719 GALECTIN 3
                 (GALECTIN(W)3)
          1274 GALECTIN
           711 GALECTINS
          1608 GALECTIN
                 (GALECTIN OR GALECTINS)
       2888534 3
           719 GALECTIN-3
                 (GALECTIN(W)3)
            14 LGALS3
         25066 GALACTOSE
            49 GALACTOSES
         25091 GALACTOSE
                 (GALACTOSE OR GALACTOSES)
             4 SPEIFIC
         22459 LECTIN
         29601 LECTINS
         39471 LECTIN
                 (LECTIN OR LECTINS)
       2888534 3
               0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
               0 LEG3
          257916 DIABET?
           62447 SYMPTOM
          321408 SYMPTOMS
          357249 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
          223161 DISORDER
          703052 DISORDERS
          839211 DISORDER
                 (DISORDER OR DISORDERS)
       2935618 DISEASE#
          693583 CONDITION#
             120 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
                 TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
                 DISORDER OR DISEASE# OR CONDITION#)

FILE 'NAPRALERT'
                28 "GAL"
             29894 "3"
                 1 GAL 3
                   ("GAL"(W)"3")
                28 "GAL"
             29894 "3"
                 1 GAL-3
```

```
              ("GAL"(W)"3")
        0 "GALECTIN"
    29894 "3"
        0 GALECTIN 3
              ("GALECTIN"(W)"3")
        0 "GALECTIN"
    29894 "3"
        0 GALECTIN-3
              ("GALECTIN"(W)"3")
        0 LGALS3
      229 "GALACTOSE"
        0 "SPEIFIC"
      475 "LECTIN"
      119 "LECTINS"
      515 "LECTIN"
              ("LECTIN" OR "LECTINS")
    29894 "3"
        0 GALACTOSE SPEIFIC LECTIN 3
              ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
        0 LEG3
     1502 DIABET?
       74 SYMPTOM
      845 SYMPTOMS
      881 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
      155 DISORDER
      834 DISORDERS
      927 DISORDER
              (DISORDER OR DISORDERS)
     1545 DISEASE#
      596 CONDITION#
        0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
          TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
          DISORDER OR DISEASE# OR CONDITION#)

FILE 'NLDB'
    10367 "GAL"
      513 "GALS"
    10755 "GAL"
              ("GAL" OR "GALS")
   822485 "3"
       50 GAL 3
              ("GAL"(W)"3")
    10367 "GAL"
      513 "GALS"
    10755 "GAL"
              ("GAL" OR "GALS")
   822485 "3"
       50 GAL-3
              ("GAL"(W)"3")
       26 "GALECTIN"
        5 "GALECTINS"
       30 "GALECTIN"
              ("GALECTIN" OR "GALECTINS")
   822485 "3"
       17 GALECTIN 3
              ("GALECTIN"(W)"3")
       26 "GALECTIN"
        5 "GALECTINS"
       30 "GALECTIN"
              ("GALECTIN" OR "GALECTINS")
   822485 "3"
       17 GALECTIN-3
              ("GALECTIN"(W)"3")
        0 LGALS3
      225 "GALACTOSE"
        2 "SPEIFIC"
      202 "LECTIN"
      105 "LECTINS"
```

```
      276 "LECTIN"
            ("LECTIN" OR "LECTINS")
   822485 "3"
        0 GALACTOSE SPEIFIC LECTIN 3
            ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
        0 LEG3
    17295 DIABET?
     3069 SYMPTOM
    21336 SYMPTOMS
    23164 SYMPTOM
            (SYMPTOM OR SYMPTOMS)
     9961 DISORDER
    17403 DISORDERS
    24728 DISORDER
            (DISORDER OR DISORDERS)
   137805 DISEASE#
   251009 CONDITION#
        1 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
          TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
          DISORDER OR DISEASE# OR CONDITION#)

FILE 'NUTRACEUT'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
        1 GAL
        1 GALS
        2 GAL
            (GAL OR GALS)
     1659 3
        0 GAL 3
            (GAL(W)3)
        1 GAL
        1 GALS
        2 GAL
            (GAL OR GALS)
     1659 3
        0 GAL-3
            (GAL(W)3)
        0 GALECTIN
     1659 3
        0 GALECTIN 3
            (GALECTIN(W)3)
        0 GALECTIN
     1659 3
        0 GALECTIN-3
            (GALECTIN(W)3)
        0 LGALS3
        0 GALACTOSE
        0 SPEIFIC
        1 LECTIN
     1659 3
        0 GALACTOSE SPEIFIC LECTIN 3
            (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
        0 LEG3
      309 DIABET?
       24 SYMPTOM
      280 SYMPTOMS
      291 SYMPTOM
            (SYMPTOM OR SYMPTOMS)
       51 DISORDER
      132 DISORDERS
      174 DISORDER
            (DISORDER OR DISORDERS)
     1150 DISEASE#
      496 CONDITION#
        0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
          TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
          DISORDER OR DISEASE# OR CONDITION#)
```

```
FILE 'PASCAL'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
         4360 GAL
           76 GALS
         4420 GAL
                (GAL OR GALS)
      2037415 3
           55 GAL 3
                (GAL(W)3)
         4360 GAL
           76 GALS
         4420 GAL
                (GAL OR GALS)
      2037415 3
           55 GAL-3
                (GAL(W)3)
          390 GALECTIN
           80 GALECTINS
          399 GALECTIN
                (GALECTIN OR GALECTINS)
      2037415 3
          252 GALECTIN 3
                (GALECTIN(W)3)
          390 GALECTIN
           80 GALECTINS
          399 GALECTIN
                (GALECTIN OR GALECTINS)
      2037415 3
          252 GALECTIN-3
                (GALECTIN(W)3)
            4 LGALS3
         8368 GALACTOSE
           27 GALACTOSES
         8382 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            3 SPEIFIC
        11450 LECTIN
         3250 LECTINS
        12485 LECTIN
                (LECTIN OR LECTINS)
      2037415 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            3 LEG3
       102866 DIABET?
        26412 SYMPTOM
       109501 SYMPTOMS
       123248 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
       400448 DISORDER
       132925 DISORDERS
       492220 DISORDER
                (DISORDER OR DISORDERS)
      2188686 DISEASE#
       833322 CONDITION#
          178 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'PCTGEN'
               0 GAL
           35942 3
               0 GAL 3
                   (GAL(W)3)
               0 GAL
           35942 3
               0 GAL-3
                   (GAL(W)3)
```

```
        0 GALECTIN
    35942 3
        0 GALECTIN 3
            (GALECTIN(W)3)
        0 GALECTIN
    35942 3
        0 GALECTIN-3
            (GALECTIN(W)3)
        0 LGALS3
        0 GALACTOSE
        0 SPEIFIC
        0 LECTIN
    35942 3
        0 GALACTOSE SPEIFIC LECTIN 3
            (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
        0 LEG3
     1484 DIABET?
        0 SYMPTOM
        0 DISORDER
    25258 DISORDERS
    25258 DISORDER
            (DISORDER OR DISORDERS)
    52646 DISEASE#
       70 CONDITION#
        0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
          TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
          DISORDER OR DISEASE# OR CONDITION#)

FILE 'PHARMAML'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
       10 GAL
    13634 3
        0 GAL 3
            (GAL(W)3)
       10 GAL
    13634 3
        0 GAL-3
            (GAL(W)3)
        0 GALECTIN
    13634 3
        0 GALECTIN 3
            (GALECTIN(W)3)
        0 GALECTIN
    13634 3
        0 GALECTIN-3
            (GALECTIN(W)3)
        0 LGALS3
        5 GALACTOSE
        0 SPEIFIC
        3 LECTIN
        3 LECTINS
        6 LECTIN
            (LECTIN OR LECTINS)
    13634 3
        0 GALACTOSE SPEIFIC LECTIN 3
            (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
        0 LEG3
     2769 DIABET?
      301 SYMPTOM
     1954 SYMPTOMS
     2096 SYMPTOM
            (SYMPTOM OR SYMPTOMS)
     1087 DISORDER
     1491 DISORDERS
     2439 DISORDER
            (DISORDER OR DISORDERS)
    10467 DISEASE#
     3720 CONDITION#
```

```
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'PHIC'
            0 "GAL"
          129 "3"
            0 GAL 3
                ("GAL"(W)"3")
            0 "GAL"
          129 "3"
            0 GAL-3
                ("GAL"(W)"3")
            0 "GALECTIN"
          129 "3"
            0 GALECTIN 3
                ("GALECTIN"(W)"3")
            0 "GALECTIN"
          129 "3"
            0 GALECTIN-3
                ("GALECTIN"(W)"3")
            0 LGALS3
            0 "GALACTOSE"
            0 "SPEIFIC"
            0 "LECTIN"
          129 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
            0 LEG3
           53 DIABET?
            4 SYMPTOM
           25 SYMPTOMS
           28 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
           16 DISORDER
           33 DISORDERS
           43 DISORDER
                (DISORDER OR DISORDERS)
          254 DISEASE#
          120 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'PHIN'
           39 "GAL"
        48787 "3"
            0 GAL 3
                ("GAL"(W)"3")
           39 "GAL"
        48787 "3"
            0 GAL-3
                ("GAL"(W)"3")
            2 "GALECTIN"
        48787 "3"
            2 GALECTIN 3
                ("GALECTIN"(W)"3")
            2 "GALECTIN"
        48787 "3"
            2 GALECTIN-3
                ("GALECTIN"(W)"3")
            0 LGALS3
           44 "GALACTOSE"
            0 "SPEIFIC"
           49 "LECTIN"
           26 "LECTINS"
           67 "LECTIN"
                ("LECTIN" OR "LECTINS")
        48787 "3"
```

```
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
            0 LEG3
         8748 DIABET?
          831 SYMPTOM
         6703 SYMPTOMS
         7191 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         2801 DISORDER
         8452 DISORDERS
        10671 DISORDER
                (DISORDER OR DISORDERS)
        57994 DISEASE#
        22085 CONDITION#
            1 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'SCISEARCH'
         10628 GAL
           128 GALS
         10733 GAL
                (GAL OR GALS)
       2795057 3
           118 GAL 3
                (GAL(W)3)
         10628 GAL
           128 GALS
         10733 GAL
                (GAL OR GALS)
       2795057 3
           118 GAL-3
                (GAL(W)3)
          1560 GALECTIN
           462 GALECTINS
          1678 GALECTIN
                (GALECTIN OR GALECTINS)
       2795057 3
           799 GALECTIN 3
                (GALECTIN(W)3)
          1560 GALECTIN
           462 GALECTINS
          1678 GALECTIN
                (GALECTIN OR GALECTINS)
       2795057 3
           799 GALECTIN-3
                (GALECTIN(W)3)
            17 LGALS3
         15920 GALACTOSE
            49 GALACTOSES
         15947 GALACTOSE
                (GALACTOSE OR GALACTOSES)
             5 SPEIFIC
         23348 LECTIN
         10349 LECTINS
         28453 LECTIN
                (LECTIN OR LECTINS)
       2795057 3
               0 GALACTOSE SPEIFIC LECTIN 3
                   (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
               3 LEG3
          214457 DIABET?
           41780 SYMPTOM
          204906 SYMPTOMS
          227054 SYMPTOM
                   (SYMPTOM OR SYMPTOMS)
          159758 DISORDER
          188614 DISORDERS
          315866 DISORDER
```

```
              (DISORDER OR DISORDERS)
      1222743 DISEASE#
      1076937 CONDITION#
          132 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'TOXCENTER'
         8744 GAL
          263 GALS
         8956 GAL
              (GAL OR GALS)
      1605513 3
           35 GAL 3
              (GAL(W)3)
         8744 GAL
          263 GALS
         8956 GAL
              (GAL OR GALS)
      1605513 3
           35 GAL-3
              (GAL(W)3)
          399 GALECTIN
          123 GALECTINS
          433 GALECTIN
              (GALECTIN OR GALECTINS)
      1605513 3
          198 GALECTIN 3
              (GALECTIN(W)3)
          399 GALECTIN
          123 GALECTINS
          433 GALECTIN
              (GALECTIN OR GALECTINS)
      1605513 3
          198 GALECTIN-3
              (GALECTIN(W)3)
            1 LGALS3
        10408 GALACTOSE
           20 GALACTOSES
        10427 GALACTOSE
              (GALACTOSE OR GALACTOSES)
            3 SPEIFIC
         9999 LECTIN
         7614 LECTINS
        14004 LECTIN
              (LECTIN OR LECTINS)
      1605513 3
            0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
        73889 DIABET?
        24076 SYMPTOM
       142262 SYMPTOMS
       155333 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
        90003 DISORDER
       222649 DISORDERS
       281521 DISORDER
              (DISORDER OR DISORDERS)
       849201 DISEASE#
       432920 CONDITION#
           51 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'USPATFULL'
         33990 GAL
          1338 GALS
         34701 GAL
```

```
            (GAL OR GALS)
   4284903 3
       362 GAL 3
             (GAL(W)3)
     33990 GAL
      1338 GALS
     34701 GAL
             (GAL OR GALS)
   4284903 3
       362 GAL-3
             (GAL(W)3)
       473 GALECTIN
       475 GALECTINS
       834 GALECTIN
             (GALECTIN OR GALECTINS)
   4284903 3
       207 GALECTIN 3
             (GALECTIN(W)3)
       473 GALECTIN
       475 GALECTINS
       834 GALECTIN
             (GALECTIN OR GALECTINS)
   4284903 3
       207 GALECTIN-3
             (GALECTIN(W)3)
        40 LGALS3
     27373 GALACTOSE
       240 GALACTOSES
     27390 GALACTOSE
             (GALACTOSE OR GALACTOSES)
        41 SPEIFIC
     15108 LECTIN
      8775 LECTINS
     19922 LECTIN
             (LECTIN OR LECTINS)
   4284903 3
         0 GALACTOSE SPEIFIC LECTIN 3
             (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
        16 LEG3
     56887 DIABET?
     19162 SYMPTOM
     83725 SYMPTOMS
     89339 SYMPTOM
             (SYMPTOM OR SYMPTOMS)
     66559 DISORDER
     99218 DISORDERS
    119741 DISORDER
             (DISORDER OR DISORDERS)
    254158 DISEASE#
   2102962 CONDITION#
       109 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
           TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
           DISORDER OR DISEASE# OR CONDITION#)

FILE 'USPAT2'
        2342 GAL
          54 GALS
        2374 GAL
             (GAL OR GALS)
      343029 3
          23 GAL 3
             (GAL(W)3)
        2342 GAL
          54 GALS
        2374 GAL
             (GAL OR GALS)
      343029 3
          23 GAL-3
             (GAL(W)3)
```

```
        40 GALECTIN
        39 GALECTINS
        72 GALECTIN
             (GALECTIN OR GALECTINS)
    343029 3
        17 GALECTIN 3
             (GALECTIN(W)3)
        40 GALECTIN
        39 GALECTINS
        72 GALECTIN
             (GALECTIN OR GALECTINS)
    343029 3
        17 GALECTIN-3
             (GALECTIN(W)3)
         2 LGALS3
      1874 GALACTOSE
        17 GALACTOSES
      1874 GALACTOSE
             (GALACTOSE OR GALACTOSES)
         2 SPEIFIC
      1368 LECTIN
       584 LECTINS
      1689 LECTIN
             (LECTIN OR LECTINS)
    343029 3
         0 GALACTOSE SPEIFIC LECTIN 3
             (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         0 LEG3
      5741 DIABET?
      1807 SYMPTOM
      7617 SYMPTOMS
      8138 SYMPTOM
             (SYMPTOM OR SYMPTOMS)
      6823 DISORDER
      9512 DISORDERS
     11539 DISORDER
             (DISORDER OR DISORDERS)
     21979 DISEASE#
    175276 CONDITION#
         7 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
           TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
           DISORDER OR DISEASE# OR CONDITION#)

FILE 'AGRICOLA'
          773 GAL
            9 GALS
          779 GAL
                (GAL OR GALS)
    184199 3
           11 GAL 3
                (GAL(W)3)
          773 GAL
            9 GALS
          779 GAL
                (GAL OR GALS)
    184199 3
           11 GAL-3
                (GAL(W)3)
           25 GALECTIN
           12 GALECTINS
           33 GALECTIN
                (GALECTIN OR GALECTINS)
    184199 3
            6 GALECTIN 3
                (GALECTIN(W)3)
           25 GALECTIN
           12 GALECTINS
           33 GALECTIN
                (GALECTIN OR GALECTINS)
```

```
       184199 3
            6 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
         2597 GALACTOSE
            3 GALACTOSES
         2600 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            1 SPEIFIC
         2319 LECTIN
         2529 LECTINS
         3577 LECTIN
                (LECTIN OR LECTINS)
       184199 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
        10475 DIABET?
         1300 SYMPTOM
        19284 SYMPTOMS
        19930 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         2352 DISORDER
        14736 DISORDERS
        16359 DISORDER
                (DISORDER OR DISORDERS)
       190403 DISEASE#
        99587 CONDITION#
            4 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'ANABSTR'
           65 GAL
            1 GALS
           65 GAL
                (GAL OR GALS)
       122838 3
            0 GAL 3
                (GAL(W)3)
           65 GAL
            1 GALS
           65 GAL
                (GAL OR GALS)
       122838 3
            0 GAL-3
                (GAL(W)3)
           12 GALECTIN
            4 GALECTINS
           13 GALECTIN
                (GALECTIN OR GALECTINS)
       122838 3
            4 GALECTIN 3
                (GALECTIN(W)3)
           12 GALECTIN
            4 GALECTINS
           13 GALECTIN
                (GALECTIN OR GALECTINS)
       122838 3
            4 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
          737 GALACTOSE
            1 GALACTOSES
          737 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            0 SPEIFIC
          267 LECTIN
          124 LECTINS
```

```
          317 LECTIN
                (LECTIN OR LECTINS)
       122838 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
          569 DIABET?
            8 SYMPTOM
          101 SYMPTOMS
          108 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
           93 DISORDER
          405 DISORDERS
          491 DISORDER
                (DISORDER OR DISORDERS)
         2003 DISEASE#
        26133 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'ANTE'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
            14 GAL
             2 GALS
            16 GAL
                (GAL OR GALS)
        20571 3
            0 GAL 3
                (GAL(W)3)
           14 GAL
            2 GALS
           16 GAL
                (GAL OR GALS)
        20571 3
            0 GAL-3
                (GAL(W)3)
            2 GALECTIN
        20571 3
            0 GALECTIN 3
                (GALECTIN(W)3)
            2 GALECTIN
        20571 3
            0 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
           51 GALACTOSE
            0 SPEIFIC
           20 LECTIN
           26 LECTINS
           37 LECTIN
                (LECTIN OR LECTINS)
        20571 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
          130 DIABET?
           19 SYMPTOM
          195 SYMPTOMS
          212 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
          337 DISORDER
          205 DISORDERS
          535 DISORDER
                (DISORDER OR DISORDERS)
         1321 DISEASE#
        16754 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
```

```
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'AQUALINE'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
            785 GAL
          36923 3
              0 GAL 3
                  (GAL(W)3)
            785 GAL
          36923 3
              0 GAL-3
                  (GAL(W)3)
              0 GALECTIN
          36923 3
              0 GALECTIN 3
                  (GALECTIN(W)3)
              0 GALECTIN
          36923 3
              0 GALECTIN-3
                  (GALECTIN(W)3)
              0 LGALS3
             57 GALACTOSE
              0 SPEIFIC
              8 LECTIN
              5 LECTINS
             11 LECTIN
                  (LECTIN OR LECTINS)
          36923 3
              0 GALACTOSE SPEIFIC LECTIN 3
                  (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
              0 LEG3
              9 DIABET?
             26 SYMPTOM
            435 SYMPTOMS
            441 SYMPTOM
                  (SYMPTOM OR SYMPTOMS)
             16 DISORDER
             73 DISORDERS
             89 DISORDER
                  (DISORDER OR DISORDERS)
           5003 DISEASE#
          37849 CONDITION#
              0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'AQUASCI'
            384 "GAL"
             13 "GALS"
            395 "GAL"
                  ("GAL" OR "GALS")
         159947 "3"
              5 GAL 3
                  ("GAL"(W)"3")
            384 "GAL"
             13 "GALS"
            395 "GAL"
                  ("GAL" OR "GALS")
         159947 "3"
              5 GAL-3
                  ("GAL"(W)"3")
             22 "GALECTIN"
             14 "GALECTINS"
             25 "GALECTIN"
                  ("GALECTIN" OR "GALECTINS")
         159947 "3"
              1 GALECTIN 3
```

```
              ("GALECTIN"(W)"3")
          22 "GALECTIN"
          14 "GALECTINS"
          25 "GALECTIN"
              ("GALECTIN" OR "GALECTINS")
      159947 "3"
           1 GALECTIN-3
              ("GALECTIN"(W)"3")
           0 LGALS3
         933 "GALACTOSE"
           1 "GALACTOSES"
         933 "GALACTOSE"
              ("GALACTOSE" OR "GALACTOSES")
           1 "SPEIFIC"
         699 "LECTIN"
         597 "LECTINS"
         908 "LECTIN"
              ("LECTIN" OR "LECTINS")
      159947 "3"
           0 GALACTOSE SPEIFIC LECTIN 3
              ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
           3 LEG3
         142 DIABET?
         274 SYMPTOM
        2259 SYMPTOMS
        2472 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
         235 DISORDER
         556 DISORDERS
         776 DISORDER
              (DISORDER OR DISORDERS)
       30719 DISEASE#
      128532 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'BIOBUSINESS'
         277 "GAL"
           1 "GALS"
         278 "GAL"
              ("GAL" OR "GALS")
       73514 "3"
           0 GAL 3
              ("GAL"(W)"3")
         277 "GAL"
           1 "GALS"
         278 "GAL"
              ("GAL" OR "GALS")
       73514 "3"
           0 GAL-3
              ("GAL"(W)"3")
           2 "GALECTIN"
           1 "GALECTINS"
           3 "GALECTIN"
              ("GALECTIN" OR "GALECTINS")
       73514 "3"
           2 GALECTIN 3
              ("GALECTIN"(W)"3")
           2 "GALECTIN"
           1 "GALECTINS"
           3 "GALECTIN"
              ("GALECTIN" OR "GALECTINS")
       73514 "3"
           2 GALECTIN-3
              ("GALECTIN"(W)"3")
           0 LGALS3
         972 "GALACTOSE"
           0 "SPEIFIC"
```

```
          362 "LECTIN"
          204 "LECTINS"
          467 "LECTIN"
                ("LECTIN" OR "LECTINS")
        73514 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
            0 LEG3
         2407 DIABET?
         1250 SYMPTOM
         6188 SYMPTOMS
         6863 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         1871 DISORDER
         3102 DISORDERS
         4578 DISORDER
                (DISORDER OR DISORDERS)
       106693 DISEASE#
        44102 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'BIOCOMMERCE'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
           21 GAL
         7922 3
            0 GAL 3
                (GAL(W)3)
           21 GAL
         7922 3
            0 GAL-3
                (GAL(W)3)
            6 GALECTIN
         7922 3
            1 GALECTIN 3
                (GALECTIN(W)3)
            6 GALECTIN
         7922 3
            1 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
           46 GALACTOSE
            0 SPEIFIC
           68 LECTIN
           29 LECTINS
           92 LECTIN
                (LECTIN OR LECTINS)
         7922 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
         1815 DIABET?
           14 SYMPTOM
          270 SYMPTOMS
          282 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
          273 DISORDER
         1390 DISORDERS
         1648 DISORDER
                (DISORDER OR DISORDERS)
        12760 DISEASE#
         1153 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'BIOENG'
```

```
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
          1158 GAL
             1 GALS
          1159 GAL
                 (GAL OR GALS)
        104786 3
             5 GAL 3
                 (GAL(W)3)
          1158 GAL
             1 GALS
          1159 GAL
                 (GAL OR GALS)
        104786 3
             5 GAL-3
                 (GAL(W)3)
            38 GALECTIN
            14 GALECTINS
            39 GALECTIN
                 (GALECTIN OR GALECTINS)
        104786 3
             9 GALECTIN 3
                 (GALECTIN(W)3)
            38 GALECTIN
            14 GALECTINS
            39 GALECTIN
                 (GALECTIN OR GALECTINS)
        104786 3
             9 GALECTIN-3
                 (GALECTIN(W)3)
             0 LGALS3
          1860 GALACTOSE
             1 GALACTOSES
          1860 GALACTOSE
                 (GALACTOSE OR GALACTOSES)
             0 SPEIFIC
           998 LECTIN
           785 LECTINS
          1228 LECTIN
                 (LECTIN OR LECTINS)
        104786 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             0 LEG3
          1723 DIABET?
          1234 SYMPTOM
          7116 SYMPTOMS
          7734 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
          1911 DISORDER
          3630 DISORDERS
          5004 DISORDER
                 (DISORDER OR DISORDERS)
         55293 DISEASE#
         57648 CONDITION#
             1 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
               TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
               DISORDER OR DISEASE# OR CONDITION#)

FILE 'BIOTECHABS'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
          1844 GAL
             6 GALS
          1846 GAL
                 (GAL OR GALS)
        158028 3
             7 GAL 3
                 (GAL(W)3)
```

```
  1844 GAL
     6 GALS
  1846 GAL
          (GAL OR GALS)
158028 3
     7 GAL-3
          (GAL(W)3)
    77 GALECTIN
     8 GALECTINS
    77 GALECTIN
          (GALECTIN OR GALECTINS)
158028 3
    21 GALECTIN 3
          (GALECTIN(W)3)
    77 GALECTIN
     8 GALECTINS
    77 GALECTIN
          (GALECTIN OR GALECTINS)
158028 3
    21 GALECTIN-3
          (GALECTIN(W)3)
     1 LGALS3
  3126 GALACTOSE
     6 GALACTOSES
  3130 GALACTOSE
          (GALACTOSE OR GALACTOSES)
     1 SPEIFIC
  1186 LECTIN
   353 LECTINS
  1362 LECTIN
          (LECTIN OR LECTINS)
158028 3
     0 GALACTOSE SPEIFIC LECTIN 3
          (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
     0 LEG3
  8055 DIABET?
   481 SYMPTOM
  2218 SYMPTOMS
  2524 SYMPTOM
          (SYMPTOM OR SYMPTOMS)
 13438 DISORDER
 12360 DISORDERS
 17950 DISORDER
          (DISORDER OR DISORDERS)
 61465 DISEASE#
 60972 CONDITION#
    16 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
       TOSE SPEIFIC LECTIN 3  OR LEG3) (P)   (DIABET? OR SYMPTOM OR
       DISORDER OR DISEASE# OR CONDITION#)

FILE 'BIOTECHDS'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
  1844 GAL
     6 GALS
  1846 GAL
          (GAL OR GALS)
158028 3
     7 GAL 3
          (GAL(W)3)
  1844 GAL
     6 GALS
  1846 GAL
          (GAL OR GALS)
158028 3
     7 GAL-3
          (GAL(W)3)
    77 GALECTIN
     8 GALECTINS
```

```
        77 GALECTIN
             (GALECTIN OR GALECTINS)
    158028 3
        21 GALECTIN 3
             (GALECTIN(W)3)
        77 GALECTIN
         8 GALECTINS
        77 GALECTIN
             (GALECTIN OR GALECTINS)
    158028 3
        21 GALECTIN-3
             (GALECTIN(W)3)
         1 LGALS3
      3126 GALACTOSE
         6 GALACTOSES
      3130 GALACTOSE
             (GALACTOSE OR GALACTOSES)
         1 SPEIFIC
      1186 LECTIN
       353 LECTINS
      1362 LECTIN
             (LECTIN OR LECTINS)
    158028 3
         0 GALACTOSE SPEIFIC LECTIN 3
             (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         0 LEG3
      8055 DIABET?
       481 SYMPTOM
      2218 SYMPTOMS
      2524 SYMPTOM
             (SYMPTOM OR SYMPTOMS)
     13438 DISORDER
     12360 DISORDERS
     17950 DISORDER
             (DISORDER OR DISORDERS)
     61465 DISEASE#
     60972 CONDITION#
        16 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
           TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
           DISORDER OR DISEASE# OR CONDITION#)

FILE 'CABA'
      4857 GAL
        17 GALS
      4865 GAL
             (GAL OR GALS)
   1093924 3
        26 GAL 3
             (GAL(W)3)
      4857 GAL
        17 GALS
      4865 GAL
             (GAL OR GALS)
   1093924 3
        26 GAL-3
             (GAL(W)3)
        73 GALECTIN
        37 GALECTINS
        81 GALECTIN
             (GALECTIN OR GALECTINS)
   1093924 3
        17 GALECTIN 3
             (GALECTIN(W)3)
        73 GALECTIN
        37 GALECTINS
        81 GALECTIN
             (GALECTIN OR GALECTINS)
   1093924 3
        17 GALECTIN-3
```

```
              (GALECTIN(W)3)
           1 LGALS3
        7369 GALACTOSE
           9 GALACTOSES
        7372 GALACTOSE
              (GALACTOSE OR GALACTOSES)
           1 SPEIFIC
        4992 LECTIN
        4688 LECTINS
        6553 LECTIN
              (LECTIN OR LECTINS)
     1093924 3
           0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
           1 LEG3
       22877 DIABET?
        7322 SYMPTOM
       81885 SYMPTOMS
       85636 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
       10049 DISORDER
       68184 DISORDERS
       73568 DISORDER
              (DISORDER OR DISORDERS)
      810772 DISEASE#
      404967 CONDITION#
           4 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'CEABA-VTB'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
         853 GAL
          10 GALS
         862 GAL
              (GAL OR GALS)
      105004 3
           1 GAL 3
              (GAL(W)3)
         853 GAL
          10 GALS
         862 GAL
              (GAL OR GALS)
      105004 3
           1 GAL-3
              (GAL(W)3)
           1 GALECTIN
      105004 3
           0 GALECTIN 3
              (GALECTIN(W)3)
           1 GALECTIN
      105004 3
           0 GALECTIN-3
              (GALECTIN(W)3)
           0 LGALS3
         646 GALACTOSE
           0 SPEIFIC
         163 LECTIN
          53 LECTINS
         191 LECTIN
              (LECTIN OR LECTINS)
      105004 3
           0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
           0 LEG3
         503 DIABET?
          66 SYMPTOM
         296 SYMPTOMS
```

```
          352 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
          212 DISORDER
          556 DISORDERS
          756 DISORDER
                (DISORDER OR DISORDERS)
        13072 DISEASE#
        47728 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'CIN'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
         2569 "GAL"
           78 "GALS"
         2641 "GAL"
                ("GAL" OR "GALS")
       155469 "3"
            0 GAL 3
                ("GAL"(W)"3")
         2569 "GAL"
           78 "GALS"
         2641 "GAL"
                ("GAL" OR "GALS")
       155469 "3"
            0 GAL-3
                ("GAL"(W)"3")
            4 "GALECTIN"
            1 "GALECTINS"
            5 "GALECTIN"
                ("GALECTIN" OR "GALECTINS")
       155469 "3"
            0 GALECTIN 3
                ("GALECTIN"(W)"3")
            4 "GALECTIN"
            1 "GALECTINS"
            5 "GALECTIN"
                ("GALECTIN" OR "GALECTINS")
       155469 "3"
            0 GALECTIN-3
                ("GALECTIN"(W)"3")
            0 LGALS3
           50 "GALACTOSE"
            0 "SPEIFIC"
           65 "LECTIN"
           19 "LECTINS"
           73 "LECTIN"
                ("LECTIN" OR "LECTINS")
       155469 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
            0 LEG3
         3704 DIABET?
          224 SYMPTOM
         1736 SYMPTOMS
         1889 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         1697 DISORDER
         2964 DISORDERS
         4149 DISORDER
                (DISORDER OR DISORDERS)
        20474 DISEASE#
        18991 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)
```

```
FILE 'CONFSCI'
           77 "GAL"
            1 "GALS"
           78 "GAL"
                ("GAL" OR "GALS")
        26826 "3"
            0 GAL 3
                ("GAL"(W)"3")
           77 "GAL"
            1 "GALS"
           78 "GAL"
                ("GAL" OR "GALS")
        26826 "3"
            0 GAL-3
                ("GAL"(W)"3")
           39 "GALECTIN"
            8 "GALECTINS"
           46 "GALECTIN"
                ("GALECTIN" OR "GALECTINS")
        26826 "3"
           22 GALECTIN 3
                ("GALECTIN"(W)"3")
           39 "GALECTIN"
            8 "GALECTINS"
           46 "GALECTIN"
                ("GALECTIN" OR "GALECTINS")
        26826 "3"
           22 GALECTIN-3
                ("GALECTIN"(W)"3")
            1 LGALS3
          298 "GALACTOSE"
            1 "GALACTOSES"
          299 "GALACTOSE"
                ("GALACTOSE" OR "GALACTOSES")
            0 "SPEIFIC"
          749 "LECTIN"
          262 "LECTINS"
         1010 "LECTIN"
                ("LECTIN" OR "LECTINS")
        26826 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
            0 LEG3
         6759 DIABET?
          422 SYMPTOM
         1705 SYMPTOMS
         2120 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         2976 DISORDER
         3814 DISORDERS
         6750 DISORDER
                (DISORDER OR DISORDERS)
        28486 DISEASE#
        11266 CONDITION#
            1 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'CROPB'
            2 GAL
         8609 3
            0 GAL 3
                (GAL(W)3)
            2 GAL
         8609 3
            0 GAL-3
                (GAL(W)3)
            0 GALECTIN
         8609 3
```

```
            0 GALECTIN 3
                (GALECTIN(W)3)
            0 GALECTIN
         8609 3
            0 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
           49 GALACTOSE
            0 SPEIFIC
           35 LECTIN
            8 LECTINS
           37 LECTIN
                (LECTIN OR LECTINS)
         8609 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
            7 DIABET?
          874 SYMPTOM
          223 SYMPTOMS
         1038 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
           97 DISORDER
           36 DISORDERS
          132 DISORDER
                (DISORDER OR DISORDERS)
         7376 DISEASE#
         1168 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'CROPU'
         8563 GAL
           19 GALS
         8574 GAL
                (GAL OR GALS)
        90216 3
           15 GAL 3
                (GAL(W)3)
         8563 GAL
           19 GALS
         8574 GAL
                (GAL OR GALS)
        90216 3
           15 GAL-3
                (GAL(W)3)
            0 GALECTIN
        90216 3
            0 GALECTIN 3
                (GALECTIN(W)3)
            0 GALECTIN
        90216 3
            0 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
          102 GALACTOSE
            0 SPEIFIC
          118 LECTIN
           57 LECTINS
          132 LECTIN
                (LECTIN OR LECTINS)
        90216 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
           20 DIABET?
          345 SYMPTOM
         4301 SYMPTOMS
```

```
 4512 SYMPTOM
        (SYMPTOM OR SYMPTOMS)
  112 DISORDER
  135 DISORDERS
  236 DISORDER
        (DISORDER OR DISORDERS)
16375 DISEASE#
13947 CONDITION#
    9 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
      TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
      DISORDER OR DISEASE# OR CONDITION#)

FILE 'FEDRIP'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
  270 GAL
    6 GALS
  276 GAL
        (GAL OR GALS)
86483 3
    2 GAL 3
        (GAL(W)3)
  270 GAL
    6 GALS
  276 GAL
        (GAL OR GALS)
86483 3
    2 GAL-3
        (GAL(W)3)
   46 GALECTIN
   15 GALECTINS
   48 GALECTIN
        (GALECTIN OR GALECTINS)
86483 3
   25 GALECTIN 3
        (GALECTIN(W)3)
   46 GALECTIN
   15 GALECTINS
   48 GALECTIN
        (GALECTIN OR GALECTINS)
86483 3
   25 GALECTIN-3
        (GALECTIN(W)3)
    0 LGALS3
  167 GALACTOSE
    2 SPEIFIC
  254 LECTIN
   99 LECTINS
  301 LECTIN
        (LECTIN OR LECTINS)
86483 3
    0 GALACTOSE SPEIFIC LECTIN 3
        (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
    0 LEG3
 6589 DIABET?
 1942 SYMPTOM
 6544 SYMPTOMS
 7474 SYMPTOM
        (SYMPTOM OR SYMPTOMS)
21583 DISORDER
10449 DISORDERS
28119 DISORDER
        (DISORDER OR DISORDERS)
54769 DISEASE#
31777 CONDITION#
   13 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
      TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
      DISORDER OR DISEASE# OR CONDITION#)
```

```
FILE 'FOMAD'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
            16 GAL
             3 GALS
            19 GAL
                 (GAL OR GALS)
         47683 3
             0 GAL 3
                 (GAL(W)3)
            16 GAL
             3 GALS
            19 GAL
                 (GAL OR GALS)
         47683 3
             0 GAL-3
                 (GAL(W)3)
             0 GALECTIN
         47683 3
             0 GALECTIN 3
                 (GALECTIN(W)3)
             0 GALECTIN
         47683 3
             0 GALECTIN-3
                 (GALECTIN(W)3)
             0 LGALS3
             0 GALACTOSE
             0 SPEIFIC
             1 LECTIN
         47683 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             0 LEG3
           155 DIABET?
             1 SYMPTOM
             8 SYMPTOMS
             9 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
             1 DISORDER
             8 DISORDERS
             9 DISORDER
                 (DISORDER OR DISORDERS)
           307 DISEASE#
           401 CONDITION#
             0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
               TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
               DISORDER OR DISEASE# OR CONDITION#)

FILE 'FOREGE'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
             1 GAL
            22 GALS
            23 GAL
                 (GAL OR GALS)
          1592 3
             2 GAL 3
                 (GAL(W)3)
             1 GAL
            22 GALS
            23 GAL
                 (GAL OR GALS)
          1592 3
             2 GAL-3
                 (GAL(W)3)
             0 GALECTIN
          1592 3
             0 GALECTIN 3
                 (GALECTIN(W)3)
```

```
            0 GALECTIN
         1592 3
            0 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
            0 GALACTOSE
            0 SPEIFIC
            0 LECTIN
         1592 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
           94 DIABET?
            0 SYMPTOM
            0 DISORDER
           85 DISORDERS
           85 DISORDER
                (DISORDER OR DISORDERS)
            3 DISEASE#
          234 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'FROSTI'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
            64 GAL
             3 GALS
            65 GAL
                (GAL OR GALS)
         29000 3
            0 GAL 3
                (GAL(W)3)
            64 GAL
             3 GALS
            65 GAL
                (GAL OR GALS)
         29000 3
            0 GAL-3
                (GAL(W)3)
            0 GALECTIN
            1 GALECTINS
            1 GALECTIN
                (GALECTIN OR GALECTINS)
         29000 3
            0 GALECTIN 3
                (GALECTIN(W)3)
            0 GALECTIN
            1 GALECTINS
            1 GALECTIN
                (GALECTIN OR GALECTINS)
         29000 3
            0 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
         1275 GALACTOSE
            4 GALACTOSES
         1277 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            0 SPEIFIC
          348 LECTIN
          511 LECTINS
          652 LECTIN
                (LECTIN OR LECTINS)
         29000 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
```

```
          4865 DIABET?
           129 SYMPTOM
          3648 SYMPTOMS
          3717 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
           657 DISORDER
          5197 DISORDERS
          5606 DISORDER
                 (DISORDER OR DISORDERS)
         37215 DISEASE#
         28759 CONDITION#
             0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
               TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
               DISORDER OR DISEASE# OR CONDITION#)

FILE 'FSTA'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
          1535 GAL
             4 GALS
          1538 GAL
                 (GAL OR GALS)
        185118 3
            10 GAL 3
                 (GAL(W)3)
          1535 GAL
             4 GALS
          1538 GAL
                 (GAL OR GALS)
        185118 3
            10 GAL-3
                 (GAL(W)3)
             1 GALECTIN
        185118 3
             1 GALECTIN 3
                 (GALECTIN(W)3)
             1 GALECTIN
        185118 3
             1 GALECTIN-3
                 (GALECTIN(W)3)
             0 LGALS3
          2881 GALACTOSE
             4 GALACTOSES
          2883 GALACTOSE
                 (GALACTOSE OR GALACTOSES)
             1 SPEIFIC
           551 LECTIN
           687 LECTINS
           929 LECTIN
                 (LECTIN OR LECTINS)
        185118 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             1 LEG3
          1542 DIABET?
           150 SYMPTOM
          2191 SYMPTOMS
          2277 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
           632 DISORDER
          2063 DISORDERS
          2539 DISORDER
                 (DISORDER OR DISORDERS)
         18661 DISEASE#
         59028 CONDITION#
             1 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
               TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
               DISORDER OR DISEASE# OR CONDITION#)
```

```
FILE 'GENBANK'
         6443 "GAL"
      7231364 "3"
           21 GAL 3
                ("GAL"(W)"3")
         6443 "GAL"
      7231364 "3"
           21 GAL-3
                ("GAL"(W)"3")
         2514 "GALECTIN"
      7231364 "3"
          436 GALECTIN 3
                ("GALECTIN"(W)"3")
         2514 "GALECTIN"
      7231364 "3"
          436 GALECTIN-3
                ("GALECTIN"(W)"3")
           34 LGALS3
         3357 "GALACTOSE"
            3 "SPEIFIC"
         7203 "LECTIN"
      7231364 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
           51 LEG3
        60342 DIABET?
         5178 SYMPTOM
         6400 DISORDER
       689346 DISEASE#
      2252288 CONDITION#
            7 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'HEALSAFE'
           61 "GAL"
            1 "GALS"
           62 "GAL"
                ("GAL" OR "GALS")
        17810 "3"
            0 GAL 3
                ("GAL"(W)"3")
           61 "GAL"
            1 "GALS"
           62 "GAL"
                ("GAL" OR "GALS")
        17810 "3"
            0 GAL-3
                ("GAL"(W)"3")
            0 "GALECTIN"
        17810 "3"
            0 GALECTIN 3
                ("GALECTIN"(W)"3")
            0 "GALECTIN"
        17810 "3"
            0 GALECTIN-3
                ("GALECTIN"(W)"3")
            0 LGALS3
           10 "GALACTOSE"
            0 "SPEIFIC"
            9 "LECTIN"
            6 "LECTINS"
           13 "LECTIN"
                ("LECTIN" OR "LECTINS")
        17810 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
            0 LEG3
          519 DIABET?
```

```
          824 SYMPTOM
         5265 SYMPTOMS
         5568 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         1086 DISORDER
         3044 DISORDERS
         3633 DISORDER
                (DISORDER OR DISORDERS)
        15297 DISEASE#
        16482 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'IMSRESEARCH'
            8 "GAL"
         6623 "3"
            0 GAL 3
                ("GAL"(W)"3")
            8 "GAL"
         6623 "3"
            0 GAL-3
                ("GAL"(W)"3")
            2 "GALECTIN"
            1 "GALECTINS"
            2 "GALECTIN"
                ("GALECTIN" OR "GALECTINS")
         6623 "3"
            0 GALECTIN 3
                ("GALECTIN"(W)"3")
            2 "GALECTIN"
            1 "GALECTINS"
            2 "GALECTIN"
                ("GALECTIN" OR "GALECTINS")
         6623 "3"
            0 GALECTIN-3
                ("GALECTIN"(W)"3")
            0 LGALS3
            8 "GALACTOSE"
            0 "SPEIFIC"
           10 "LECTIN"
            8 "LECTINS"
           17 "LECTIN"
                ("LECTIN" OR "LECTINS")
         6623 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
            0 LEG3
         1265 DIABET?
          149 SYMPTOM
          822 SYMPTOMS
          881 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
          690 DISORDER
         1766 DISORDERS
         2194 DISORDER
                (DISORDER OR DISORDERS)
         6691 DISEASE#
          702 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'NIOSHTIC'
           38 GAL
        49071 3
            0 GAL 3
                (GAL(W)3)
           38 GAL
```

```
 49071 3
     0 GAL-3
         (GAL(W)3)
     0 GALECTIN
 49071 3
     0 GALECTIN 3
         (GALECTIN(W)3)
     0 GALECTIN
 49071 3
     0 GALECTIN-3
         (GALECTIN(W)3)
     0 LGALS3
    67 GALACTOSE
     0 SPEIFIC
    45 LECTIN
    30 LECTINS
    60 LECTIN
         (LECTIN OR LECTINS)
 49071 3
     0 GALACTOSE SPEIFIC LECTIN 3
         (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
     0 LEG3
   603 DIABET?
  1416 SYMPTOM
 16500 SYMPTOMS
 16912 SYMPTOM
         (SYMPTOM OR SYMPTOMS)
  1027 DISORDER
 46202 DISORDERS
 46476 DISORDER
         (DISORDER OR DISORDERS)
 23696 DISEASE#
 22425 CONDITION#
     0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
       TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
       DISORDER OR DISEASE# OR CONDITION#)

FILE 'NTIS'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
  1100 GAL
    27 GALS
  1124 GAL
         (GAL OR GALS)
298671 3
     5 GAL 3
         (GAL(W)3)
  1100 GAL
    27 GALS
  1124 GAL
         (GAL OR GALS)
298671 3
     5 GAL-3
         (GAL(W)3)
    14 GALECTIN
298671 3
     9 GALECTIN 3
         (GALECTIN(W)3)
    14 GALECTIN
298671 3
     9 GALECTIN-3
         (GALECTIN(W)3)
     0 LGALS3
   228 GALACTOSE
     1 SPEIFIC
   108 LECTIN
    82 LECTINS
   147 LECTIN
         (LECTIN OR LECTINS)
```

```
        298671 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             0 LEG3
          1174 DIABET?
           667 SYMPTOM
          5781 SYMPTOMS
          6128 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
          3035 DISORDER
          5216 DISORDERS
          7875 DISORDER
                 (DISORDER OR DISORDERS)
         40536 DISEASE#
        211538 CONDITION#
             0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
               TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
               DISORDER OR DISEASE# OR CONDITION#)

FILE 'OCEAN'
           106 "GAL"
             4 "GALS"
           110 "GAL"
                 ("GAL" OR "GALS")
         45682 "3"
             4 GAL 3
                 ("GAL"(W)"3")
           106 "GAL"
             4 "GALS"
           110 "GAL"
                 ("GAL" OR "GALS")
         45682 "3"
             4 GAL-3
                 ("GAL"(W)"3")
             7 "GALECTIN"
             3 "GALECTINS"
             8 "GALECTIN"
                 ("GALECTIN" OR "GALECTINS")
         45682 "3"
             0 GALECTIN 3
                 ("GALECTIN"(W)"3")
             7 "GALECTIN"
             3 "GALECTINS"
             8 "GALECTIN"
                 ("GALECTIN" OR "GALECTINS")
         45682 "3"
             0 GALECTIN-3
                 ("GALECTIN"(W)"3")
             0 LGALS3
           268 "GALACTOSE"
             0 "SPEIFIC"
           166 "LECTIN"
           157 "LECTINS"
           221 "LECTIN"
                 ("LECTIN" OR "LECTINS")
         45682 "3"
             0 GALACTOSE SPEIFIC LECTIN 3
                 ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
             1 LEG3
            22 DIABET?
            50 SYMPTOM
           504 SYMPTOMS
           539 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
            49 DISORDER
           114 DISORDERS
           159 DISORDER
                 (DISORDER OR DISORDERS)
          8224 DISEASE#
```

```
        42091 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'PHAR'
           13 "GAL"
        20535 "3"
            0 GAL 3
                ("GAL"(W)"3")
           13 "GAL"
        20535 "3"
            0 GAL-3
                ("GAL"(W)"3")
           14 "GALECTIN"
        20535 "3"
           13 GALECTIN 3
                ("GALECTIN"(W)"3")
           14 "GALECTIN"
        20535 "3"
           13 GALECTIN-3
                ("GALECTIN"(W)"3")
           12 LGALS3
           26 "GALACTOSE"
            0 "SPEIFIC"
           54 "LECTIN"
            2 "LECTINS"
           56 "LECTIN"
                ("LECTIN" OR "LECTINS")
        20535 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
            0 LEG3
         1509 DIABET?
          133 SYMPTOM
          836 SYMPTOMS
          897 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
          446 DISORDER
         2638 DISORDERS
         2913 DISORDER
                (DISORDER OR DISORDERS)
         5633 DISEASE#
          678 CONDITION#
            2 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'PROMT'
        22895 "GAL"
         2445 "GALS"
        24856 "GAL"
                ("GAL" OR "GALS")
      2222643 "3"
           71 GAL 3
                ("GAL"(W)"3")
        22895 "GAL"
         2445 "GALS"
        24856 "GAL"
                ("GAL" OR "GALS")
      2222643 "3"
           71 GAL-3
                ("GAL"(W)"3")
           36 "GALECTIN"
            6 "GALECTINS"
           39 "GALECTIN"
                ("GALECTIN" OR "GALECTINS")
      2222643 "3"
           27 GALECTIN 3
```

```
              ("GALECTIN"(W)"3")
          36 "GALECTIN"
           6 "GALECTINS"
          39 "GALECTIN"
              ("GALECTIN" OR "GALECTINS")
     2222643 "3"
          27 GALECTIN-3
              ("GALECTIN"(W)"3")
           0 LGALS3
         349 "GALACTOSE"
           5 "SPEIFIC"
           1 "SPEIFICS"
           6 "SPEIFIC"
              ("SPEIFIC" OR "SPEIFICS")
         239 "LECTIN"
         160 "LECTINS"
         366 "LECTIN"
              ("LECTIN" OR "LECTINS")
     2222643 "3"
           0 GALACTOSE SPEIFIC LECTIN 3
              ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
           0 LEG3
       51038 DIABET?
        7931 SYMPTOM
       47000 SYMPTOMS
       51685 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
       22813 DISORDER
       49982 DISORDERS
       66074 DISORDER
              (DISORDER OR DISORDERS)
      302268 DISEASE#
      815273 CONDITION#
           8 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'PROUSDDR'
          24 "GAL"
      142384 "3"
           0 GAL 3
              ("GAL"(W)"3")
          24 "GAL"
      142384 "3"
           0 GAL-3
              ("GAL"(W)"3")
           3 "GALECTIN"
      142384 "3"
           0 GALECTIN 3
              ("GALECTIN"(W)"3")
           3 "GALECTIN"
      142384 "3"
           0 GALECTIN-3
              ("GALECTIN"(W)"3")
           0 LGALS3
          48 "GALACTOSE"
           0 "SPEIFIC"
          22 "LECTIN"
           1 "LECTINS"
          23 "LECTIN"
              ("LECTIN" OR "LECTINS")
      142384 "3"
           0 GALACTOSE SPEIFIC LECTIN 3
              ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
           0 LEG3
       14030 DIABET?
          25 SYMPTOM
        1237 SYMPTOMS
        1260 SYMPTOM
```

```
              (SYMPTOM OR SYMPTOMS)
         3189 DISORDER
        55258 DISORDERS
        55761 DISORDER
              (DISORDER OR DISORDERS)
        41234 DISEASE#
         8461 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'PS'
            0 GAL
         1829 3
            0 GAL 3
                (GAL(W)3)
            0 GAL
         1829 3
            0 GAL-3
                (GAL(W)3)
            0 GALECTIN
         1829 3
            0 GALECTIN 3
                (GALECTIN(W)3)
            0 GALECTIN
         1829 3
            0 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
            0 GALACTOSE
            0 SPEIFIC
            0 LECTIN
         1829 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
            8 DIABET?
            0 SYMPTOM
            2 SYMPTOMS
            2 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
            2 DISORDER
            5 DISORDERS
            7 DISORDER
                (DISORDER OR DISORDERS)
           12 DISEASE#
            0 CONDITION#
            0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'RDISCLOSURE'
           35 GAL
            4 GALS
           37 GAL
                (GAL OR GALS)
        17108 3
            1 GAL 3
                (GAL(W)3)
           35 GAL
            4 GALS
           37 GAL
                (GAL OR GALS)
        17108 3
            1 GAL-3
                (GAL(W)3)
            0 GALECTIN
        17108 3
            0 GALECTIN 3
```

```
              (GALECTIN(W)3)
           0 GALECTIN
       17108 3
           0 GALECTIN-3
              (GALECTIN(W)3)
           0 LGALS3
          11 GALACTOSE
           0 SPEIFIC
           3 LECTIN
       17108 3
           0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
           0 LEG3
          14 DIABET?
          12 SYMPTOM
          26 SYMPTOMS
          35 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
          12 DISORDER
          15 DISORDERS
          25 DISORDER
              (DISORDER OR DISORDERS)
         107 DISEASE#
        5248 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'SYNTHLINE'
           0 "GAL"
        8013 "3"
           0 GAL 3
              ("GAL"(W)"3")
           0 "GAL"
        8013 "3"
           0 GAL-3
              ("GAL"(W)"3")
           0 "GALECTIN"
        8013 "3"
           0 GALECTIN 3
              ("GALECTIN"(W)"3")
           0 "GALECTIN"
        8013 "3"
           0 GALECTIN-3
              ("GALECTIN"(W)"3")
           0 LGALS3
           8 "GALACTOSE"
           0 "SPEIFIC"
           0 "LECTIN"
        8013 "3"
           0 GALACTOSE SPEIFIC LECTIN 3
              ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
           0 LEG3
          47 DIABET?
           0 SYMPTOM
           3 SYMPTOMS
           3 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
           4 DISORDER
          69 DISORDERS
          73 DISORDER
              (DISORDER OR DISORDERS)
         138 DISEASE#
         842 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'VETB'
```

```
          12 GAL
        1840 3
           0 GAL 3
               (GAL(W)3)
          12 GAL
        1840 3
           0 GAL-3
               (GAL(W)3)
           0 GALECTIN
        1840 3
           0 GALECTIN 3
               (GALECTIN(W)3)
           0 GALECTIN
        1840 3
           0 GALECTIN-3
               (GALECTIN(W)3)
           0 LGALS3
          18 GALACTOSE
           0 SPEIFIC
           4 LECTIN
           3 LECTINS
           4 LECTIN
               (LECTIN OR LECTINS)
        1840 3
           0 GALACTOSE SPEIFIC LECTIN 3
               (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
           0 LEG3
          95 DIABET?
          16 SYMPTOM
          33 SYMPTOMS
          48 SYMPTOM
               (SYMPTOM OR SYMPTOMS)
          56 DISORDER
          81 DISORDERS
         130 DISORDER
               (DISORDER OR DISORDERS)
       21528 DISEASE#
         372 CONDITION#
           0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
             TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
             DISORDER OR DISEASE# OR CONDITION#)

FILE 'VETU'
          70 GAL
       47581 3
           0 GAL 3
               (GAL(W)3)
          70 GAL
       47581 3
           0 GAL-3
               (GAL(W)3)
           0 GALECTIN
           1 GALECTINS
           1 GALECTIN
               (GALECTIN OR GALECTINS)
       47581 3
           0 GALECTIN 3
               (GALECTIN(W)3)
           0 GALECTIN
           1 GALECTINS
           1 GALECTIN
               (GALECTIN OR GALECTINS)
       47581 3
           0 GALECTIN-3
               (GALECTIN(W)3)
           0 LGALS3
          63 GALACTOSE
           1 SPEIFIC
          36 LECTIN
```

```
     25 LECTINS
     53 LECTIN
          (LECTIN OR LECTINS)
  47581 3
      0 GALACTOSE SPEIFIC LECTIN 3
          (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
      0 LEG3
    437 DIABET?
    144 SYMPTOM
   2992 SYMPTOMS
   3067 SYMPTOM
          (SYMPTOM OR SYMPTOMS)
   2943 DISORDER
   1389 DISORDERS
   4113 DISORDER
          (DISORDER OR DISORDERS)
  19531 DISEASE#
   6363 CONDITION#
      0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
        TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
        DISORDER OR DISEASE# OR CONDITION#)

FILE 'WATER'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
   1684 GAL
     27 GALS
   1706 GAL
          (GAL OR GALS)
  82135 3
      4 GAL 3
          (GAL(W)3)
   1684 GAL
     27 GALS
   1706 GAL
          (GAL OR GALS)
  82135 3
      4 GAL-3
          (GAL(W)3)
      0 GALECTIN
  82135 3
      0 GALECTIN 3
          (GALECTIN(W)3)
      0 GALECTIN
  82135 3
      0 GALECTIN-3
          (GALECTIN(W)3)
      0 LGALS3
     79 GALACTOSE
      0 SPEIFIC
      6 LECTIN
      3 LECTINS
      8 LECTIN
          (LECTIN OR LECTINS)
  82135 3
      0 GALACTOSE SPEIFIC LECTIN 3
          (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
      0 LEG3
     13 DIABET?
     79 SYMPTOM
    848 SYMPTOMS
    900 SYMPTOM
          (SYMPTOM OR SYMPTOMS)
     62 DISORDER
    155 DISORDERS
    215 DISORDER
          (DISORDER OR DISORDERS)
   5186 DISEASE#
  75216 CONDITION#
```

```
            1 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'WPIDS'
         1903 GAL
          137 GALS
         2024 GAL
                (GAL OR GALS)
      4638627 3
            8 GAL 3
                (GAL(W)3)
         1903 GAL
          137 GALS
         2024 GAL
                (GAL OR GALS)
      4638627 3
            8 GAL-3
                (GAL(W)3)
          104 GALECTIN
           10 GALECTINS
          108 GALECTIN
                (GALECTIN OR GALECTINS)
      4638627 3
           45 GALECTIN 3
                (GALECTIN(W)3)
          104 GALECTIN
           10 GALECTINS
          108 GALECTIN
                (GALECTIN OR GALECTINS)
      4638627 3
           45 GALECTIN-3
                (GALECTIN(W)3)
            1 LGALS3
         4388 GALACTOSE
            4 GALACTOSES
         4390 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            7 SPEIFIC
         1888 LECTIN
          770 LECTINS
         2424 LECTIN
                (LECTIN OR LECTINS)
      4638627 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            1 LEG3
        35710 DIABET?
         3889 SYMPTOM
        12492 SYMPTOMS
        13972 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
        40721 DISORDER
        54460 DISORDERS
        67442 DISORDER
                (DISORDER OR DISORDERS)
       151547 DISEASE#
       740885 CONDITION#
           31 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
              TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
              DISORDER OR DISEASE# OR CONDITION#)

FILE 'WPIFV'
           12 GAL
        13719 3
            0 GAL 3
                (GAL(W)3)
           12 GAL
        13719 3
```

```
        0 GAL-3
            (GAL(W)3)
        0 GALECTIN
    13719 3
        0 GALECTIN 3
            (GALECTIN(W)3)
        0 GALECTIN
    13719 3
        0 GALECTIN-3
            (GALECTIN(W)3)
        0 LGALS3
       18 GALACTOSE
        0 SPEIFIC
       11 LECTIN
        5 LECTINS
       11 LECTIN
            (LECTIN OR LECTINS)
    13719 3
        0 GALACTOSE SPEIFIC LECTIN 3
            (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
        0 LEG3
      330 DIABET?
       35 SYMPTOM
       84 SYMPTOMS
      117 SYMPTOM
            (SYMPTOM OR SYMPTOMS)
      226 DISORDER
      511 DISORDERS
      644 DISORDER
            (DISORDER OR DISORDERS)
     1487 DISEASE#
     3670 CONDITION#
        0 (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
          TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
          DISORDER OR DISEASE# OR CONDITION#)

FILE 'WPINDEX'
     1903 GAL
      137 GALS
     2024 GAL
            (GAL OR GALS)
  4638627 3
        8 GAL 3
            (GAL(W)3)
     1903 GAL
      137 GALS
     2024 GAL
            (GAL OR GALS)
  4638627 3
        8 GAL-3
            (GAL(W)3)
      104 GALECTIN
       10 GALECTINS
      108 GALECTIN
            (GALECTIN OR GALECTINS)
  4638627 3
       45 GALECTIN 3
            (GALECTIN(W)3)
      104 GALECTIN
       10 GALECTINS
      108 GALECTIN
            (GALECTIN OR GALECTINS)
  4638627 3
       45 GALECTIN-3
            (GALECTIN(W)3)
        1 LGALS3
     4388 GALACTOSE
        4 GALACTOSES
     4390 GALACTOSE
```

```
                (GALACTOSE OR GALACTOSES)
             7  SPEIFIC
          1888  LECTIN
           770  LECTINS
          2424  LECTIN
                (LECTIN OR LECTINS)
       4638627  3
             0  GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             1  LEG3
         35710  DIABET?
          3889  SYMPTOM
         12492  SYMPTOMS
         13972  SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         40721  DISORDER
         54460  DISORDERS
         67442  DISORDER
                (DISORDER OR DISORDERS)
        151547  DISEASE#
        740885  CONDITION#
            31  (GAL 3 OR GAL-3  OR GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALAC
                TOSE SPEIFIC LECTIN 3  OR LEG3) (P)    (DIABET? OR SYMPTOM OR
                DISORDER OR DISEASE# OR CONDITION#)

L1    QUE (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTOSE SPE
          IFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER OR DISEASE#
           OR CONDITION#)

=>

=> D rank
F1          402   DGENE
F2          191   CAPLUS
F3          178*  PASCAL
F4          142*  ESBIOBASE
F5          135   BIOSIS
F6          132   SCISEARCH
F7          120   MEDLINE
F8          109   USPATFULL
F9          107   EMBASE
F10          51   TOXCENTER
F11          50*  BIOTECHNO
F12          31   WPIDS
F13          31   WPINDEX
F14          29   IFIPAT
F15          28   CANCERLIT
F16          21   LIFESCI
F17          16*  BIOTECHABS
F18          16*  BIOTECHDS
F19          13*  FEDRIP
F20          11   DISSABS
F21           9   DRUGU
F22           9   CROPU
F23           8   PROMT
F24           7   USPAT2
F25           7   GENBANK
F26           5   DDFU
F27           4   EMBAL
F28           4   AGRICOLA
F29           4   CABA
F30           2   PHAR
F31           1   ADISINSIGHT
F32           1   JICST-EPLUS
F33           1   NLDB
F34           1   PHIN
F35           1   CONFSCI
F36           1*  BIOENG
F37           1*  FSTA
```

F38 1* WATER

=> FIL F2-7 F9-20
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 24.78 24.99

FILE 'CAPLUS' ENTERED AT 14:05:42 ON 05 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PASCAL' ENTERED AT 14:05:42 ON 05 DEC 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:05:42 ON 05 DEC 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 14:05:42 ON 05 DEC 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 14:05:42 ON 05 DEC 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 14:05:42 ON 05 DEC 2005

FILE 'EMBASE' ENTERED AT 14:05:42 ON 05 DEC 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 14:05:42 ON 05 DEC 2005
COPYRIGHT (C) 2005 ACS

FILE 'BIOTECHNO' ENTERED AT 14:05:42 ON 05 DEC 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:05:42 ON 05 DEC 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'IFIPAT' ENTERED AT 14:05:42 ON 05 DEC 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'CANCERLIT' ENTERED AT 14:05:42 ON 05 DEC 2005

FILE 'LIFESCI' ENTERED AT 14:05:42 ON 05 DEC 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 14:05:42 ON 05 DEC 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'FEDRIP' ENTERED AT 14:05:42 ON 05 DEC 2005

FILE 'DISSABS' ENTERED AT 14:05:42 ON 05 DEC 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

=> s l1
FILE 'CAPLUS'
33957 GAL
2460 GALS
35876 GAL
(GAL OR GALS)

```
      6440362 3
          193 GAL 3
                (GAL(W)3)
        33957 GAL
         2460 GALS
        35876 GAL
                (GAL OR GALS)
      6440362 3
          193 GAL-3
                (GAL(W)3)
         1551 GALECTIN
          430 GALECTINS
         1607 GALECTIN
                (GALECTIN OR GALECTINS)
      6440362 3
          723 GALECTIN 3
                (GALECTIN(W)3)
         1551 GALECTIN
          430 GALECTINS
         1607 GALECTIN
                (GALECTIN OR GALECTINS)
      6440362 3
          723 GALECTIN-3
                (GALECTIN(W)3)
           33 LGALS3
        54327 GALACTOSE
          192 GALACTOSES
        54388 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            1 SPEIFIC
        26760 LECTIN
        27892 LECTINS
        39179 LECTIN
                (LECTIN OR LECTINS)
      6440362 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            2 LEG3
       119163 DIABET?
        10877 SYMPTOM
        77867 SYMPTOMS
        83816 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
       248854 DISORDER
       166416 DISORDERS
       370696 DISORDER
                (DISORDER OR DISORDERS)
       921353 DISEASE#
      1840233 CONDITION#
L2        191 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
              SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
               OR DISEASE# OR CONDITION#)

FILE 'PASCAL'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
         4360 GAL
           76 GALS
         4420 GAL
                (GAL OR GALS)
      2037415 3
           55 GAL 3
                (GAL(W)3)
         4360 GAL
           76 GALS
         4420 GAL
                (GAL OR GALS)
      2037415 3
           55 GAL-3
```

```
              (GAL(W)3)
          390 GALECTIN
           80 GALECTINS
          399 GALECTIN
              (GALECTIN OR GALECTINS)
      2037415 3
          252 GALECTIN 3
              (GALECTIN(W)3)
          390 GALECTIN
           80 GALECTINS
          399 GALECTIN
              (GALECTIN OR GALECTINS)
      2037415 3
          252 GALECTIN-3
              (GALECTIN(W)3)
            4 LGALS3
         8368 GALACTOSE
           27 GALACTOSES
         8382 GALACTOSE
              (GALACTOSE OR GALACTOSES)
            3 SPEIFIC
        11450 LECTIN
         3250 LECTINS
        12485 LECTIN
              (LECTIN OR LECTINS)
      2037415 3
            0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            3 LEG3
       102866 DIABET?
        26412 SYMPTOM
       109501 SYMPTOMS
       123248 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
       400448 DISORDER
       132925 DISORDERS
       492220 DISORDER
              (DISORDER OR DISORDERS)
      2188686 DISEASE#
       833322 CONDITION#
L3        178 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
              SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
               OR DISEASE# OR CONDITION#)

FILE 'ESBIOBASE'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
         5522 GAL
           27 GALS
         5539 GAL
              (GAL OR GALS)
       829781 3
           71 GAL 3
              (GAL(W)3)
         5522 GAL
           27 GALS
         5539 GAL
              (GAL OR GALS)
       829781 3
           71 GAL-3
              (GAL(W)3)
          902 GALECTIN
          280 GALECTINS
          938 GALECTIN
              (GALECTIN OR GALECTINS)
       829781 3
          439 GALECTIN 3
              (GALECTIN(W)3)
          902 GALECTIN
```

```
          280 GALECTINS
          938 GALECTIN
                (GALECTIN OR GALECTINS)
       829781 3
          439 GALECTIN-3
                (GALECTIN(W)3)
           12 LGALS3
         5804 GALACTOSE
           18 GALACTOSES
         5815 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            2 SPEIFIC
         8489 LECTIN
         3794 LECTINS
         9693 LECTIN
                (LECTIN OR LECTINS)
       829781 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            1 LEG3
        51349 DIABET?
        12602 SYMPTOM
        59426 SYMPTOMS
        65570 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
        37571 DISORDER
       145317 DISORDERS
       170419 DISORDER
                (DISORDER OR DISORDERS)
       678943 DISEASE#
       255374 CONDITION#
L4         142 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
               SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                OR DISEASE# OR CONDITION#)

FILE 'BIOSIS'
         11580 GAL
            58 GALS
         11619 GAL
                (GAL OR GALS)
       2577076 3
           138 GAL 3
                (GAL(W)3)
         11580 GAL
            58 GALS
         11619 GAL
                (GAL OR GALS)
       2577076 3
           138 GAL-3
                (GAL(W)3)
          1531 GALECTIN
           375 GALECTINS
          1593 GALECTIN
                (GALECTIN OR GALECTINS)
       2577076 3
           789 GALECTIN 3
                (GALECTIN(W)3)
          1531 GALECTIN
           375 GALECTINS
          1593 GALECTIN
                (GALECTIN OR GALECTINS)
       2577076 3
           789 GALECTIN-3
                (GALECTIN(W)3)
            18 LGALS3
         26599 GALACTOSE
            67 GALACTOSES
         26630 GALACTOSE
                (GALACTOSE OR GALACTOSES)
```

```
           42 SPEIFIC
        29253 LECTIN
        12409 LECTINS
        34652 LECTIN
                (LECTIN OR LECTINS)
      2577076 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            2 LEG3
       224777 DIABET?
        87370 SYMPTOM
       215117 SYMPTOMS
       271724 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
       165294 DISORDER
       349544 DISORDERS
       440744 DISORDER
                (DISORDER OR DISORDERS)
      2848236 DISEASE#
       798917 CONDITION#
L5        135 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
              SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
               OR DISEASE# OR CONDITION#)

FILE 'SCISEARCH'
        10628 GAL
          128 GALS
        10733 GAL
                (GAL OR GALS)
      2795057 3
          118 GAL 3
                (GAL(W)3)
        10628 GAL
          128 GALS
        10733 GAL
                (GAL OR GALS)
      2795057 3
          118 GAL-3
                (GAL(W)3)
         1560 GALECTIN
          462 GALECTINS
         1678 GALECTIN
                (GALECTIN OR GALECTINS)
      2795057 3
          799 GALECTIN 3
                (GALECTIN(W)3)
         1560 GALECTIN
          462 GALECTINS
         1678 GALECTIN
                (GALECTIN OR GALECTINS)
      2795057 3
          799 GALECTIN-3
                (GALECTIN(W)3)
           17 LGALS3
        15920 GALACTOSE
           49 GALACTOSES
        15947 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            5 SPEIFIC
        23348 LECTIN
        10349 LECTINS
        28453 LECTIN
                (LECTIN OR LECTINS)
      2795057 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            3 LEG3
       214457 DIABET?
        41780 SYMPTOM
```

```
        204906 SYMPTOMS
        227054 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
        159758 DISORDER
        188614 DISORDERS
        315866 DISORDER
                 (DISORDER OR DISORDERS)
       1222743 DISEASE#
       1076937 CONDITION#
L6          132 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
                SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                 OR DISEASE# OR CONDITION#)

FILE 'MEDLINE'
         10170 GAL
            44 GALS
         10195 GAL
                 (GAL OR GALS)
       2888534 3
           113 GAL 3
                 (GAL(W)3)
         10170 GAL
            44 GALS
         10195 GAL
                 (GAL OR GALS)
       2888534 3
           113 GAL-3
                 (GAL(W)3)
          1274 GALECTIN
           711 GALECTINS
          1608 GALECTIN
                 (GALECTIN OR GALECTINS)
       2888534 3
           719 GALECTIN 3
                 (GALECTIN(W)3)
          1274 GALECTIN
           711 GALECTINS
          1608 GALECTIN
                 (GALECTIN OR GALECTINS)
       2888534 3
           719 GALECTIN-3
                 (GALECTIN(W)3)
            14 LGALS3
         25066 GALACTOSE
            49 GALACTOSES
         25091 GALACTOSE
                 (GALACTOSE OR GALACTOSES)
             4 SPEIFIC
         22459 LECTIN
         29601 LECTINS
         39471 LECTIN
                 (LECTIN OR LECTINS)
       2888534 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             0 LEG3
        257916 DIABET?
         62447 SYMPTOM
        321408 SYMPTOMS
        357249 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
        223161 DISORDER
        703052 DISORDERS
        839211 DISORDER
                 (DISORDER OR DISORDERS)
       2935618 DISEASE#
        693583 CONDITION#
L7          120 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
                SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
```

```
                OR DISEASE# OR CONDITION#)

FILE 'EMBASE'
          9659 "GAL"
            41 "GALS"
          9682 "GAL"
                 ("GAL" OR "GALS")
       1763017 "3"
            98 GAL 3
                 ("GAL"(W)"3")
          9659 "GAL"
            41 "GALS"
          9682 "GAL"
                 ("GAL" OR "GALS")
       1763017 "3"
            98 GAL-3
                 ("GAL"(W)"3")
          1245 "GALECTIN"
           308 "GALECTINS"
          1259 "GALECTIN"
                 ("GALECTIN" OR "GALECTINS")
       1763017 "3"
           617 GALECTIN 3
                 ("GALECTIN"(W)"3")
          1245 "GALECTIN"
           308 "GALECTINS"
          1259 "GALECTIN"
                 ("GALECTIN" OR "GALECTINS")
       1763017 "3"
           617 GALECTIN-3
                 ("GALECTIN"(W)"3")
            13 LGALS3
         18013 "GALACTOSE"
            43 "GALACTOSES"
         18033 "GALACTOSE"
                 ("GALACTOSE" OR "GALACTOSES")
             5 "SPEIFIC"
         22701 "LECTIN"
          8160 "LECTINS"
         24761 "LECTIN"
                 ("LECTIN" OR "LECTINS")
       1763017 "3"
             0 GALACTOSE SPEIFIC LECTIN 3
                 ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
             0 LEG3
        221957 DIABET?
        127806 SYMPTOM
        303221 SYMPTOMS
        380608 SYMPTOM
                 (SYMPTOM OR SYMPTOMS)
        489775 DISORDER
        215022 DISORDERS
        633323 DISORDER
                 (DISORDER OR DISORDERS)
       1967989 DISEASE#
        630174 CONDITION#
L8         107 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
               SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                OR DISEASE# OR CONDITION#)

FILE 'TOXCENTER'
          8744 GAL
           263 GALS
          8956 GAL
                 (GAL OR GALS)
       1605513 3
            35 GAL 3
                 (GAL(W)3)
          8744 GAL
```

```
          263 GALS
         8956 GAL
                (GAL OR GALS)
      1605513 3
           35 GAL-3
                (GAL(W)3)
          399 GALECTIN
          123 GALECTINS
          433 GALECTIN
                (GALECTIN OR GALECTINS)
      1605513 3
          198 GALECTIN 3
                (GALECTIN(W)3)
          399 GALECTIN
          123 GALECTINS
          433 GALECTIN
                (GALECTIN OR GALECTINS)
      1605513 3
          198 GALECTIN-3
                (GALECTIN(W)3)
            1 LGALS3
        10408 GALACTOSE
           20 GALACTOSES
        10427 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            3 SPEIFIC
         9999 LECTIN
         7614 LECTINS
        14004 LECTIN
                (LECTIN OR LECTINS)
      1605513 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
        73889 DIABET?
        24076 SYMPTOM
       142262 SYMPTOMS
       155333 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
        90003 DISORDER
       222649 DISORDERS
       281521 DISORDER
                (DISORDER OR DISORDERS)
       849201 DISEASE#
       432920 CONDITION#
L9          51 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
               SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                OR DISEASE# OR CONDITION#)

FILE 'BIOTECHNO'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
          5467 GAL
            24 GALS
          5479 GAL
                 (GAL OR GALS)
        485790 3
            43 GAL 3
                 (GAL(W)3)
          5467 GAL
            24 GALS
          5479 GAL
                 (GAL OR GALS)
        485790 3
            43 GAL-3
                 (GAL(W)3)
           505 GALECTIN
           128 GALECTINS
           509 GALECTIN
```

```
                (GALECTIN OR GALECTINS)
        485790 3
           238 GALECTIN 3
                (GALECTIN(W)3)
           505 GALECTIN
           128 GALECTINS
           509 GALECTIN
                (GALECTIN OR GALECTINS)
        485790 3
           238 GALECTIN-3
                (GALECTIN(W)3)
             9 LGALS3
          7047 GALACTOSE
            16 GALACTOSES
          7055 GALACTOSE
                (GALACTOSE OR GALACTOSES)
             1 SPEIFIC
          8950 LECTIN
          2979 LECTINS
          9780 LECTIN
                (LECTIN OR LECTINS)
        485790 3
             0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             1 LEG3
         18109 DIABET?
          4745 SYMPTOM
         15478 SYMPTOMS
         18436 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         35405 DISORDER
         20670 DISORDERS
         51333 DISORDER
                (DISORDER OR DISORDERS)
        217011 DISEASE#
        130059 CONDITION#
L10          50 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
                SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                 OR DISEASE# OR CONDITION#)

FILE 'WPIDS'
             1903 GAL
              137 GALS
             2024 GAL
                (GAL OR GALS)
          4638627 3
                8 GAL 3
                (GAL(W)3)
             1903 GAL
              137 GALS
             2024 GAL
                (GAL OR GALS)
          4638627 3
                8 GAL-3
                (GAL(W)3)
              104 GALECTIN
               10 GALECTINS
              108 GALECTIN
                (GALECTIN OR GALECTINS)
          4638627 3
               45 GALECTIN 3
                (GALECTIN(W)3)
              104 GALECTIN
               10 GALECTINS
              108 GALECTIN
                (GALECTIN OR GALECTINS)
          4638627 3
               45 GALECTIN-3
                (GALECTIN(W)3)
```

```
            1 LGALS3
         4388 GALACTOSE
            4 GALACTOSES
         4390 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            7 SPEIFIC
         1888 LECTIN
          770 LECTINS
         2424 LECTIN
                (LECTIN OR LECTINS)
      4638627 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            1 LEG3
        35710 DIABET?
         3889 SYMPTOM
        12492 SYMPTOMS
        13972 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
        40721 DISORDER
        54460 DISORDERS
        67442 DISORDER
                (DISORDER OR DISORDERS)
       151547 DISEASE#
       740885 CONDITION#
L11         31 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
               SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                OR DISEASE# OR CONDITION#)

FILE 'IFIPAT'
         2548 GAL
           49 GALS
         2588 GAL
                (GAL OR GALS)
      4499320 3
           23 GAL 3
                (GAL(W)3)
         2548 GAL
           49 GALS
         2588 GAL
                (GAL OR GALS)
      4499320 3
           23 GAL-3
                (GAL(W)3)
           94 GALECTIN
           24 GALECTINS
           98 GALECTIN
                (GALECTIN OR GALECTINS)
      4499320 3
           43 GALECTIN 3
                (GALECTIN(W)3)
           94 GALECTIN
           24 GALECTINS
           98 GALECTIN
                (GALECTIN OR GALECTINS)
      4499320 3
           43 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
         3393 GALACTOSE
            1 GALACTOSES
         3394 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            3 SPEIFIC
         1632 LECTIN
          835 LECTINS
         2229 LECTIN
                (LECTIN OR LECTINS)
      4499320 3
```

```
            0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
        14963 DIABET?
         1948 SYMPTOM
         7892 SYMPTOMS
         9029 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
        20331 DISORDER
        36445 DISORDERS
        44997 DISORDER
                (DISORDER OR DISORDERS)
        75146 DISEASE#
       510092 CONDITION#
L12        29 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
              SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
               OR DISEASE# OR CONDITION#)

FILE 'CANCERLIT'
         2142 GAL
            3 GALS
         2145 GAL
                (GAL OR GALS)
       508438 3
           14 GAL 3
                (GAL(W)3)
         2142 GAL
            3 GALS
         2145 GAL
                (GAL OR GALS)
       508438 3
           14 GAL-3
                (GAL(W)3)
          306 GALECTIN
           83 GALECTINS
          315 GALECTIN
                (GALECTIN OR GALECTINS)
       508438 3
          190 GALECTIN 3
                (GALECTIN(W)3)
          306 GALECTIN
           83 GALECTINS
          315 GALECTIN
                (GALECTIN OR GALECTINS)
       508438 3
          190 GALECTIN-3
                (GALECTIN(W)3)
            1 LGALS3
         2797 GALACTOSE
            6 GALACTOSES
         2798 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            0 SPEIFIC
         6023 LECTIN
         4835 LECTINS
         8090 LECTIN
                (LECTIN OR LECTINS)
       508438 3
            0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
            0 LEG3
        12854 DIABET?
         9527 SYMPTOM
        51416 SYMPTOMS
        57843 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
        16218 DISORDER
        54993 DISORDERS
        67220 DISORDER
```

```
                (DISORDER OR DISORDERS)
        435031 DISEASE#
         98194 CONDITION#
L13         28 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
               SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                OR DISEASE# OR CONDITION#)

FILE 'LIFESCI'
           4162 "GAL"
             26 "GALS"
           4174 "GAL"
                  ("GAL" OR "GALS")
        447770 "3"
             33 GAL 3
                  ("GAL"(W)"3")
           4162 "GAL"
             26 "GALS"
           4174 "GAL"
                  ("GAL" OR "GALS")
        447770 "3"
             33 GAL-3
                  ("GAL"(W)"3")
            248 "GALECTIN"
             64 "GALECTINS"
            258 "GALECTIN"
                  ("GALECTIN" OR "GALECTINS")
        447770 "3"
             96 GALECTIN 3
                  ("GALECTIN"(W)"3")
            248 "GALECTIN"
             64 "GALECTINS"
            258 "GALECTIN"
                  ("GALECTIN" OR "GALECTINS")
        447770 "3"
             96 GALECTIN-3
                  ("GALECTIN"(W)"3")
              7 LGALS3
           6390 "GALACTOSE"
             12 "GALACTOSES"
           6397 "GALACTOSE"
                  ("GALACTOSE" OR "GALACTOSES")
              1 "SPEIFIC"
           7872 "LECTIN"
           5112 "LECTINS"
           9504 "LECTIN"
                  ("LECTIN" OR "LECTINS")
        447770 "3"
              0 GALACTOSE SPEIFIC LECTIN 3
                  ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
              0 LEG3
          13598 DIABET?
           4297 SYMPTOM
          32691 SYMPTOMS
          34989 SYMPTOM
                  (SYMPTOM OR SYMPTOMS)
          15022 DISORDER
          25743 DISORDERS
          37837 DISORDER
                  (DISORDER OR DISORDERS)
        252140 DISEASE#
        204808 CONDITION#
L14         21 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
               SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                OR DISEASE# OR CONDITION#)

FILE 'BIOTECHDS'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
           1844 GAL
```

```
          6 GALS
       1846 GAL
              (GAL OR GALS)
     158028 3
          7 GAL 3
              (GAL(W)3)
       1844 GAL
          6 GALS
       1846 GAL
              (GAL OR GALS)
     158028 3
          7 GAL-3
              (GAL(W)3)
         77 GALECTIN
          8 GALECTINS
         77 GALECTIN
              (GALECTIN OR GALECTINS)
     158028 3
         21 GALECTIN 3
              (GALECTIN(W)3)
         77 GALECTIN
          8 GALECTINS
         77 GALECTIN
              (GALECTIN OR GALECTINS)
     158028 3
         21 GALECTIN-3
              (GALECTIN(W)3)
          1 LGALS3
       3126 GALACTOSE
          6 GALACTOSES
       3130 GALACTOSE
              (GALACTOSE OR GALACTOSES)
          1 SPEIFIC
       1186 LECTIN
        353 LECTINS
       1362 LECTIN
              (LECTIN OR LECTINS)
     158028 3
          0 GALACTOSE SPEIFIC LECTIN 3
              (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
          0 LEG3
       8055 DIABET?
        481 SYMPTOM
       2218 SYMPTOMS
       2524 SYMPTOM
              (SYMPTOM OR SYMPTOMS)
      13438 DISORDER
      12360 DISORDERS
      17950 DISORDER
              (DISORDER OR DISORDERS)
      61465 DISEASE#
      60972 CONDITION#
L15      16 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
            SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
             OR DISEASE# OR CONDITION#)

FILE 'FEDRIP'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LEG3) (P) '
         270 GAL
           6 GALS
         276 GAL
               (GAL OR GALS)
       86483 3
           2 GAL 3
               (GAL(W)3)
         270 GAL
           6 GALS
         276 GAL
```

```
                (GAL OR GALS)
         86483 3
             2 GAL-3
                (GAL(W)3)
            46 GALECTIN
            15 GALECTINS
            48 GALECTIN
                (GALECTIN OR GALECTINS)
         86483 3
            25 GALECTIN 3
                (GALECTIN(W)3)
            46 GALECTIN
            15 GALECTINS
            48 GALECTIN
                (GALECTIN OR GALECTINS)
         86483 3
            25 GALECTIN-3
                (GALECTIN(W)3)
             0 LGALS3
           167 GALACTOSE
             2 SPEIFIC
           254 LECTIN
            99 LECTINS
           301 LECTIN
                (LECTIN OR LECTINS)
         86483 3
             0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             0 LEG3
          6589 DIABET?
          1942 SYMPTOM
          6544 SYMPTOMS
          7474 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         21583 DISORDER
         10449 DISORDERS
         28119 DISORDER
                (DISORDER OR DISORDERS)
         54769 DISEASE#
         31777 CONDITION#
L16         13 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
               SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                OR DISEASE# OR CONDITION#)

FILE 'DISSABS'
            954 GAL
             25 GALS
            972 GAL
                (GAL OR GALS)
        287467 3
             30 GAL 3
                (GAL(W)3)
            954 GAL
             25 GALS
            972 GAL
                (GAL OR GALS)
        287467 3
             30 GAL-3
                (GAL(W)3)
             55 GALECTIN
             19 GALECTINS
             56 GALECTIN
                (GALECTIN OR GALECTINS)
        287467 3
             31 GALECTIN 3
                (GALECTIN(W)3)
             55 GALECTIN
             19 GALECTINS
             56 GALECTIN
```

```
                (GALECTIN OR GALECTINS)
        287467 3
            31 GALECTIN-3
                (GALECTIN(W)3)
             1 LGALS3
          1368 GALACTOSE
             1 GALACTOSES
          1369 GALACTOSE
                (GALACTOSE OR GALACTOSES)
             0 SPEIFIC
          1170 LECTIN
           545 LECTINS
          1416 LECTIN
                (LECTIN OR LECTINS)
        287467 3
             0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
             0 LEG3
          5275 DIABET?
          5770 SYMPTOM
         15533 SYMPTOMS
         18626 SYMPTOM
                (SYMPTOM OR SYMPTOMS)
         14668 DISORDER
         11092 DISORDERS
         22405 DISORDER
                (DISORDER OR DISORDERS)
         38063 DISEASE#
        179899 CONDITION#
L17          11 (GAL 3 OR GAL-3 OR GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTO
               SE SPEIFIC LECTIN 3 OR LEG3) (P) (DIABET? OR SYMPTOM OR DISORDER
                OR DISEASE# OR CONDITION#)

TOTAL FOR ALL FILES
L18        1255 L1

=> s (Gal-3 or Gal 3 galectin 3 or galectin-3 or LGALS3  or galactose speific lectin 3) (P)  (
diabet? or diabet? (A) symptom?)
FILE 'CAPLUS'
          33957 GAL
           2460 GALS
          35876 GAL
                (GAL OR GALS)
        6440362 3
            193 GAL-3
                (GAL(W)3)
          33957 GAL
           2460 GALS
          35876 GAL
                (GAL OR GALS)
        6440362 3
           1551 GALECTIN
            430 GALECTINS
           1607 GALECTIN
                (GALECTIN OR GALECTINS)
        6440362 3
              1 GAL 3 GALECTIN 3
                (GAL(W)3(W)GALECTIN(W)3)
           1551 GALECTIN
            430 GALECTINS
           1607 GALECTIN
                (GALECTIN OR GALECTINS)
        6440362 3
            723 GALECTIN-3
                (GALECTIN(W)3)
             33 LGALS3
          54327 GALACTOSE
            192 GALACTOSES
          54388 GALACTOSE
```

```
                (GALACTOSE OR GALACTOSES)
            1 SPEIFIC
        26760 LECTIN
        27892 LECTINS
        39179 LECTIN
                (LECTIN OR LECTINS)
      6440362 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
       119163 DIABET?
       119163 DIABET?
        91995 SYMPTOM?
L19        24 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'PASCAL'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED '3) (P) '
         4360 GAL
           76 GALS
         4420 GAL
                (GAL OR GALS)
      2037415 3
           55 GAL-3
                (GAL(W)3)
         4360 GAL
           76 GALS
         4420 GAL
                (GAL OR GALS)
      2037415 3
          390 GALECTIN
           80 GALECTINS
          399 GALECTIN
                (GALECTIN OR GALECTINS)
      2037415 3
            0 GAL 3 GALECTIN 3
                (GAL(W)3(W)GALECTIN(W)3)
          390 GALECTIN
           80 GALECTINS
          399 GALECTIN
                (GALECTIN OR GALECTINS)
      2037415 3
          252 GALECTIN-3
                (GALECTIN(W)3)
            4 LGALS3
         8368 GALACTOSE
           27 GALACTOSES
         8382 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            3 SPEIFIC
        11450 LECTIN
         3250 LECTINS
        12485 LECTIN
                (LECTIN OR LECTINS)
      2037415 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
       102866 DIABET?
       102866 DIABET?
       219064 SYMPTOM?
          107 DIABET? (A) SYMPTOM?
L20          7 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'ESBIOBASE'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED '3) (P) '
         5522 GAL
           27 GALS
```

```
          5539 GAL
                 (GAL OR GALS)
        829781 3
            71 GAL-3
                 (GAL(W)3)
          5522 GAL
            27 GALS
          5539 GAL
                 (GAL OR GALS)
        829781 3
           902 GALECTIN
           280 GALECTINS
           938 GALECTIN
                 (GALECTIN OR GALECTINS)
        829781 3
             0 GAL 3 GALECTIN 3
                 (GAL(W)3(W)GALECTIN(W)3)
           902 GALECTIN
           280 GALECTINS
           938 GALECTIN
                 (GALECTIN OR GALECTINS)
        829781 3
           439 GALECTIN-3
                 (GALECTIN(W)3)
            12 LGALS3
          5804 GALACTOSE
            18 GALACTOSES
          5815 GALACTOSE
                 (GALACTOSE OR GALACTOSES)
             2 SPEIFIC
          8489 LECTIN
          3794 LECTINS
          9693 LECTIN
                 (LECTIN OR LECTINS)
        829781 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         51349 DIABET?
         51349 DIABET?
         75678 SYMPTOM?
            55 DIABET? (A) SYMPTOM?
L21         11 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'BIOSIS'
         11580 GAL
            58 GALS
          11619 GAL
                 (GAL OR GALS)
       2577076 3
           138 GAL-3
                 (GAL(W)3)
          11580 GAL
             58 GALS
          11619 GAL
                 (GAL OR GALS)
       2577076 3
           1531 GALECTIN
            375 GALECTINS
           1593 GALECTIN
                 (GALECTIN OR GALECTINS)
       2577076 3
              0 GAL 3 GALECTIN 3
                 (GAL(W)3(W)GALECTIN(W)3)
           1531 GALECTIN
            375 GALECTINS
           1593 GALECTIN
                 (GALECTIN OR GALECTINS)
       2577076 3
```

```
          789 GALECTIN-3
                (GALECTIN(W)3)
           18 LGALS3
        26599 GALACTOSE
           67 GALACTOSES
        26630 GALACTOSE
                (GALACTOSE OR GALACTOSES)
           42 SPEIFIC
        29253 LECTIN
        12409 LECTINS
        34652 LECTIN
                (LECTIN OR LECTINS)
      2577076 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
       224777 DIABET?
       224777 DIABET?
       310831 SYMPTOM?
L22         28 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'SCISEARCH'
        10628 GAL
          128 GALS
        10733 GAL
                (GAL OR GALS)
      2795057 3
          118 GAL-3
                (GAL(W)3)
        10628 GAL
          128 GALS
        10733 GAL
                (GAL OR GALS)
      2795057 3
         1560 GALECTIN
          462 GALECTINS
         1678 GALECTIN
                (GALECTIN OR GALECTINS)
      2795057 3
            0 GAL 3 GALECTIN 3
                (GAL(W)3(W)GALECTIN(W)3)
         1560 GALECTIN
          462 GALECTINS
         1678 GALECTIN
                (GALECTIN OR GALECTINS)
      2795057 3
          799 GALECTIN-3
                (GALECTIN(W)3)
           17 LGALS3
        15920 GALACTOSE
           49 GALACTOSES
        15947 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            5 SPEIFIC
        23348 LECTIN
        10349 LECTINS
        28453 LECTIN
                (LECTIN OR LECTINS)
      2795057 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
       214457 DIABET?
       214457 DIABET?
       266658 SYMPTOM?
L23         23 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'MEDLINE'
        10170 GAL
```

```
         44 GALS
      10195 GAL
               (GAL OR GALS)
    2888534 3
        113 GAL-3
               (GAL(W)3)
      10170 GAL
         44 GALS
      10195 GAL
               (GAL OR GALS)
    2888534 3
       1274 GALECTIN
        711 GALECTINS
       1608 GALECTIN
               (GALECTIN OR GALECTINS)
    2888534 3
          0 GAL 3 GALECTIN 3
               (GAL(W)3(W)GALECTIN(W)3)
       1274 GALECTIN
        711 GALECTINS
       1608 GALECTIN
               (GALECTIN OR GALECTINS)
    2888534 3
        719 GALECTIN-3
               (GALECTIN(W)3)
         14 LGALS3
      25066 GALACTOSE
         49 GALACTOSES
      25091 GALACTOSE
               (GALACTOSE OR GALACTOSES)
          4 SPEIFIC
      22459 LECTIN
      29601 LECTINS
      39471 LECTIN
               (LECTIN OR LECTINS)
    2888534 3
          0 GALACTOSE SPEIFIC LECTIN 3
               (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
     257916 DIABET?
     257916 DIABET?
     418437 SYMPTOM?
L24      17 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
             SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'EMBASE'
       9659 "GAL"
         41 "GALS"
       9682 "GAL"
               ("GAL" OR "GALS")
    1763017 "3"
         98 GAL-3
               ("GAL"(W)"3")
       9659 "GAL"
         41 "GALS"
       9682 "GAL"
               ("GAL" OR "GALS")
    1763017 "3"
       1245 "GALECTIN"
        308 "GALECTINS"
       1259 "GALECTIN"
               ("GALECTIN" OR "GALECTINS")
    1763017 "3"
          0 GAL 3 GALECTIN 3
               ("GAL"(W)"3"(W)"GALECTIN"(W)"3")
       1245 "GALECTIN"
        308 "GALECTINS"
       1259 "GALECTIN"
               ("GALECTIN" OR "GALECTINS")
    1763017 "3"
```

```
          617 GALECTIN-3
                ("GALECTIN"(W)"3")
           13 LGALS3
        18013 "GALACTOSE"
           43 "GALACTOSES"
        18033 "GALACTOSE"
                ("GALACTOSE" OR "GALACTOSES")
            5 "SPEIFIC"
        22701 "LECTIN"
         8160 "LECTINS"
        24761 "LECTIN"
                ("LECTIN" OR "LECTINS")
      1763017 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
       221957 DIABET?
       221957 DIABET?
       454594 SYMPTOM?
L25        13 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
              SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'TOXCENTER'
        8744 GAL
         263 GALS
        8956 GAL
                (GAL OR GALS)
      1605513 3
          35 GAL-3
                (GAL(W)3)
        8744 GAL
         263 GALS
        8956 GAL
                (GAL OR GALS)
      1605513 3
         399 GALECTIN
         123 GALECTINS
         433 GALECTIN
                (GALECTIN OR GALECTINS)
      1605513 3
            0 GAL 3 GALECTIN 3
                (GAL(W)3(W)GALECTIN(W)3)
         399 GALECTIN
         123 GALECTINS
         433 GALECTIN
                (GALECTIN OR GALECTINS)
      1605513 3
         198 GALECTIN-3
                (GALECTIN(W)3)
           1 LGALS3
       10408 GALACTOSE
          20 GALACTOSES
       10427 GALACTOSE
                (GALACTOSE OR GALACTOSES)
           3 SPEIFIC
        9999 LECTIN
        7614 LECTINS
       14004 LECTIN
                (LECTIN OR LECTINS)
      1605513 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
       73889 DIABET?
       73889 DIABET?
      172289 SYMPTOM?
L26        14 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
              SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'BIOTECHNO'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
```

```
FIELD CODE - 'AND' OPERATOR ASSUMED '3) (P) '
          5467 GAL
            24 GALS
          5479 GAL
                 (GAL OR GALS)
        485790 3
            43 GAL-3
                 (GAL(W)3)
          5467 GAL
            24 GALS
          5479 GAL
                 (GAL OR GALS)
        485790 3
           505 GALECTIN
           128 GALECTINS
           509 GALECTIN
                 (GALECTIN OR GALECTINS)
        485790 3
             0 GAL 3 GALECTIN 3
                 (GAL(W)3(W)GALECTIN(W)3)
           505 GALECTIN
           128 GALECTINS
           509 GALECTIN
                 (GALECTIN OR GALECTINS)
        485790 3
           238 GALECTIN-3
                 (GALECTIN(W)3)
             9 LGALS3
          7047 GALACTOSE
            16 GALACTOSES
          7055 GALACTOSE
                 (GALACTOSE OR GALACTOSES)
             1 SPEIFIC
          8950 LECTIN
          2979 LECTINS
          9780 LECTIN
                 (LECTIN OR LECTINS)
        485790 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         18109 DIABET?
         18109 DIABET?
         22208 SYMPTOM?
            15 DIABET? (A) SYMPTOM?
L27          5 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'WPIDS'
          1903 GAL
           137 GALS
          2024 GAL
                 (GAL OR GALS)
       4638627 3
             8 GAL-3
                 (GAL(W)3)
          1903 GAL
           137 GALS
          2024 GAL
                 (GAL OR GALS)
       4638627 3
           104 GALECTIN
            10 GALECTINS
           108 GALECTIN
                 (GALECTIN OR GALECTINS)
       4638627 3
             0 GAL 3 GALECTIN 3
                 (GAL(W)3(W)GALECTIN(W)3)
           104 GALECTIN
            10 GALECTINS
```

```
          108 GALECTIN
                (GALECTIN OR GALECTINS)
      4638627 3
           45 GALECTIN-3
                (GALECTIN(W)3)
            1 LGALS3
         4388 GALACTOSE
            4 GALACTOSES
         4390 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            7 SPEIFIC
         1888 LECTIN
          770 LECTINS
         2424 LECTIN
                (LECTIN OR LECTINS)
      4638627 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
        35710 DIABET?
        35710 DIABET?
        14757 SYMPTOM?
L28         5 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'IFIPAT'
         2548 GAL
           49 GALS
         2588 GAL
                (GAL OR GALS)
      4499320 3
           23 GAL-3
                (GAL(W)3)
         2548 GAL
           49 GALS
         2588 GAL
                (GAL OR GALS)
      4499320 3
           94 GALECTIN
           24 GALECTINS
           98 GALECTIN
                (GALECTIN OR GALECTINS)
      4499320 3
            0 GAL 3 GALECTIN 3
                (GAL(W)3(W)GALECTIN(W)3)
           94 GALECTIN
           24 GALECTINS
           98 GALECTIN
                (GALECTIN OR GALECTINS)
      4499320 3
           43 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
         3393 GALACTOSE
            1 GALACTOSES
         3394 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            3 SPEIFIC
         1632 LECTIN
          835 LECTINS
         2229 LECTIN
                (LECTIN OR LECTINS)
      4499320 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
        14963 DIABET?
        14963 DIABET?
         9562 SYMPTOM?
L29         1 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)
```

```
FILE 'CANCERLIT'
          2142 GAL
             3 GALS
          2145 GAL
                 (GAL OR GALS)
        508438 3
            14 GAL-3
                 (GAL(W)3)
          2142 GAL
             3 GALS
          2145 GAL
                 (GAL OR GALS)
        508438 3
           306 GALECTIN
            83 GALECTINS
           315 GALECTIN
                 (GALECTIN OR GALECTINS)
        508438 3
             0 GAL 3 GALECTIN 3
                 (GAL(W)3(W)GALECTIN(W)3)
           306 GALECTIN
            83 GALECTINS
           315 GALECTIN
                 (GALECTIN OR GALECTINS)
        508438 3
           190 GALECTIN-3
                 (GALECTIN(W)3)
             1 LGALS3
          2797 GALACTOSE
             6 GALACTOSES
          2798 GALACTOSE
                 (GALACTOSE OR GALACTOSES)
             0 SPEIFIC
          6023 LECTIN
          4835 LECTINS
          8090 LECTIN
                 (LECTIN OR LECTINS)
        508438 3
             0 GALACTOSE SPEIFIC LECTIN 3
                 (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         12854 DIABET?
         12854 DIABET?
         67825 SYMPTOM?
L30         1 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
               SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'LIFESCI'
          4162 "GAL"
            26 "GALS"
          4174 "GAL"
                 ("GAL" OR "GALS")
        447770 "3"
            33 GAL-3
                 ("GAL"(W)"3")
          4162 "GAL"
            26 "GALS"
          4174 "GAL"
                 ("GAL" OR "GALS")
        447770 "3"
           248 "GALECTIN"
            64 "GALECTINS"
           258 "GALECTIN"
                 ("GALECTIN" OR "GALECTINS")
        447770 "3"
             0 GAL 3 GALECTIN 3
                 ("GAL"(W)"3"(W)"GALECTIN"(W)"3")
           248 "GALECTIN"
            64 "GALECTINS"
```

```
          258 "GALECTIN"
                ("GALECTIN" OR "GALECTINS")
       447770 "3"
           96 GALECTIN-3
                ("GALECTIN"(W)"3")
            7 LGALS3
         6390 "GALACTOSE"
           12 "GALACTOSES"
         6397 "GALACTOSE"
                ("GALACTOSE" OR "GALACTOSES")
            1 "SPEIFIC"
         7872 "LECTIN"
         5112 "LECTINS"
         9504 "LECTIN"
                ("LECTIN" OR "LECTINS")
       447770 "3"
            0 GALACTOSE SPEIFIC LECTIN 3
                ("GALACTOSE"(W)"SPEIFIC"(W)"LECTIN"(W)"3")
        13598 DIABET?
        13598 DIABET?
        40236 SYMPTOM?
L31         1 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
              SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'BIOTECHDS'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED '3) (P) '
         1844 GAL
            6 GALS
         1846 GAL
                (GAL OR GALS)
       158028 3
            7 GAL-3
                (GAL(W)3)
         1844 GAL
            6 GALS
         1846 GAL
                (GAL OR GALS)
       158028 3
           77 GALECTIN
            8 GALECTINS
           77 GALECTIN
                (GALECTIN OR GALECTINS)
       158028 3
            0 GAL 3 GALECTIN 3
                (GAL(W)3(W)GALECTIN(W)3)
           77 GALECTIN
            8 GALECTINS
           77 GALECTIN
                (GALECTIN OR GALECTINS)
       158028 3
           21 GALECTIN-3
                (GALECTIN(W)3)
            1 LGALS3
         3126 GALACTOSE
            6 GALACTOSES
         3130 GALACTOSE
                (GALACTOSE OR GALACTOSES)
            1 SPEIFIC
         1186 LECTIN
          353 LECTINS
         1362 LECTIN
                (LECTIN OR LECTINS)
       158028 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         8055 DIABET?
         8055 DIABET?
         2696 SYMPTOM?
```

```
            7 DIABET? (A) SYMPTOM?
L32         2 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
              SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'FEDRIP'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED '3) (P) '
          270 GAL
            6 GALS
          276 GAL
                (GAL OR GALS)
        86483 3
            2 GAL-3
                (GAL(W)3)
          270 GAL
            6 GALS
          276 GAL
                (GAL OR GALS)
        86483 3
           46 GALECTIN
           15 GALECTINS
           48 GALECTIN
                (GALECTIN OR GALECTINS)
        86483 3
            0 GAL 3 GALECTIN 3
                (GAL(W)3(W)GALECTIN(W)3)
           46 GALECTIN
           15 GALECTINS
           48 GALECTIN
                (GALECTIN OR GALECTINS)
        86483 3
           25 GALECTIN-3
                (GALECTIN(W)3)
            0 LGALS3
          167 GALACTOSE
            2 SPEIFIC
          254 LECTIN
           99 LECTINS
          301 LECTIN
                (LECTIN OR LECTINS)
        86483 3
            0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
         6589 DIABET?
         6589 DIABET?
         8426 SYMPTOM?
            9 DIABET? (A) SYMPTOM?
L33         0 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
              SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

FILE 'DISSABS'
          954 GAL
           25 GALS
          972 GAL
                (GAL OR GALS)
       287467 3
           30 GAL-3
                (GAL(W)3)
          954 GAL
           25 GALS
          972 GAL
                (GAL OR GALS)
       287467 3
           55 GALECTIN
           19 GALECTINS
           56 GALECTIN
                (GALECTIN OR GALECTINS)
       287467 3
            0 GAL 3 GALECTIN 3
```

```
                (GAL(W)3(W)GALECTIN(W)3)
            55 GALECTIN
            19 GALECTINS
            56 GALECTIN
                (GALECTIN OR GALECTINS)
        287467 3
            31 GALECTIN-3
                (GALECTIN(W)3)
             1 LGALS3
          1368 GALACTOSE
             1 GALACTOSES
          1369 GALACTOSE
                (GALACTOSE OR GALACTOSES)
             0 SPEIFIC
          1170 LECTIN
           545 LECTINS
          1416 LECTIN
                (LECTIN OR LECTINS)
        287467 3
             0 GALACTOSE SPEIFIC LECTIN 3
                (GALACTOSE(W)SPEIFIC(W)LECTIN(W)3)
          5275 DIABET?
          5275 DIABET?
         22057 SYMPTOM?
L34           0 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3  OR GALACTOSE
                 SPEIFIC LECTIN 3) (P)  ( DIABET? OR DIABET? (A) SYMPTOM?)

TOTAL FOR ALL FILES
L35         152 (GAL-3 OR GAL 3 GALECTIN 3 OR GALECTIN-3 OR LGALS3 OR GALACTOSE
                SPEIFIC LECTIN 3) (P) (DIABET? OR DIABET? (A) SYMPTOM?)

=> dup rem l35
DUPLICATE IS NOT AVAILABLE IN 'FEDRIP'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L35
L36           59 DUP REM L35 (93 DUPLICATES REMOVED)

=> d L36 1-59 ibib abs

L36  ANSWER 1 OF 59  WPIDS  COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER:     2005-759023 [77]   WPIDS
DOC. NO. CPI:         C2005-231602
TITLE:                Prophylactic and/or therapeutic agent of diabetic
                      nephropathy and symptoms of diabetic nephropathy such as
                      proteinuria, renomegaly, comprises polypeptide capable of
                      binding specifically to beta-galactoside, as active
                      ingredient.
DERWENT CLASS:        B04
INVENTOR(S):          BABA, M; EGUCHI, J; MAKINO, H; WADA, J
PATENT ASSIGNEE(S):   (PROT-N) PROTEGENE KK; (UYOK-N) UNIV OKAYAMA; (PROT-N)
                      PROTEGENE INC
COUNTRY COUNT:        110
PATENT INFORMATION:

     PATENT NO        KIND DATE     WEEK      LA   PG
     ---------------------------------------------
     WO 2005102376    A1 20051103 (200577)* JA   42
        RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IS IT
            KE LS LT LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG
            ZM ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
            DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM
            KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
            OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA
            UG US UZ VC VN YU ZA ZM ZW
     JP 2005314252    A  20051110 (200577)       26

APPLICATION DETAILS:
```

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| WO 2005102376 | A1 | WO 2005-JP8068 | 20050427 |
| JP 2005314252 | A | JP 2004-132275 | 20040427 |

PRIORITY APPLN. INFO: JP 2004-132275 20040427
AN 2005-759023 [77] WPIDS
AB WO2005102376 A UPAB: 20051130
NOVELTY - Prophylactic and/or therapeutic agent of **diabetic** nephropathy, comprising a polypeptide capable of binding specifically to beta -galactoside, and having an amino acid sequence of (SEQ ID Number 1), or an amino acid sequence having deletion, substitution or addition of one or more amino acids in (SEQ ID Number 1), as an active ingredient, is new.

ACTIVITY - Antidiabetic; Nephrotropic. No biological data is given.

MECHANISM OF ACTION - Inhibits activity of **galectin-3**.

USE - (I) is useful for preventing or treating **diabetic** nephropathy (claimed), and symptoms of **diabetic** nephropathy such as proteinuria, glomerulus enlargement, renomegaly, arteriocapillary sclerosis, etc.

ADVANTAGE - (I) binds specifically to beta galactoside and thus contributes in the treatment of **diabetic** nephropathy.

DESCRIPTION OF DRAWING(S) - The figure is a graph representing the albumin excretion amount in urine of 9 groups of mice.

Dwg.1/9

L36 ANSWER 2 OF 59 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2005-676492 [69] WPIDS
DOC. NO. NON-CPI: N2005-554865
DOC. NO. CPI: C2005-205323
TITLE: Array of glycan molecules, useful for detecting transplant tissue rejection, has solid support and library of glycan molecules being covalently attached to solid support through amide or amine group.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BLIXT, O; HEAD, S
PATENT ASSIGNEE(S): (BLIX-I) BLIXT O; (HEAD-I) HEAD S; (SCRI) SCRIPPS RES INST
COUNTRY COUNT: 109
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 2005088310 | A2 | 20050922 | (200569)* | EN | 228 |

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IS IT KE LS LT LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| WO 2005088310 | A2 | WO 2005-US7370 | 20050307 |

PRIORITY APPLN. INFO: US 2004-629833P 20041119; US 2004-550667P 20040305; US 2004-558598P 20040331
AN 2005-676492 [69] WPIDS
AB WO2005088310 A UPAB: 20051027
NOVELTY - An array (I) of glycan molecules, has a solid support and a library of glycan molecules, where each glycan molecule is covalently attached to the solid support through amide or amine group.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a library (II) comprising 225-7500 separate, isolated glycans as given in the specification e.g. D-glucopyranose, D-galactopyranose, N-acetylglucopyranose, etc.;

(2) a composition (III) comprising:

(a) a carrier and one or more glycan molecules, which binds an antibody found in a patient with a disease, where serum form a patient without the disease has substantially no antibodies that bind any of the glycan molecules in the composition; or

(b) a carrier and one or more glycan molecules, which binds an antibody found in a healthy person, where serum from a patient with the disease has substantially no antibodies that bind any of the glycan molecules in the composition;

(3) treating or preventing (M1) disease in a mammal, involves administering the mammal a composition comprising one or more glycan molecules that binds antibodies detected in a patient with the disease;

(4) an isolated antibody that can binding an alpha -**Gal**-**3** glycan; and

(5) a kit comprising (I) and instructions for using (I), or (II) and instructions for producing (I) from (II).

ACTIVITY - Antibacterial; Virucide; Antiinflammatory; Cytostatic; Immunosuppressive.

MECHANISM OF ACTION - Immunomodulator.

No biological data given.

USE - (I) is useful for detecting antibodies in a test sample (e.g. blood, serum, antiserum, monoclonal antibody preparation, lymph, plasma, saliva, urine, semen, breast milk, ascites fluid, tissue extract, cell lysate, cell suspension, viral suspension or their combinations, preferably serum) which involves contacting the test sample with (I) and observing whether one or more glycans or bound by an antibody in the test sample. The method further involves observing whether antibodies in a control sample bind to the same glycan molecules as are bound by the antibodies in the test sample.

(I) is useful for detecting transplant tissue rejection (preferably xenotransplant tissue rejection) in a transplant recipient which involves contacting the test sample (e.g. blood, serum, plasma, saliva, urine, breast milk, ascites fluid or lymph) from the transplant recipient with (I) and observing whether one or more glycans are bound by antibodies in the test sample.

Preferably, (I) comprises alpha Gal-LeX (Gal- alpha 3-Gal- beta 4-GlcNAc( alpha 3-fucose)- beta ). (I) or (II) is useful for testing whether a molecule (such as antibody, enzyme, viral protein, cellular receptor, cell type specific antigen and nucleic acid e.g. RNA) in a test sample can bind to glycan which involves contacting glycans in (I) or (II) with the test sample, and observing whether a molecule in the test sample binds to a glycan in (I) or (II). The method further involves determining which molecule in the test sample binds to the glycan. The molecule is from prokaryote (e.g. prion, virus, bacterium) or eukaryote. The molecule is a cellular or tissue component.

(III) is useful for treating or preventing bacterial infection, viral infection, inflammation, cancer, transplant rejection or autoimmune disease (preferably transplant tissue rejection), or as a food supplement. (M1) is useful for treating or preventing disease in a mammal (claimed).

ADVANTAGE - (I) enables rapid, reliable and non-invasive detection or diagnosis of the disease.

DESCRIPTION OF DRAWING(S) - The figure is a graph representing the immune response directed against transplanted tissue in a **diabetic** patient.

Dwg.11D/12

L36 ANSWER 3 OF 59 IFIPAT COPYRIGHT 2005 IFI on STN

AN 10793965 IFIPAT;IFIUDB;IFICDB

TITLE: PHARMACEUTICAL COMPOSITION HAVING INHIBITORY EFFECT ON OVERPRODUCTION AND ACCUMULATION OF EXTRACELLULAR MATRIX

INVENTOR(S): Hughes; Reginald Colin, London, GB
Sasaki; Satoshi, Tokyo, JP
Sumi; Yoshihiko, Tokyo, JP

PATENT ASSIGNEE(S): TEIJIN LIMITED

AGENT: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US

| | NUMBER | PK | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 2005032675 | A1 | 20050210 |
| APPLICATION INFORMATION: | US 2004-928407 | | 20040830 |

| | APPLN. NUMBER | DATE | GRANTED PATENT NO. OR STATUS |
|---|---|---|---|
| CONTINUATION OF: | US 2001-744328 | 20010123 | ABANDONED |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY APPLN. INFO.: | JP 1998-233499 | 19980806 |
| FAMILY INFORMATION: | US 2005032675 | 20050210 |

DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION

NUMBER OF CLAIMS: 6

AB A pharmaceutical composition having an inhibitory effect on the overproduction and the accumulation of extracellular matrix, said composition comprising as an active ingredient a compound that inhibits the biological activity of **galectin-3**, which pharmaceutical composition can serve as a therapeutic or preventive agent for glomerular nephritis, **diabetic** nephropathy or tissue fibrosis, as well as the use of said compound for the production of pharmaceuticals for the above-mentioned use, and a method for inhibition of the overproduction and accumulation of the extracellular matrix.
CLMN 6

L36 ANSWER 4 OF 59 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 1

ACCESSION NUMBER: 2005:1157016 SCISEARCH
THE GENUINE ARTICLE: 984JY
TITLE: Up-regulation of advanced glycated products receptors in the brain of diabetic rats is prevented by antioxidant treatment
AUTHOR: Aragno M (Reprint); Mastrocola R; Medana C; Restivo F; Catalano M G; Pons N; Danni O; Boccuzzi G
CORPORATE SOURCE: Univ Turin, Dept Expt Med & Oncol, Gen Pathol Sect, Corso Raffaello 30, I-10125 Turin, Italy (Reprint); Univ Turin, Dept Expt Med & Oncol, Gen Pathol Sect, I-10125 Turin, Italy; Univ Turin, Dept Anat Pharmacol & Forens Med, Gen Pathol Sect, I-10125 Turin, Italy; Univ Turin, Dept Analyt Chem, I-10125 Turin, Italy; Univ Turin, Dept Clin Physiopathol, I-10126 Turin, Italy
manuela.aragno@unito.it
COUNTRY OF AUTHOR: Italy
SOURCE: ENDOCRINOLOGY, (DEC 2005) Vol. 146, No. 12, pp. 5561-5567. ISSN: 0013-7227.
PUBLISHER: ENDOCRINE SOC, 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 61
ENTRY DATE: Entered STN: 1 Dec 2005
Last Updated on STN: 1 Dec 2005
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

AB **Diabetics** have at least twice the risk of stroke and may show performance deficit in a wide range of cognitive domains. The mechanisms underlying this gradually developing end-organ damage may involve both vascular changes and direct damage to neuronal cells as a result of overproduction of superoxide by the respiratory chain and consequent oxidative stress. The study aimed to assess the role of oxidative stress on the aldose reductase-polyol pathway, on advanced

glycated end-product (AGE)/AGE-receptor interaction, and on downstream signaling in the hippocampus of streptozotocintreated rats. Data show that, in **diabetic** rats, levels of prooxidant compounds increase, whereas levels of antioxidant compounds fall. Receptor for AGE and **galectin**-3 content and polyol flux increase, whereas glyceraldehyde-3-phosphate dehydrogenase activity is impaired. Moreover, nuclear factor kappa B (p65) transcription factor levels and S-100 protein are increased in the hippocampus cytosol, suggesting that oxidative stress triggers the cascade of events that finally leads to neuronal damage. Dehydroepiandrosterone, the most abundant hormonal steroid in the blood, has been reported to possess antioxidant properties. When dehydroepiandrosterone was administered to **diabetic** rats, the improved oxidative imbalance and the marked reduction of AGE receptors paralleled the reduced activation of nuclear factor kappa B and the reduction of S-100 levels, reinforcing the suggestion that oxidative stress plays a role in **diabetes**-related neuronal damage.

L36 ANSWER 5 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:233319 CAPLUS
DOCUMENT NUMBER: 142:277926
TITLE: Impaired retinal angiogenesis in **diabetes**: role of advanced glycation end products and **galectin-3**
AUTHOR(S): Stitt, Alan W.; McGoldrick, Ciara; Rice-McCaldin, Aine; McCance, David R.; Glenn, Josephine V.; Hsu, Daniel K.; Liu, Fu-Tong; Thorpe, Suzanne R.; Gardiner, Tom A.
CORPORATE SOURCE: Ophthalmology and Vision Science Research Centre, Queens University of Belfast, Belfast, BT12 6BA, UK
SOURCE: Diabetes (2005), 54(3), 785-794
CODEN: DIAEAZ; ISSN: 0012-1797
PUBLISHER: American Diabetes Association
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Suppression of angiogenesis during **diabetes** is a recognized phenomenon but is less appreciated within the context of **diabetic** retinopathy. The current study has investigated regulation of retinal angiogenesis by **diabetic** serum and determined if advanced glycation end products (AGEs) could modulate this response, possibly via AGE-receptor interactions. A novel in vitro model of retinal angiogenesis was developed and the ability of **diabetic** sera to regulate this process was quantified. AGE-modified serum albumin was prepared according to a range of protocols, and these were also analyzed along with neutralization of the AGE receptors **galectin-3** and RAGE. Retinal ischemia and neovascularization were also studied in a murine model of oxygen-induced proliferative retinopathy (OIR) in wild-type and **galectin-3** knockout mice (gal3-/-) after perfusion of preformed AGEs. Serum from nondiabetic patients showed significantly more angiogenic potential than **diabetic** serum ($P < 0.0001$) and within the **diabetic** group, poor glycemic control resulted in more AGEs but less angiogenic potential than tight control ($P < 0.01$). AGE-modified albumin caused a dose-dependent inhibition of angiogenesis ($P < 0.001$), and AGE receptor neutralization significantly reversed the AGE-mediated suppression of angiogenesis ($P < 0.01$). AGE-treated wild-type mice showed a significant increase in inner retinal ischemia and a reduction in neovascularization compared with non-AGE controls ($P < 0.001$). However, ablation of **galectin-3** abolished the AGE-mediated increase in retinal ischemia and restored the neovascular response to that seen in controls. The data suggest a significant suppression of angiogenesis by the retinal microvasculature during **diabetes** and implicate AGEs and AGE-receptor interactions in its causation.
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 6 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2005:1017498 CAPLUS
DOCUMENT NUMBER: 143:384418
TITLE: Development of age-dependent glomerular lesions in

galectin-3/AGE-receptor-3 knockout mice
AUTHOR(S): Iacobini, Carla; Oddi, Giovanna; Menini, Stefano; Amadio, Lorena; Ricci, Carlo; Di Pippo, Clelia; Sorcini, Mariella; Pricci, Flavia; Pugliese, Francesco; Pugliese, Giuseppe
CORPORATE SOURCE: Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Rome, Italy
SOURCE: American Journal of Physiology (2005), 289(3, Pt. 2), F611-F621
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Aging is characterized by renal functional and structural abnormalities resembling those observed in **diabetes**. These changes have been related to the progressive accumulation of advanced glycation end-products (AGEs) and cumulative oxidative stress occurring in both conditions. We previously reported that **galectin-3** ablation is associated with increased susceptibility to **diabetes**- and AGE-induced glomerulopathy, thus indicating a protective role of **galectin-3** as an AGE receptor. To investigate the role of the AGE/AGE receptor pathway in the pathogenesis of age-related renal disease, we evaluated the development of glomerular lesions in aging **galectin-3** knockout (KO) vs. wild-type (WT) mice and their relation to the increased AGE levels and oxidative stress characterizing the aging process. KO mice showed significantly more pronounced age-dependent increases in proteinuria, albuminuria, glomerular sclerosis, and glomerular and mesangial areas, starting at 18 mo, as well as renal extracellular matrix mRNA and protein expression, starting at 12 mo vs. age-matched WT mice. Circulating and renal AGEs, plasma isoprostane 8-epi-PGF2α levels, glomerular content of the glycoxidn. and lipoxidn. products Nε-carboxymethyllysine and 4-hydroxy-2-nonenal, and renal nuclear factor-κB activity also increased more markedly with age in KO than WT mice. AGE levels correlated significantly with renal functional and structural parameters. These data indicate that aging **galectin-3** KO mice develop more pronounced changes in renal function and structure than coeval WT mice, in parallel with a more marked degree of AGE accumulation, oxidative stress, and associated low-grade inflammation, thus supporting the concept that the AGE/AGE receptor pathway is implicated in age-related renal disease.
REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 7 OF 59 Elsevier BIOBASE COPYRIGHT 2005 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2005227767 ESBIOBASE
TITLE: Development of age-dependent glomerular lesions in **galectin-3**/AGE-receptor- 3 knockout mice
AUTHOR: Iacobini C.; Oddi G.; Menini S.; Amadio L.; Ricci C.; Di Pippo C.; Sorcini M.; Pricci F.; Pugliese F.; Pugliese G.
CORPORATE SOURCE: G. Pugliese, Dipartimento di Scienze Cliniche (Endocrinologia), Viale del Policlinico, 155, 00161 Rome, Italy.
E-mail: giuseppe.pugliese@uniroma1.it
SOURCE: American Journal of Physiology - Renal Physiology, (2005), 289/3 58-3 (F611-F621), 60 reference(s)
CODEN: AJPPFK ISSN: 0363-6127
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Aging is characterized by renal functional and structural abnormalities resembling those observed in **diabetes**. These changes have been related to the progressive accumulation of advanced glycation end-products (AGEs) and cumulative oxidative stress occurring in both conditions. We previously reported that **galectin-3**

ablation is associated with increased susceptibility to **diabetes** - and AGE-induced glomerulopathy, thus indicating a protective role of **galectin-3** as an AGE receptor. To investigate the role of the AGE/AGE receptor pathway in the pathogenesis of age-related renal disease, we evaluated the development of glomerular lesions in aging **galectin-3** knockout (KO) vs. wild-type (WT) mice and their relation to the increased AGE levels and oxidative stress characterizing the aging process. KO mice showed significantly more pronounced age-dependent increases in proteinuria, albuminuria, glomerular sclerosis, and glomerular and mesangial areas, starting at 18 mo, as well as renal extracellular matrix mRNA and protein expression, starting at 12 mo vs. age-matched WT mice. Circulating and renal AGEs, plasma isoprostane 8-epi-PGF.sub.2.sub.&.sub.a.sub.l.sub.p.sub.h.sub.a.sub.b.; levels, glomerular content of the glycoxidation and lipoxidation products N.sup.&.sup.e.sup.p.sup.s.sup.i.sup.;-carboxymethyllysine and 4-hydroxy-2-non-enal, and renal nuclear factor-κB activity also increased more markedly with age in KO than WT mice. AGE levels correlated significantly with renal functional and structural parameters. These data indicate that aging **galectin-3** KO mice develop more pronounced changes in renal function and structure than coeval WT mice, in parallel with a more marked degree of AGE accumulation, oxidative stress, and associated low-grade inflammation, thus supporting the concept that the AGE/AGE receptor pathway is implicated in age-related renal disease. Copyright .COPYRGT. 2005 the American Physiological Society.

L36 ANSWER 8 OF 59 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2005:113562 SCISEARCH
THE GENUINE ARTICLE: 889CB
TITLE: Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium
AUTHOR: McFarlane S; Glenn J V; Lichanska A M; Simpson D A C; Stitt A W (Reprint)
CORPORATE SOURCE: Queens Univ Belfast, Inst Clin Sci, Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland (Reprint)
a.stitt@qub.ac.uk
COUNTRY OF AUTHOR: North Ireland
SOURCE: BRITISH JOURNAL OF OPHTHALMOLOGY, (JAN 2005) Vol. 89, No. 1, pp. 107-112.
ISSN: 0007-1161.
PUBLISHER: B M J PUBLISHING GROUP, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 32
ENTRY DATE: Entered STN: 10 Feb 2005
Last Updated on STN: 10 Feb 2005

*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

AB Aims: Advanced glycation endproducts (AGEs) accumulate with ageing and may have a significant impact on age related dysfunction of the retinal pigment epithelium (RPE). Many of the cellular effects of AGEs in other cell types are mediated through AGE binding proteins. The aim of this study was to characterise the AGE receptor complex in RPE cells in vitro and to focus on the role of the R3 component (galectin-3) as the primary effector of the complex.

Methods: Primary cultures of bovine RPE cells and the human D407 RPE cell line were exposed to AGE modified albumin. Receptor expression was determined using mRNA analysis by quantitative real time RT-PCR and protein characterisation by western blotting. Immunocytochemical analysis examined the cellular localisation of the various components of the AGE receptor complex. The role of the galectin-3 receptor component was examined by transfection and overexpression using the D407 cell line and analysis of soluble AGE-R3 by ELISA.

Results: All three components of the AGE receptor complex were expressed by bovine and human RPE cells. AGE exposure upregulated two components of the receptor complex and also induced significant RPE expression of VEGF mRNA ( p< 0.05). RPE D407 cells stably transfected to overexpress galectin-3 showed less VEGF induction. In non-transfected RPE

which were exposed to AGEs, there was less soluble galectin-3 protein released into the medium ( p< 0.05), a response that was not evident in transfected cells.

Conclusion: A conserved AGE receptor complex is evident in primary cultures of bovine RPE cells and also in a human cell line. These cells show a pathological response to AGE exposure, an effect which appears to be modulated by the galectin-3 component of the receptor complex.

L36 ANSWER 9 OF 59 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2005-0415744 PASCAL
COPYRIGHT NOTICE: Copyright .COPYRGT. 2005 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): Development of age-dependent glomerular lesions in **galectin**-3/AGE-receptor-3 knockout mice
AUTHOR: IACOBINI Carla; ODDI Giovanna; MENINI Stefano; AMADIO Lorena; RICCI Carlo; DI PIPPO Clelia; SORCINI Mariella; PRICCI Flavia; PUGLIESE Francesco; PUGLIESE Giuseppe
CORPORATE SOURCE: Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Rome, Italy; Department of Clinical Sciences. "La Sapieza" University, Rome, Italy
SOURCE: American journal of physiology. Renal physiology, (2005), 58(3), F611-F621, 60 refs.
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: United States
LANGUAGE: English
AVAILABILITY: INIST-670F, 354000132662430160
AN 2005-0415744 PASCAL
CP Copyright .COPYRGT. 2005 INIST-CNRS. All rights reserved.
AB Aging is characterized by renal functional and structural abnormalities resembling those observed in **diabetes**. These changes have been related to the progressive accumulation of advanced glycation end-products (AGEs) and cumulative oxidative stress occurring in both conditions. We previously reported that **galectin-3** ablation is associated with increased susceptibility to **diabetes** - and AGE-induced glomerulopathy, thus indicating a protective role of **galectin-3** as an AGE receptor. To investigate the role of the AGE/AGE receptor pathway in the pathogenesis of age-related renal disease, we evaluated the development of glomerular lesions in aging **galectin-3** knockout (KO) vs. wild-type (WT) mice and their relation to the increased AGE levels and oxidative stress characterizing the aging process. KO mice showed significantly more pronounced age-dependent increases in proteinuria, albuminuria, glomerular sclerosis, and glomerular and mesangial areas, starting at 18 mo, as well as renal extracellular matrix mRNA and protein expression, starting at 12 mo vs. age-matched WT mice. Circulating and renal AGEs, plasma isoprostane 8-epi-PGF.sub.2.sub.α levels, glomerular content of the glycoxidation and lipoxidation products N.sup.ε-carboxymethyllysine and 4-hydroxy-2-non-enal, and renal nuclear factor-KB activity also increased more markedly with age in KO than WT mice. AGE levels correlated significantly with renal functional and structural parameters. These data indicate that aging **galectin-3** KO mice develop more pronounced changes in renal function and structure than coeval WT mice, in parallel with a more marked degree of AGE accumulation, oxidative stress, and associated low-grade inflammation, thus supporting the concept that the AGE/AGE receptor pathway is implicated in agerelated renal disease.

L36 ANSWER 10 OF 59 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005389805 EMBASE
TITLE: Development of age-dependent glomerular lesions in galectin-3/AGE-receptor- 3 knockout mice.
AUTHOR: Iacobini C.; Oddi G.; Menini S.; Amadio L.; Ricci C.; Di Pippo C.; Sorcini M.; Pricci F.; Pugliese F.; Pugliese G.

CORPORATE SOURCE: G. Pugliese, Dipartimento di Scienze Cliniche (Endocrinologia), Viale del Policlinico, 155, 00161 Rome, Italy. giuseppe.pugliese@uniroma1.it
SOURCE: American Journal of Physiology - Renal Physiology, (2005) Vol. 289, No. 3 58-3, pp. F611-F621.
Refs: 60
ISSN: 0363-6127 CODEN: AJPPFK
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 028 Urology and Nephrology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20050929
Last Updated on STN: 20050929

AB Aging is characterized by renal functional and structural abnormalities resembling those observed in **diabetes**. These changes have been related to the progressive accumulation of advanced glycation end-products (AGEs) and cumulative oxidative stress occurring in both conditions. We previously reported that **galectin-3** ablation is associated with increased susceptibility to **diabetes**- and AGE-induced glomerulopathy, thus indicating a protective role of **galectin-3** as an AGE receptor. To investigate the role of the AGE/AGE receptor pathway in the pathogenesis of age-related renal disease, we evaluated the development of glomerular lesions in aging **galectin-3** knockout (KO) vs. wild-type (WT) mice and their relation to the increased AGE levels and oxidative stress characterizing the aging process. KO mice showed significantly more pronounced age-dependent increases in proteinuria, albuminuria, glomerular sclerosis, and glomerular and mesangial areas, starting at 18 mo, as well as renal extracellular matrix mRNA and protein expression, starting at 12 mo vs. age-matched WT mice. Circulating and renal AGEs, plasma isoprostane 8-epi-PGF(2α) levels, glomerular content of the glycoxidation and lipoxidation products N(ε)-carboxymethyllysine and 4-hydroxy-2-non-enal, and renal nuclear factor-κB activity also increased more markedly with age in KO than WT mice. AGE levels correlated significantly with renal functional and structural parameters. These data indicate that aging **galectin-3** KO mice develop more pronounced changes in renal function and structure than coeval WT mice, in parallel with a more marked degree of AGE accumulation, oxidative stress, and associated low-grade inflammation, thus supporting the concept that the AGE/AGE receptor pathway is implicated in age-related renal disease. Copyright .COPYRGT. 2005 the American Physiological Society.

L36 ANSWER 11 OF 59 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN DUPLICATE 4
ACCESSION NUMBER: 2004-386132 [36] WPIDS
DOC. NO. CPI: C2004-144562
TITLE: New alkaline phosphatase protein is useful in the prevention and treatment of diseases associated with **galectin-3**, e.g., cancer and **diabetes**.
DERWENT CLASS: B04 D16
INVENTOR(S): DUBEAU, L; SHIN, B H
PATENT ASSIGNEE(S): (SHIN-I) SHIN B H
COUNTRY COUNT: 1
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| KR 2004005687 | A | 20040116 | (200436)* | | 1 |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| KR 2004005687 | A | KR 2003-46425 | 20030709 |

PRIORITY APPLN. INFO: KR 2002-39778 20020709

AN 2004-386132 [36] WPIDS
AB KR2004005687 A UPAB: 20040608
NOVELTY - A protein for prevention and treatment of diseases associated with **galectin-3** which improves degradation of **galectin-3** associating with cancer metastasis, is new.
DETAILED DESCRIPTION - A protein for prevention and treatment of diseases associated with **galectin-3** is provided, wherein the protein is alkaline phosphatase; the protein is encoded by a gene having the nucleotide sequence selected from SEQ ID NO: 1 to SEQ ID NO: 5; the protein comprises the amino acid sequence of SEQ ID NO: 6; and the disease associated with **galectin-3** is selected from cancer, inflammatory disease, **diabetes**, atherosclerosis and acute allergic disease.
Dwg.1/10

L36 ANSWER 12 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2004:973270 CAPLUS
DOCUMENT NUMBER: 141:393401
TITLE: Galectin-3/AGE-receptor 3 knockout mice show accelerated age-induced glomerular injury: evidence for a protective role of galectin-3 as an age receptor
AUTHOR(S): Iacobini, Carla; Menini, Stefano; Oddi, Giovanna; Ricci, Carlo; Amadio, Lorena; Pricci, Flavia; Olivieri, Antonella; Sorcini, Mariella; Di Mario, Umberto; Pugliese, Giuseppe
CORPORATE SOURCE: Dep. of Cell Biol. and Neurosci., Inst. Superiore di Sanita, Rome, 00161, Italy
SOURCE: FASEB Journal (2004), 18(14), 1773-1775, 10.1096/fj.04-2031fje
CODEN: FAJOEC; ISSN: 0892-6638
PUBLISHER: Federation of American Societies for Experimental Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The authors previously showed that mice lacking **galectin-3**/AGE-receptor 3 develop accelerated **diabetic** glomerulopathy. To further investigate the role of **galectin-3**/AGE-receptor function in the pathogenesis of **diabetic** renal disease, **galectin-3** knockout (KO) and coeval wild-type (WT) mice were injected for 3 mo with 30 μg/day of Nε-carboxymethyllysine (CML)-modified or unmodified mouse serum albumin (MSA). Despite receiving equal doses of CML, KO had higher circulating and renal AGE levels and showed more marked renal functional and structural changes than WT mice, with significantly higher proteinuria, albuminuria, glomerular, and mesangial area and glomerular sclerosis index. Renal 4-hydroxy-2-nonenal content and NFκB activation were also more pronounced in KO-CML vs. WT-CML. Kidney mRNA levels of fibronectin, laminin, collagen IV, and TGF-β were up-regulated, whereas those of matrix metalloproteinase-2 and -14 were down-regulated, again more markedly in KO-CML than WT- CML mice. Basal and CML-induced RAGE and 80K-H mRNA levels were higher in KO vs. WT mice. MSA injection did not produce any significant effect in both genotypes. The association of **galectin-3** ablation with enhanced susceptibility to AGE-induced renal disease, increased AGE levels and signaling, and altered AGE-receptor pattern indicates that **galectin-3** is operating in vivo as an AGE receptor to afford protection toward AGE-dependent tissue injury.
REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 13 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2004:106870 CAPLUS
DOCUMENT NUMBER: 141:5292
TITLE: **Galectin-3**-positive cell infiltration in human **diabetic** nephropathy
AUTHOR(S): Kikuchi, Yuichi; Kobayashi, Shuzo; Hemmi, Noriaki; Ikee, Ryota; Hyodo, Naomi; Saigusa, Takamitsu; Namikoshi, Tamehachi; Yamada, Muneharu; Suzuki, Shigenobu; Miura, Soichiro

CORPORATE SOURCE: Second Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
SOURCE: Nephrology, Dialysis, Transplantation (2004), 19(3), 602-607
CODEN: NDTREA; ISSN: 0931-0509
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **Galectin-3** has several functions, such as cell proliferation, regulation of apoptosis and interaction of cell adhesion, and has a high binding affinity for advanced glycation end products. In animal models with **diabetic** nephropathy (DMN) or acute renal failure, **galectin-3** is known to be upregulated. However, **galectin-3** expression has not been investigated in human kidney diseases. Methods. Using immunohistochem. we examined **galectin-3** expression in renal biopsy specimens obtained from 37 patients with nephropathy: DMN (n = 9), IgA nephropathy (n = 9), crescentic glomerulonephritis (n = 8), membranous nephropathy (n = 6) and minimal change nephrotic syndrome (n = 5). In normal human kidney, **galectin-3** was found in distal tubuli, but not in glomeruli. However, **galectin-3**-pos. cell infiltration was observed in glomeruli of 12 patients. **Galectin-3**-pos. cells, also stained with CD68, were significantly more numerous in glomeruli of DMN than in glomeruli of other nephropathies. The ratio of **galectin-3**-pos. cells to the total number of macrophages in tubules was also significantly increased in DMN. There was a significant correlation between the number of **galectin-3** -pos. cells in glomeruli and urinary protein excretion in all patients ($r = 0.616$, $P<0.001$). In **diabetic** patients, the number of **galectin-3**-pos. cells in glomeruli closely correlated with the regression rate of renal function ($r = -0.930$, $P<0.005$). These findings suggest that **galectin-3**-pos. cell infiltration may play an important role in the progression of DMN, and the degree of its expression may be predictive of poor prognosis of DMN.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 14 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2005:456550 BIOSIS
DOCUMENT NUMBER: PREV200510251018
TITLE: Galectin-3 mediates advanced glycation endproduct (AGE)-induced breakdown of the blood-retinal barrier.
AUTHOR(S): Stitt, A. W. [Reprint Author]; Canning, P.; Hsu, D. K.; Liu, F.-T.; Quinn, N.
CORPORATE SOURCE: Queens Univ Belfast, Belfast BT7 1NN, Antrim, UK
SOURCE: IOVS, (APR 2004) Vol. 45, No. Suppl. 2, pp. U85. Meeting Info.: Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology. Ft Lauderdale, FL, USA. April 24 -29, 2004. Assoc Res Vis & Ophthalmol. CODEN: IOVSDA. ISSN: 0146-0404.
DOCUMENT TYPE: Conference; (Meeting)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Nov 2005
Last Updated on STN: 9 Nov 2005

AB Purpose: Advanced glycation endproducts (AGEs) accumulate during **diabetes** and have been previously shown to induce leakage from the retinal microvasculature. **Galectin-3** has been described as a component of the AGE-receptor complex andmay control AGE-mediated effects on a variety of cells and tissues. Using **galectin-3** deficient mice (**gal-3** (-/-)) we have examined the role of thisreceptor in breakdown of the inner blood retinal barrier (iBRB) during **diabetic** retinopathy.Methods: Two experimental models were used in the study. Firstly, **diabetes** wasestablished in wild-type (WT) and **gal-3**(-/-) C57/BL6 mice with a single streptozocin injection (165mg/ kg) for 3 weeks. Animals were assigned intonon-

**diabetic** and **diabetic** groups and pyridoxamine, an AGE-inhibitor, was orally administered to a sub-group of **diabetic** mice (1g/L). In a previously established, complementary model, non-**diabetic** WT and **gal-3**(-/-) mice received daily infusion of AGE-modified albumin or native albumin (10mg/kg) for 7days. In both experimental models, iBRB dysfunction was assessed by the Evans Blue leakage assay. Gene expression analysis of the tight junction component ZO-1 was also assessed by real-time RT-PCR and immunofluorescence staining of retinal flat-mounts.Results: When compared to controls, there was a fourfold increase in retinal microvascular permeability in **diabetic** WT mice ($p<0.05$) and this was returned to non-**diabetic** levels by pyridoxamine treatment. ZO-1 mRNA and protein was significantly down-regulated in **diabetes**, an effect abolished by pyridoxamine. Ingal-3(-/-), animals there was no significant difference in permeability between **diabetic** and non-**diabetic** groups, suggesting a protective effect when **gal** -**3** is absent. Compared to native-albumin, AGE-infusion caused significant breakdown of the iBRB ($p<0.03$) although there was no difference between WT and **gal-3**(-/-) mice.Conclusions: AGEs appear to induce significant retinal microvascular leakage in **diabetic** mice, an effect that can be prevented by the AGE-specific inhibitorpyridoxamine. iBRB compromise during **diabetic** retinopathy may be mediated, atleast in part, by **galectin-3**.

L36 ANSWER 15 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2004:1011101 CAPLUS
DOCUMENT NUMBER: 142:72773
TITLE: AGE-R3/galectin-3 expression in osteoblast-like cells: Regulation by AGEs
AUTHOR(S): Mercer, Natalia; Ahmed, Hafiz; McCarthy, Antonio D.; Etcheverry, Susana B.; Vasta, Gerardo R.; Cortizo, Ana M.
CORPORATE SOURCE: Catedra de Bioquimica Patologica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argent.
SOURCE: Molecular and Cellular Biochemistry (2004), 266(1&2), 17-24
CODEN: MCBIB8; ISSN: 0300-8177
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The accumulation of irreversible advanced glycation endproducts (AGEs) on long-lived proteins, and the interaction of AGEs with cellular receptors such as AGE-R3/**galectin-3** and RAGE, are considered to be key events in the development of long-term complications of **diabetes** mellitus, Alzheimer's disease, uremia and aging. The aim of this study was to investigate the expression and subcellular distribution of **galectin-3**, as well as its possible modulation by AGEs, in MC3T3E1 mouse calvaria-derived osteoblasts and in UMR106 rat osteosarcoma cells. Both osteoblastic lines were cultured either with control bovine serum albumin (BSA) or with AGEs-BSA for 48 h. Cells were evaluated for **galectin-3** expression by fixing and immunofluorescent microscopic anal., or Western blot anal. of whole cell exts., sub-cellular fractions and culture media. Both cell lines express 30 kDa (monomeric) **galectin-3**, although expression was about 15-fold lower in the UMR106 osteosarcoma cells. Dimeric (70 kDa) **galectin-3** was addnl. observed in the UMR106 cells. Immunofluorescent anal. of **galectin-3** distribution showed a diffuse cytoplasmic and strong nuclear pattern in MC3T3E1 osteoblasts, and a patchy cytoplasmic pattern in UMR106 cells. Western blot anal. for both cell lines showed that **galectin-3** was mainly found in the cytoplasm and in minor amts. in the microsomal fraction, while considerable amts. were secreted into the culture media. Exposure to 100-200 μg/mL AGEs-BSA increased the cellular content of 30 kDa **galectin-3** (20-25% for MC3T3E1 and 35-70% for UMR106 vs. control BSA), and decreased the culture media levels of **galectin-3** (10-20% for MC3T3E1 and for UMR106 vs. control BSA). These results confirm the expression of

**galectin-3** in osteoblastic cells, and suggest different levels and subcellular distribution of this protein in transformed vs. nontransformed osteoblasts. Osteoblastic exposure to AGEs alters their expression and secretion of **galectin-3**, which could have significant consequences on osteoblast metabolism and thus on bone turnover.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 16 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 8

ACCESSION NUMBER: 2005:58797 BIOSIS
DOCUMENT NUMBER: PREV200500051538
TITLE: Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor.
AUTHOR(S): Iacobini, Carla; Menini, Stefano; Oddi, Giovanna; Ricci, Carlo; Amadio, Lorena; Pricci, Flavia; Olivieri, Antonella; Sorcini, Mariella; Di Mario, Umberto; Pesce, Carlo; Pugliese, Giuseppe [Reprint Author]
CORPORATE SOURCE: Dipartimento Sci Clin Endocrinol, Viale Policlin 155, I-00161, Rome, Italy
giuseppe.pugliese@uniroma1.it
SOURCE: FASEB Journal, (September 2004) Vol. 18, No. 12. print.
ISSN: 0892-6638 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Feb 2005
Last Updated on STN: 3 Feb 2005

AB We previously showed that mice lacking **galectin-3** /AGE-receptor 3 develop accelerated **diabetic** glomerulopathy. To further investigate the role of **galectin-3** /AGE-receptor function in the pathogenesis of **diabetic** renal disease, **galectin-3** knockout ( KO) and coeval wild-type (WT) mice were injected for 3 months with 30 mug/day of Nepsilon-carboxymethyllysine (CML)-modified or unmodified mouse serum albumin (MSA). Despite receiving equal doses of CML, KO had higher circulating and renal AGE levels and showed more marked renal functional and structural changes than WT mice, with significantly higher proteinuria, albuminuria, glomerular, and mesangial area and glomerular sclerosis index. Renal 4-hydroxy-2-nonenal content and NFkappaB activation were also more pronounced in KO-CML vs. WT-CML. Kidney mRNA levels of fibronectin, laminin, collagen IV, and TGF-beta were up-regulated, whereas those of matrix metalloproteinase-2 and -14 were down-regulated, again more markedly in KO-CML than WT-CML mice. Basal and CML-induced RAGE and 80K-H mRNA levels were higher in KO vs. WT mice. MSA injection did not produce any significant effect in both genotypes. The association of **galectin-3** ablation with enhanced susceptibility to AGE-induced renal disease, increased AGE levels and signaling, and altered AGE-receptor pattern indicates that **galectin-3** is operating in vivo as an AGE receptor to afford protection toward AGE-dependent tissue injury.

L36 ANSWER 17 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:757728 CAPLUS
DOCUMENT NUMBER: 139:275232
TITLE: Human diabetes-mediating proteins with altered expression levels in islet of Langerhans cells exposed to cytokines, and uses for diagnosis, treatment and prevention of diabetes
INVENTOR(S): Larsen, Peter Mose; Fey, Stephen J.; Nerup, Jorn; Karlsen, Allan E.
PATENT ASSIGNEE(S): Syddansk Universitet, Den.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003078456 | A2 | 20030925 | WO 2003-DK190 | 20030320 |
| WO 2003078456 | A3 | 20040115 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| EP 1490399 | A2 | 20041229 | EP 2003-744324 | 20030320 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

| | | |
|---|---|---|
| PRIORITY APPLN. INFO.: | DK 2002-431 | A 20020320 |
| | WO 2003-DK190 | W 20030320 |

AB This invention relates to human diabetes-mediating proteins, methods of identifying diabetes-mediating proteins, methods for screening for drugs which affect the expression of diabetes-mediating proteins, and therapeutic compds. for the treatment and prevention of diabetes. Provided are secreted and non-secreted proteins with altered expression levels in human islet of Langerhans cells exposed to cytokines. They include protective and deleterious diabetes-mediating proteins. Also provided are the polynucleotides encoding these diabetes-mediating proteins. Drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of altering the expression of a diabetes-mediating protein are disclosed.

L36 ANSWER 18 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 9

| | |
|---|---|
| ACCESSION NUMBER: | 2003:940482 CAPLUS |
| DOCUMENT NUMBER: | 140:126455 |
| TITLE: | Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells |
| AUTHOR(S): | Seki, N.; Hashimoto, N.; Sano, H.; Horiuchi, S.; Yagui, K.; Makino, H.; Saito, Y. |
| CORPORATE SOURCE: | Graduate School of Medicine, Department of Clinical Cell Biology, Chiba University, Chiba, 260-0856, Japan |
| SOURCE: | Metabolism, Clinical and Experimental (2003), 52(12), 1558-1563<br>CODEN: METAAJ; ISSN: 0026-0495 |
| PUBLISHER: | W. B. Saunders Co. |
| DOCUMENT TYPE: | Journal |
| LANGUAGE: | English |

AB Hyperglycemia is an important cause of accelerated atherosclerosis in **diabetic** patients. We examined the effect of hyperglycemia and advanced glycation end products (AGE) on proliferation of rat aortic smooth muscle cells (SMC) in culture; in vivo, this event is believed to contribute importantly to atherogenesis in **diabetes** mellitus. Glucose itself dose-dependently inhibited thymidine uptake by SMC, but AGE increased thymidine uptake, suggesting that SMC proliferation is accelerated by AGE. To examine possible mechanisms for this effect, we studied NF-κB activation and the tyrosine phosphorylation pathway; AGE stimulated NF-κB activity, but phosphorylation of the platelet-derived growth factor (PDGF) receptor was unchanged. In Chinese hamster ovary (CHO) cells overexpressing **galectin-3**, an AGE receptor related to atherosclerosis, AGE increased thymidine uptake. This suggests SMC proliferation is enhanced by AGE via **galectin-3**. As pathways involving AGE-**galectin -3** interaction thus may be involved in macroangiopathy, AGE appears to be important to the role of SMC in accelerated atherosclerosis associated with **diabetes** mellitus.

| | | |
|---|---|---|
| REFERENCE COUNT: | 41 | THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT |

L36 ANSWER 19 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 10
ACCESSION NUMBER: 2003:897220 CAPLUS
DOCUMENT NUMBER: 140:174876
TITLE: The Protective Effect of Aminoguanidine on Erectile Function in Streptozotocin Diabetic Rats
AUTHOR(S): Usta, Mustafa F.; Bivalacqua, Trinity J.; Yang, Dae Yul; Ramanitharan, Anshiya; Sell, David R.; Viswanathan, Ashiwini; Monnier, Vincent M.; Hellstrom, Wayne J. G.
CORPORATE SOURCE: Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA
SOURCE: Journal of Urology (Hagerstown, MD, United States) (2003), 170(4, Pt. 1), 1437-1442
CODEN: JOURAA; ISSN: 0022-5347
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Erectile dysfunction (ED) is frequently associated with **diabetes** mellitus. We determined if advanced glycation end products (AGEs) are involved in ED and investigated if the selective AGE and inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine (AG) could protect against the development of ED in a **diabetic** rat model. Harlan Sprague-Dawley rats were divided into 3 groups. The 9 nondiabetic rats in group 1 served as age matched controls. **Diabetes** was induced in the 9 rats in groups 2 and 3, resp., by i.p. injection of streptozocin (60 mg/kg). While group 2 was given free access to water and a standard diet, group 3 was treated with AG added to drinking water (1 gm/l daily). Two months after **diabetes** induction in vivo intracavernous pressure measurements were determined Penile tissue glycation (furosine on high performance liquid chromatog.), AGEs (pentosidine on high performance liquid chromatog. and immunohistochem.), AGE receptor (**galectin-3** on immunohistochem. and Western blot) and iNOS (Western blot) levels were measured in control and **diabetic** penises. Cavernous tissue furosine, pentosidine, **galectin-3** and iNOS protein levels were significantly elevated in the **diabetic** group compared with controls ($p < 0.05$). On the other hand, cavernous tissue furosine, pentosidine, **galectin-3** and iNOS expression were lower in **diabetic** rats treated with AG despite an unchanged glycemia level. **Diabetic** rats had a significant decrease in erectile function compared with control rats ($p < 0.05$), while AG treated **diabetic** rats showed erectile function similar to that in control animals. Glycation, AGEs, **galectin-3** and iNOS levels are elevated in **diabetic** rat penile tissue and significantly decreased by AG treatment. Furthermore, erectile function was preserved in AG treated animals. The observation that AG improved glycation despite no effect on glycemia suggests that AG may improve penile collagen turnover.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 20 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 11
ACCESSION NUMBER: 2003:784705 CAPLUS
DOCUMENT NUMBER: 139:320909
TITLE: AGE-RAGE system in the development of diabetic vascular complications
AUTHOR(S): Yamamoto, Yasuhiko
CORPORATE SOURCE: Dep. Biochem. Mol. Vascular Biol., Kanazawa Univ. Grad. Sch. Med. Sci., Kanazawa, 920-8640, Japan
SOURCE: Seikagaku (2003), 75(9), 1230-1233
CODEN: SEIKAQ; ISSN: 0037-1017
PUBLISHER: Nippon Seikagakkai
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
AB A review on the formation of advanced glycation endproducts (AGE) in **diabetic** patients, structure and distribution of receptor for AGE (RAGE), effects of AGE-RAGE system on vascular cells, involvement of AGE-RAGE system in microvascular complications in **diabetes**, other AGE receptors (scavenger receptors, OST-48, 80K-H, **galectin**

-3, etc.), and novel RAGE variants.

L36 ANSWER 21 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 12

ACCESSION NUMBER: 2004:101295 BIOSIS
DOCUMENT NUMBER: PREV200400096810
TITLE: **Galectin-3** may play an important role for human **diabetic** nephropathy.
AUTHOR(S): Kikuchi, Yuichi [Reprint Author]; Kobayashi, Shuzo; Hemmi, Noriaki [Reprint Author]; Ikee, Ryota [Reprint Author]; Hyodo, Naomi [Reprint Author]; Saigusa, Takamitsu [Reprint Author]; Namikoshi, Tamehachi [Reprint Author]; Yamada, Muneharu [Reprint Author]; Suzuki, Shigenobu [Reprint Author]; Miura, Soichiro [Reprint Author]
CORPORATE SOURCE: Second Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
SOURCE: Journal of the American Society of Nephrology, (November 2003) Vol. 14, No. Abstracts Issue, pp. 394A. print. Meeting Info.: Meeting of the American Society of Nephrology Renal Week. San Diego, CA, USA. November 12-17, 2003. American Society of Nephrology. CODEN: JASNEU. ISSN: 1046-6673.
DOCUMENT TYPE: Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 18 Feb 2004
Last Updated on STN: 18 Feb 2004

L36 ANSWER 22 OF 59 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

ACCESSION NUMBER: 2003:37211388 BIOTECHNO
TITLE: Autoimmunity seen through the SEREX-scope
AUTHOR: Krebs P.; Kurrer M.; Sahin U.; Tureci O.; Ludewig B.
CORPORATE SOURCE: B. Ludewig, Institute of Experimental Immunology, Department of Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland.
E-mail: burkhard.ludewig@kssg.ch
SOURCE: Autoimmunity Reviews, (2003), 2/6 (339-345), 40 reference(s)
CODEN: ARUEBU ISSN: 1568-9972
DOCUMENT TYPE: Journal; General Review
COUNTRY: Netherlands
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2003:37211388 BIOTECHNO
AB Autoantibodies can be detected in autoimmune diseases with a long prodromal phase and may serve as early indicators of disease activity. Autoantibody-based screening methods are therefore potent tools for the identification of target antigens. The SEREX method (serological identification of antigens by recombinant expression cloning) has been developed for the serological definition of immunogenic tumor antigens. Recent studies indicate that the SEREX approach may also be utilized for the analysis of complex immune responses involved in autoimmune diseases.


L36 ANSWER 23 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 13

ACCESSION NUMBER: 2003:674928 CAPLUS
DOCUMENT NUMBER: 139:289902
TITLE: Role of **galectin-3** in **diabetic** nephropathy
AUTHOR(S): Iacobini, Carla; Amadio, Lorena; Oddi, Giovanna; Ricci, Carlo; Barsotti, Paola; Missori, Serena; Sorcini, Mariella; Di Mario, Umberto; Pricci, Flavia; Pugliese, Giuseppe
CORPORATE SOURCE: Laboratory of Metabolism and Pathological Biochemistry, Section of Endocrine Biochemistry, Istituto Superiore di Sanita, Rome, Italy
SOURCE: Journal of the American Society of Nephrology (2003), 14(Suppl. 3), S264-S270

CODEN: JASNEU; ISSN: 1046-6673
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. The advanced glycosylation end products (AGE) participate in the pathogenesis of nephropathy and other **diabetic** complications through several mechanisms, including their binding to cell surface receptors. The AGE receptors include RAGE, the macrophage scavenger receptors, OST-48 (AGE-R1), 80K-H (AGE-R2), and **galectin-3** (AGE-R3). **Galectin-3** interacts with the β-galactoside residues of cell surface and matrix glycoproteins via the carbohydrate recognition domain and with intracellular proteins via peptide-peptide assocns. mediated by its N-terminus domain. These structural properties enable **galectin-3** to exert multiple functions, including the mRNA splicing activity, the control of cell cycle, the regulation of cell adhesion, the modulation of allergic reactions, and the binding of AGE. The lack of transmembrane anchor sequence or signal peptide suggests that it is associated with other AGE receptors, possibly AGE-R1 and AGE-R2, to form an AGE-receptor complex, rather than playing an independent role. In target tissues of **diabetic** vascular complications, such as the endothelium and mesangium, **galectin-3** is weakly expressed under basal conditions and is markedly upregulated by the **diabetic** milieu (and to a lesser extent by aging). **Galectin-3** -deficient mice were found to develop accelerated **diabetic** glomerulopathy vs. the wild-type animals, as evidenced by the more pronounced increase in proteinuria, mesangial expansion, and matrix gene expression. This was associated with a more marked renal/glomerular AGE accumulation, suggesting that it was attributable to the lack of **galectin-3** AGE-receptor function. These data indicate that **galectin-3** is upregulated under **diabetic** conditions and is operating in vivo to provide protection toward AGE-induced tissue injury, as opposed to RAGE.
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 24 OF 59 MEDLINE on STN
ACCESSION NUMBER: 2003342052 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12874444
TITLE: Role of **galectin-3** in **diabetic** nephropathy.
AUTHOR: Iacobini Carla; Amadio Lorena; Oddi Giovanna; Ricci Carlo; Barsotti Paola; Missori Serena; Sorcini Mariella; Di Mario Umberto; Pricci Flavia; Pugliese Giuseppe
CORPORATE SOURCE: Laboratory of Metabolism and Pathological Biochemistry, Section of Endocrine Biochemistry, Istituto Superiore di Sanita, Rome, Italy.
SOURCE: Journal of the American Society of Nephrology : JASN, (2003 Aug) 14 (8 Suppl 3) S264-70. Ref: 49
Journal code: 9013836. ISSN: 1046-6673.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200311
ENTRY DATE: Entered STN: 20030723
Last Updated on STN: 20031113
Entered Medline: 20031112
AB The advanced glycosylation end products (AGE) participate in the pathogenesis of nephropathy and other **diabetic** complications through several mechanisms, including their binding to cell surface receptors. The AGE receptors include RAGE, the macrophage scavenger receptors, OST-48 (AGE-R1), 80K-H (AGE-R2), and **galectin-3** (AGE-R3). **Galectin-3** interacts with the beta-galactoside residues of cell surface and matrix glycoproteins via the carbohydrate recognition domain and with intracellular proteins via peptide-peptide associations mediated by its N-terminus domain. These

structural properties enable **galectin-3** to exert multiple functions, including the mRNA splicing activity, the control of cell cycle, the regulation of cell adhesion, the modulation of allergic reactions, and the binding of AGE. The lack of transmembrane anchor sequence or signal peptide suggests that it is associated with other AGE receptors, possibly AGE-R1 and AGE-R2, to form an AGE-receptor complex, rather than playing an independent role. In target tissues of **diabetic** vascular complications, such as the endothelium and mesangium, **galectin-3** is weakly expressed under basal conditions and is markedly upregulated by the **diabetic** milieu (and to a lesser extent by aging). **Galectin-3** -deficient mice were found to develop accelerated **diabetic** glomerulopathy versus the wild-type animals, as evidenced by the more pronounced increase in proteinuria, mesangial expansion, and matrix gene expression. This was associated with a more marked renal/glomerular AGE accumulation, suggesting that it was attributable to the lack of **galectin-3** AGE-receptor function. These data indicate that **galectin-3** is upregulated under **diabetic** conditions and is operating in vivo to provide protection toward AGE-induced tissue injury, as opposed to RAGE.

L36 ANSWER 25 OF 59 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2003:36903938 BIOTECHNO
TITLE: Role of **galectin-3** in **diabetic** nephropathy
AUTHOR: Iacobini C.; Amadio L.; Oddi G.; Ricci C.; Barsotti P.; Missori S.; Sorcini M.; Di Mario U.; Pricci F.; Pugliese G.
CORPORATE SOURCE: Dr. G. Pugliese, Dipto. Sci. Clin. (Endocrinologia), Viale del Policlinico, 155-00161 Rome, Italy. E-mail: giuseppe.pugliese@uniromal.it
SOURCE: Journal of the American Society of Nephrology, (01 AUG 2003), 14/SUPPL. 3 (S264-S270), 49 reference(s) CODEN: JASNEU ISSN: 1046-6673
DOCUMENT TYPE: Journal; Conference Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2003:36903938 BIOTECHNO
AB The advanced glycosylation end products (AGE) participate in the pathogenesis of nephropathy and other **diabetic** complications through several mechanisms, including their binding to cell surface receptors. The AGE receptors include RAGE, the macrophage scavenger receptors, OST-48 (AGE-R1), 80K-H (AGE-R2), and **galectin-3** (AGE-R3). **Galectin-3** interacts with the β-galactoside residues of cell surface and matrix glycoproteins via the carbohydrate recognition domain and with intracellular proteins via peptide-peptide associations mediated by its N-terminus domain. These structural properties enable **galectin-3** to exert multiple functions, including the mRNA splicing activity, the control of cell cycle, the regulation of cell adhesion, the modulation of allergic reactions, and the binding of AGE. The lack of transmembrane anchor sequence or signal peptide suggests that it is associated with other AGE receptors, possibly AGE-R1 and AGE-R2, to form an AGE-receptor complex, rather than playing an independent role. In target tissues of **diabetic** vascular complications, such as the endothelium and mesangium, **galectin-3** is weakly expressed under basal conditions and is markedly upregulated by the **diabetic** milieu (and to a lesser extent by aging). **Galectin-3**- deficient mice were found to develop accelerated **diabetic** glomerulopathy versus the wild-type animals, as evidenced by the more pronounced increase in proteinuria, mesangial expansion, and matrix gene expression. This was associated with a more marked renal/glomerular AGE accumulation, suggesting that it was attributable to the lack of **galectin-3** AGE-receptor function. These data indicate that **galectin-3** is upregulated under **diabetic** conditions and is operating in vivo to provide protection toward AGE-induced tissue injury, as opposed to RAGE.

L36 ANSWER 26 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 14

ACCESSION NUMBER: 2003:584893 BIOSIS
DOCUMENT NUMBER: PREV200300585872
TITLE: Combined proteome- and genome analysis reveal **galectin-3** as a candidate protein in type 1 **diabetes** protecting against the toxic effect of cytokines.
AUTHOR(S): Karlsen, Allan E. [Reprint Author]; Larsen, Zenia M. [Reprint Author]; Sparre, Thomas [Reprint Author]; Larsen, Martin R.; Mahmood, Amer [Reprint Author]; Storling, Joachim [Reprint Author]; Roepstorff, Peter; Larsen, Peter Mose; Fey, Stephen; Nielsen, Karin [Reprint Author]; Heding, Peter [Reprint Author]; Johannesen, Jesper [Reprint Author]; Kristiansen, Ole P. [Reprint Author]; Christensen, Ulla B. [Reprint Author]; Kockum, Ingrid; Luthrnan, Holger; Nerup, Jorn [Reprint Author]; Pociot, Flemming [Reprint Author]
CORPORATE SOURCE: Steno Diabetes Center, Gentofte, Denmark
SOURCE: European Cytokine Network, (Sept 2003) Vol. 14, No. Supplement 3, pp. 22. print.
Meeting Info.: Annual Meeting of the International Cytokine Society. Dublin, Ireland. September 20-24, 2003.
ISSN: 1148-5493.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Dec 2003
Last Updated on STN: 10 Dec 2003

L36 ANSWER 27 OF 59 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN DUPLICATE 15

ACCESSION NUMBER: 2004-0016727 PASCAL
COPYRIGHT NOTICE: Copyright .COPYRGT. 2004 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): Role of **galectin-3** in **diabetic** nephropathy
Reactive oxygen species and **diabetic** nephropathy
AUTHOR: IACOBINI Carla; AMADIO Lorena; ODDI Giovanna; RICCI Carlo; BARSOTTI Paola; MISSORI Serena; SORCINI Mariella; DI MARIO Umberto; PRICCI Flavia; PUGLIESE Giuseppe
HI BAHL LEE (ed.); HUNJOO HA (ed.); KING George L. (ed.)
CORPORATE SOURCE: Laboratory of Metabolism and Pathological Biochemistry, Section of Endocrine Biochemistry, Istituto Superiore di Sanita, Rome, Italy; Department of Clinical Sciences, Division of Endocrinology, "La Sapienza" University, Rome, Italy; Department of Experimental Medicine and Pathology, Section of Ultrastructural Pathology, "La Sapienza" University, Rome, Italy
Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, Korea, Republic of; Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United States
Soon Chun Hyang University. Hyonam Kidney Laboratory, Korea, Republic of (patr.)
SOURCE: Journal of the American Society of Nephrology, (2003), 14(SUP3), S264-S270, 49 refs.
Conference: 4 The Hyonam Kidney Laboratory, Soon Chun Hyang University International Diabetes Symposium, Seoul (Korea, Republic of), 18 Jan 2003
ISSN: 1046-6673
DOCUMENT TYPE: Journal; Conference
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: United States
LANGUAGE: English

AVAILABILITY: INIST-26049, 354000112669890120
AN 2004-0016727 PASCAL

AB The advanced glycosylation end products (AGE) participate in the pathogenesis of nephropathy and other **diabetic** complications through several mechanisms, including their binding to cell surface receptors. The AGE receptors include RAGE, the macrophage scavenger receptors, OST-48 (AGE-R1), 80K-H (AGE-R2), and **galectin-3** (AGE-R3). **Galectin-3** interacts with the β-galactoside residues of cell surface and matrix glycoproteins via the carbohydrate recognition domain and with intracellular proteins via peptide-peptide associations mediated by its N-terminus domain. These structural properties enable **galectin-3** to exert multiple functions, including the mRNA splicing activity, the control of cell cycle, the regulation of cell adhesion, the modulation of allergic reactions, and the binding of AGE. The lack of transmembrane anchor sequence or signal peptide suggests that it is associated with other AGE receptors, possibly AGE-R1 and AGE-R2, to form an AGE-receptor complex, rather than playing an independent role. In target tissues of **diabetic** vascular complications, such as the endothelium and mesangium, **galectin-3** is weakly expressed under basal conditions and is markedly upregulated by the **diabetic** milieu (and to a lesser extent by aging). **Galectin-3** -deficient mice were found to develop accelerated **diabetic** glomerulopathy versus the wild-type animals, as evidenced by the more pronounced increase in proteinuria, mesangial expansion, and matrix gene expression. This was associated with a more marked renal/glomerular AGE accumulation, suggesting that it was attributable to the lack of **galectin-3** AGE-receptor function. These data indicate that **galectin-3** is upregulated under **diabetic** conditions and is operating in vivo to provide protection toward AGE-induced tissue injury, as opposed to RAGE.

L36 ANSWER 28 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:554685 BIOSIS
DOCUMENT NUMBER: PREV200300551943
TITLE: EXPRESSION OF ADVANCED GLYCATION END PRODUCT ( AGE ) RECEPTORS IN CORNEAL ENDOTHELIAL CELLS.
AUTHOR(S): Sato, M. [Reprint Author]; Kaji, Y. [Reprint Author]; Amano, S.; Oshika, T. [Reprint Author]; Usui, T.; Yamashiro, K.; Ishida, S.; Adamis, A. P.; Nagai, R.; Horiuchi, S.
CORPORATE SOURCE: Dept of Ophthalmology, University of Tsukuba, Tsukuba Ibaraki, Japan
SOURCE: ARVO Annual Meeting Abstract Search and Program Planner, (2003) Vol. 2003, pp. Abstract No. 4716. cd-rom. Meeting Info.: Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA. May 04-08, 2003. Association for Research in Vision and Ophthalmology.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 26 Nov 2003
Last Updated on STN: 26 Nov 2003
AB Purpose: Accumulation of advanced glycation end products (AGEs) via the specific receptors plays an important role in the aging process. In the present study, we investigated the localization of AGE and the expression of AGE receptors (receptor for AGE (RAGE) and **galectin-3** ) in the corneal endothelial cells. Methods: Localization of AGEs was immunohistochemically investigated in human corneas of 12 adult (6 non-**diabetics** and 6 **diabetics**) and 2 fetal subjects. In bovine corneal endothelial cells, the expression of RAGE and **galectin-3** was assessed at the mRNA and protein levels. Results: AGE was not detected in the fetal corneal endothelium, but was found in the corneal endothelium of adult subjects irrespective to the presence of **diabetes**. The expression of RAGE and **galectin-3** was detected in the corneal endothelium of

bovine corneas. Conclusions: AGE and AGE receptors were detected in the corneal endothelium of adult corneas, but not of fetal corneas. Accumulation of AGE via AGE receptors may be one of the factors that are responsible for the aging process of corneal endothelium.

L36 ANSWER 29 OF 59 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN DUPLICATE 16
ACCESSION NUMBER: 2002-435333 [46] WPIDS
DOC. NO. CPI: C2002-123640
TITLE: Identifying anchor proteins that bind Ras protein, by producing complexes of Ras and cell membrane proteins in the presence and absence of a Ras antagonist and identifying a complex disrupted by the Ras antagonist.
DERWENT CLASS: B04 D16
INVENTOR(S): BALLAN, E; EL AD-SFADIA, G; HAKLAI, R; KLOOG, Y; PAZ, A
PATENT ASSIGNEE(S): (UYRA-N) UNIV RAMOT APPLIED RES & IND DEV LTD; (BALL-I) BALLAN E; (ADSF-I) EL AD-SFADIA G; (HAKL-I) HAKLAI R; (KLOO-I) KLOOG Y; (PAZA-I) PAZ A
COUNTRY COUNT: 98
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 2002029031 | A2 | 20020411 | (200246)* | EN | 62 |
| RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW | | | | | |
| W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW | | | | | |
| AU 2001095859 | A | 20020415 | (200254) | | |
| EP 1325116 | A2 | 20030709 | (200345) | EN | |
| R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR | | | | | |
| JP 2004510967 | W | 20040408 | (200425) | | 95 |
| US 2004072258 | A1 | 20040415 | (200426) | | |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| WO 2002029031 | A2 | WO 2001-IL918 | 20011001 |
| AU 2001095859 | A | AU 2001-95859 | 20011001 |
| EP 1325116 | A2 | EP 2001-976595 | 20011001 |
| | | WO 2001-IL918 | 20011001 |
| JP 2004510967 | W | WO 2001-IL918 | 20011001 |
| | | JP 2002-532601 | 20011001 |
| US 2004072258 | A1 | WO 2001-IL918 | 20011001 |
| | | US 2003-398519 | 20031015 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| AU 2001095859 | A | Based on | WO 2002029031 |
| EP 1325116 | A2 | Based on | WO 2002029031 |
| JP 2004510967 | W | Based on | WO 2002029031 |

PRIORITY APPLN. INFO: US 2000-237858P 20001004; US 2003-398519 20031015
AN 2002-435333 [46] WPIDS
AB WO 200229031 A UPAB: 20020722
NOVELTY - Identifying (M1) cell membrane anchor proteins that bind a Ras protein (RP), involves preparing 2 reaction mixtures comprising RP, its cell membranes or fragments, where one mixture has a Ras antagonist, adding a cross linking agent, where complexes (C) between RP and other proteins are produced, separating (C), identifying (C), and separating RP from other proteins in (C), is new.
DETAILED DESCRIPTION - Identifying (M1) cell membrane anchor proteins

that bind a Ras protein (RP), comprises:

(a) preparing a first reaction mixture comprising RP, its cell membranes or fragments, and a second reaction mixture comprising RP and its cell membranes or fragments but not the Ras antagonist;

(b) adding a cross-linking agent to the first and second reaction mixture, where cross linked (C) between RP and other proteins are produced;

(c) separating each of the cross-linked (C) individually;

(d) identifying (C) formed in the second reaction mixture that is disrupted by the Ras antagonist present in the first reaction mixture; and

(e) separating the identified (C) from the other (C), and separating RP from the other protein in the separated (C)

INDEPENDENT CLAIMS are also included for the following:

(1) Identifying (M2) drug candidates that inhibit aberrant Ras activity, by preparing a reaction mixture containing RP, an anchor protein that binds RP and the drug candidate, and determining the effect of the drug candidate on interaction between RP and the anchor protein;

(2) determining effective dosages of Ras antagonist that disrupt Ras-anchor protein binding, by contacting cells with the antagonist in-vivo or in-vitro, collecting the cells after contacting the cells, isolating cell membranes from the collected cells, measuring the decrease in anchor protein concentration per unit of cell membrane protein, and correlating the decrease with dosage of the Ras antagonist;

(3) an antisense compound (AC) that specifically binds a nucleic acid encoding galectin-1, **galectin-3**, galectin-7 or galectin-8, and which causes degradation of the nucleic acid;

(4) a composition comprising the above method.

ACTIVITY - Cytostatic; Immunosuppressive; Antidiabetic; Antiatherosclerotic; Neuroprotective; Vasotropic; Hepatotropic.

No suitable data given.

MECHANISM OF ACTION - Antisense therapy.

USE - M1 is useful for identifying a cell membrane anchor protein that binds a Ras protein. M2 is useful for identifying drug candidates that inhibit aberrant Ras activity. AC comprising at least one phosphorathioate-modified nucleotide is useful for disrupting aberrant Ras activity in vivo, by infusing AC into a patient exhibiting this problem (claimed).

M1 is also useful for identifying anchor proteins for the farnesylated isoforms of H-Ras, K-Ras 4A, K-Ras 4B and N-Ras, whose mutated forms are known to be oncogenic. Reducing or inhibiting aberrant Ras activity in vivo is useful for treating diseases characterized by uncontrolled mitosis, including cancers and various non-malignancies such as autoimmune disease (e.g. type 1 **diabetes**, lupus and multiple sclerosis), cirrhosis, graft rejection, atherosclerosis, polycystic kidneys and post-angioplasty restenosis.

Dwg.0/6

L36 ANSWER 30 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:927718 CAPLUS
DOCUMENT NUMBER: 138:12503
TITLE: Mammalian diabetes-mediating proteins identification for diagnosis and therapy
INVENTOR(S): Larsen, Peter Mose; Fey, Stephen J.; Karlsen, Allan E.; Sparre, Thomas; Nerup, Jorn
PATENT ASSIGNEE(S): Syddansk Universitet, Den.
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002097441 | A2 | 20021205 | WO 2002-DK368 | 20020529 |
| WO 2002097441 | A3 | 20040325 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1421390 A2 20040526 EP 2002-742844 20020529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: DK 2001-852 A 20010529
DK 2002-446 A 20020322
WO 2002-DK368 W 20020529

AB Provided are mammalian secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of altering the expression of a diabetes-mediating protein. The proteins were identified by monitoring IL-1β induced protein changes in diabetes prone mammalian islets of Langerhans using two-dimensional gel electrophoresis. Protein spots that significantly changed expression levels after exposure to IL-1β were cut out of the gels and subjected to MALDI mass spectrometry. Eighty-two significantly changed protein spots were detected. Pos. identification was obtained for a total of 45 different proteins from 51 of the 82 spots.

L36 ANSWER 31 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 17
ACCESSION NUMBER: 2002:877818 CAPLUS
DOCUMENT NUMBER: 138:151940
TITLE: IL-1β induced protein changes in diabetes prone BB rat islets of Langerhans identified by proteome analysis
AUTHOR(S): Sparre, T.; Bjerre Christensen, U.; Mose Larsen, P.; Fey, S. J.; Wrzesinski, K.; Roepstorff, P.; Mandrup-Poulsen, T.; Pociot, F.; Karlsen, A. E.; Nerup, J.
CORPORATE SOURCE: Steno Diabetes Center, Gentofte, DK-2820, Den.
SOURCE: Diabetologia (2002), 45(11), 1550-1561
CODEN: DBTGAJ; ISSN: 0012-186X
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Aims/hypothesis. Type I (insulin-dependent) diabetes mellitus is characterized by selective destruction of the insulin producing beta cells. Interleukin-1β (IL-1β) modulates the beta-cell function, protein synthesis, energy production and causes apoptosis. We have previously shown changes in the expression of 82 out of 1 815 protein spots detected by two dimensional gel electrophoresis in IL-1β exposed diabetes prone Bio Breeding (BB-DP) rat islets of Langerhans in vitro. The aim of this study was to identify the proteins in these 82 spots by mass spectrometry and compare these changes with those seen in IL-1β exposed Wistar Furth (WF) rat islets. Methods. The 82 protein spots, that changed expression after IL-1β exposure, were all re-identified on preparative gels of 200 000 neonatal WF rat islets, cut out and subjected to mass spectrometry for identification. Results. Forty-five different proteins were identified from 51 spots and grouped according to function: (i) energy transduction and redox potentials; (ii) glycolytic and Krebs cycle enzymes; (iii) protein, DNA and RNA synthesis, chaperoning and protein folding; (iv) signal transduction, regulation, differentiation and apoptosis; (v) cellular defense; and (vi) other functions. Comparison of IL-1β exposed BB-DP and WF islets showed common changes in 14 proteins and several proteins influencing similar pathways, suggesting that similar routes in the two strains lead to beta-cell destruction. Conclusion/interpretation. We demonstrate that proteome anal. is a powerful tool to identify proteins and pathways in BB-DP rat islets exposed to IL-1β.

REFERENCE COUNT: 97 THERE ARE 97 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 32 OF 59 Elsevier BIOBASE COPYRIGHT 2005 Elsevier Science B.V. on STN DUPLICATE

ACCESSION NUMBER: 2002048751 ESBIOBASE
TITLE: CD36, serves as a receptor for advanced glycation endproducts (AGE)
AUTHOR: Ohgami N.; Nagai R.; Ikemoto M.; Arai H.; Miyazaki A.; Hakamata H.; Horiuchi S.; Nakayama H.
CORPORATE SOURCE: S. Horiuchi, Department of Biochemistry, Kumamoto University, School of Medicine, 2-2-1 Honjo, Kumamoto 860-0811, Japan.
E-mail: horiuchi@gpo.kumamoto-u.ac.jp
SOURCE: Journal of Diabetes and its Complications, (2002), 16/1 (56-59), 7 reference(s)
CODEN: JDICE2 ISSN: 1056-8727
PUBLISHER ITEM IDENT.: S1056872701002082
DOCUMENT TYPE: Journal; Conference Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Interaction of advanced glycation endproducts (AGE) with AGE receptors induces several cellular phenomena relating potentially to **diabetic** complications. Five AGE receptors identified so far are receptor for AGE (RAGE), 80 K-H, OST-48, **galectin-3**, and macrophage scavenger receptor, types I and II (SR-A) [Eur. J. Biochem. 230 (1995) 408; Nature 386 (1997) 292.]. Since SR-A is known to belong to the class A scavenger receptor family and the scavenger receptor collectively represents a family of multiligand lipoprotein receptors, it is possible that CD36 belonging to class B scavenger receptor family (SR-B) can recognize AGE proteins as a ligand. This was tested in the present study at the cellular level by using Chinese hamster ovary (CHO) cells overexpressing human CD36 (CHO-CD36 cells). .sup.1.sup.2.sup.5I-AGE-bovine serum albumin (BSA) was endocytosed in a dose-dependent fashion and underwent lysosomal degradation by CHO-CD36, but not wild-type CHO cells. Endocytic uptake of .sup.1.sup.2.sup.5I-AGE-BSA by these cells was inhibited 50% by oxidized low-density lipoprotein (Ox-LDL) and 60% by FA6-152, an anti-CD36 antibody inhibiting cellular binding of Ox-LDL. Our results indicate that CD36 expressed by these cells mediates endocytic uptake and subsequent intracellular degradation of AGE proteins. Since CD36 is one of the major Ox-LDL receptors and is up-regulated in macrophage- and smooth muscle cell-derived foam cells in human atherosclerotic lesions, the present results suggest that, like Ox-LDL, AGE proteins generated in situ are recognized by CD36, which might contribute to the pathogenesis of **diabetic** macrovascular complications. Copyright .COPYRGT. 2002 Elsevier Science Inc.

L36 ANSWER 33 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:179383 CAPLUS
TITLE: Nε-(carboxymethy)lysine-induced mesangial cell activation
AUTHOR(S): Lim, Hyun Jin; Song, Jaesook; Ha, Hunjoo; Lee, Hi Bahl
CORPORATE SOURCE: Department of Internal Medicine, Hyonam Kidney Laboratory, College of Medicine, Soon Chun Hyang University, Seoul, S. Korea
SOURCE: Taehan Sinjang Hakhoechi (2002), 21(1), 20-28
CODEN: TSHACY; ISSN: 1225-0015
PUBLISHER: Korean Society of Nephrology
DOCUMENT TYPE: Journal
LANGUAGE: Korean

AB Background:Advanced glycation end products (AGE) are independent risk factors in the development and progression of **diabetic** nephropathy. Receptor for AGE(RAGE) is considered the main receptor involved in AGE-induced cell activation. **Galectin-3**, another AGE receptor, has recently been found up-regulated in mesangial cells(MC) cultured under high glucose and in **diabetic** rat kidneys. Nε-(carboxymethyl)lysine(CML) is a well characterized AGE but its role in MC activation is unknown. The present study examined the effects of CML on MC proliferation and extracellular matrix(ECM) secretion. Methods: Synchronized rat MC were stimulated with different

concns. of CML-bovine serum albumin(BSA), control BSA, and transforming growth factor-β1(TGF-β1) for up to 72 h. Cell proliferation was measured by [3H]-thymidine incorporation. Fibronectin, TGF-β1, plasminogen activator inhibitor(PAI)-1 secreted into the media and RAGE and **galectin**-3 expression in MC were measured by Western blot anal. and ELISA Results: 1,000 μg/mL of CML-BSA decreased [3H]-thymidine incorporation by MC at 48 h and 10 ng/mL TGF-β1 at 24 and 48 h. CML-BSA 100 and 1,000 pg/mL, control BSA 1,000 pg/mL, and TGF 8 10 ng/mL increased fibronectin secretion at 48 h CML-BSA up to 1,000 pg/mL did not affect TGF B1 or PAI-1 secretion. TGF-β1 10 ng/mL, however, significantly increased PAI-1 secretion. Cultured MC expressed both RAGE and galec- tin-3. CML-BSA 100 μg/mL upregulated **galectin**-3 expression. Conclusion: CML-BSA decreased MC proliferation and increased fibronectin secretion, suggesting that CML may lead to ECM accumulation and glomerulosclerosis in **diabetic** animals. MC express RAGE and **galectin-3** constitutively and CML-induced **galectin-3** upregulation may have a role in AGE-induced MC activation.

L36 ANSWER 34 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:594077 BIOSIS
DOCUMENT NUMBER: PREV200200594077
TITLE: A common mutation of an age-binding protein is not associated with diabetic microvascular complications in Type II diabetes.
AUTHOR(S): Neugebauer, S. [Reprint author]; Daimon, M.; Baba, T. [Reprint author]; Kato, T.; Watanabe, T. [Reprint author]
CORPORATE SOURCE: Internal Medicine 3, Fukushima Medical University, Fukushima, Japan
SOURCE: Diabetologia, (August, 2002) Vol. 45, No. Supplement 2, pp. A 358. print.
Meeting Info.: 38th Annual Meeting of the European Association for the Study of Diabetes (EASD). Budapest, Hungary. September 01-05, 2002. European Association for the Study of Diabetes.
CODEN: DBTGAJ. ISSN: 0012-186X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Nov 2002
Last Updated on STN: 20 Nov 2002

L36 ANSWER 35 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 19

ACCESSION NUMBER: 2001:111081 CAPLUS
DOCUMENT NUMBER: 134:293886
TITLE: CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products
AUTHOR(S): Ohgami, Nobutaka; Nagai, Ryoji; Ikemoto, Mamoru; Arai, Hiroyuki; Kuniyasu, Akihiko; Horiuchi, Seikoh; Nakayama, Hitoshi
CORPORATE SOURCE: Department of Biofunctional Chemistry, Faculty of Pharmaceutical Sciences, Kumamoto University, Kumamoto, 862-0973, Japan
SOURCE: Journal of Biological Chemistry (2001), 276(5), 3195-3202
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Interaction of advanced glycation end products (AGE) with AGE receptors induces several cellular phenomena potentially relating to **diabetic** complications. Five AGE receptors identified so far are RAGE (receptor for AGE), **galectin-3**, 80K-H, OST-48, and SRA (macrophage scavenger receptor class A types I and II). Since SRA is known to belong to the class A scavenger receptor family, and the scavenger receptor collectively represents a family of multiligand

lipoprotein receptors, it is possible that CD36, although belonging to the class B scavenger receptor family, can recognize AGE proteins as ligands. This was tested at the cellular level in this study using Chinese hamster ovary (CHO) cells overexpressing human CD36 (CD36-CHO cells). Cellular expression of CD36 was confirmed by immunoblotting and immunofluorescent microscopy using anti-CD36 antibody. Upon incubation at 37°, 125I-AGE-bovine serum albumin (AGE-BSA) and 125I-oxidized low d. lipoprotein (LDL), an authentic ligand for CD36, were endocytosed in a dose-dependent fashion and underwent lysosomal degradation by CD36-CHO cells, but not wild-type CHO cells. In binding expts. at 4°, 125I-AGE-BSA exhibited specific and saturable binding to CD36-CHO cells (Kd = 5.6 μg/mL). The endocytic uptake of 125I-AGE-BSA by these cells was inhibited by 50% by oxidized LDL and by 60% by FA6-152, an anti-CD36 antibody inhibiting cellular binding of oxidized LDL. The authors' results indicate that CD36 expressed by these cells mediates the endocytic uptake and subsequent intracellular degradation of AGE proteins. Since CD36 is one of the major oxidized LDL receptors and is up-regulated in macrophage- and smooth muscle cell-derived foam cells in human atherosclerotic lesions, these results suggest that, like oxidized LDL, AGE proteins generated in situ are recognized by CD36, which might contribute to the pathogenesis of **diabetic** macrovascular complications.

REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 36 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 20

ACCESSION NUMBER: 2001:870163 CAPLUS

DOCUMENT NUMBER: 136:132985

TITLE: Accelerated **diabetic** glomerulopathy in **galectin**-3/AGE receptor 3 knockout mice

AUTHOR(S): Pugliese, Giuseppe; Pricci, Flavia; Iacobini, Carla; Leto, Gaetano; Amadio, Lorena; Barsotti, Paola; Frigeri, Luciano; Hsu, Dan K.; Vlassara, Helen; Liu, Fu-Tong; Di Mario, Umberto

CORPORATE SOURCE: Department of Clinical Sciences, Sapienza University, Rome, 00161, Italy

SOURCE: FASEB Journal (2001), 15(13), 2471-2479
CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER: Federation of American Societies for Experimental Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several mols. were shown to bind advanced glycation end products (AGEs) in vitro, but it is not known whether they all serve as AGE receptors and which functional role they play in vivo. We investigated the role of **galectin**-3, a multifunctional lectin with (anti)adhesive and growth-regulating properties, as an AGE receptor and its contribution to the development of **diabetic** glomerular disease, using a knockout mouse model. **Galectin**-3 knockout mice obtained by gene ablation and the corresponding wild-type mice were rendered **diabetic** with streptozotocin and killed 4 mo later, together with age-matched nondiabetic controls. Despite a comparable degree of metabolic derangement, **galectin**-3-deficient mice developed accelerated glomerulopathy vs. the wild-type animals, as evidenced by the more pronounced increase in proteinuria, extracellular matrix gene expression, and mesangial expansion. This was associated with a more marked renal/glomerular AGE accumulation, indicating it was attributable to the lack of **galectin**-3 AGE receptor function. The **galectin**-3-deficient genotype was associated with reduced expression of receptors implicated in AGE removal (macrophage scavenger receptor A and AGE-R1) and increased expression of those mediating cell activation (RAGE and AGE-R2). These results show that the **galectin**-3-regulated AGE receptor pathway is operating in vivo and protects toward AGE-induced tissue injury in contrast to that through RAGE.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 37 OF 59 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2001:32374557 BIOTECHNO
TITLE: Polymorphism screening of four genes encoding advanced glycation end-product putative receptors: Association study with nephropathy in type 1 **diabetic** patients
AUTHOR: Poirier O.; Nicaud V.; Vionnet N.; Raoux S.; Tarnow L.; Vlassara H.; Parving H.-H.; Cambien F.
CORPORATE SOURCE: Dr. F. Cambien, INSERM U525-SC7, 17 rue du Fer a moulin, 75005 Paris, France.
E-mail: cambien@idf.inserm.fr
SOURCE: Diabetes, (2001), 50/5 (1214-1218), 25 reference(s)
CODEN: DIAEAZ ISSN: 0012-1797
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2001:32374557 BIOTECHNO
AB Advanced glycation end-products (AGEs) may play an important role in the pathogenesis and progression of cardiovascular and renal complications of **diabetes**. Four putative AGE receptors (RAGEs), AGE-R1, AGE-R2, and AGE-R3 have been described. In this study, we scanned the sequence of the genes encoding these AGE receptors in 48 patients with type 1 **diabetes** and investigated the identified polymorphisms (n = 19) in 199 type 1 **diabetic** patients with nephropathy and 193 type 1 **diabetic** patients without nephropathy. Overall, none of the polymorphisms was strongly associated with nephropathy. The minor allele of a polymorphism located in the promoter region of the RAGE gene (C-1152A) conferred a weak protective effect ($P < 0.05$) and was associated with a longer duration of nephropathy-free **diabetes** ($P = 0.08$).

L36 ANSWER 38 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 21
ACCESSION NUMBER: 2002:76829 CAPLUS
DOCUMENT NUMBER: 137:61312
TITLE: CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products
AUTHOR(S): Ohgami, Nobutaka; Nagai, Ryoji; Ikemoto, Mamoru; Arai, Hiroyuki; Kuniyasu, Akihiko; Horiuchi, Seikoh; Nakayama, Hitoshi
CORPORATE SOURCE: Department of Biofunctional Chemistry, Kumamoto University, Kumamoto, 862-0973, Japan
SOURCE: Annals of the New York Academy of Sciences (2001), 947(Atherosclerosis VI), 350-355
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: New York Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Interaction of advanced glycation end products (AGE) with AGE-receptors induces several cellular phenomena relating potentially to **diabetic** complications. Five AGE-receptors identified so far are RAGE (receptor for AGE), 80 K-H, OST-48, **galectin-3**, and SR-A (macrophage scavenger receptor type I and II). Since SR-A belongs to the class A scavenger receptor family and the scavenger receptor collectively represents a family of multiligand lipoprotein receptors, it is possible that CD36 belonging to the class B scavenger receptor family (SR-B) can recognize AGE-proteins as a ligand. This was tested in the present study at the cellular level using CHO (Chinese hamster ovary) cells overexpressing human CD36 (CHO-CD36 cells). 125I-AGE-BSA (bovine serum albumin) was endocytosed in a dose-dependent fashion and underwent lysosomal degradation by CHO-CD36 but not wild-type CHO cells. Endocytic uptake of 125I-AGE-BSA by these cells was inhibited 50% by oxidized LDL (Ox-LDL) and 60% by FA6-152, an anti-CD36 antibody inhibiting cellular binding of Ox-LDL. The authors' results indicate that CD36 expressed by these cells mediates endocytic uptake and subsequent intracellular degradation of AGE-proteins. Because CD36 is one of the major Ox-LDL receptors and is upregulated in macrophage- and smooth muscle cell-derived foam cells in human atherosclerotic lesions, the present results suggest that, like Ox-LDL, AGE-proteins generated in situ are

recognized by CD36, which might contribute to the pathogenesis of **diabetic** macrovascular complications.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 39 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 22
ACCESSION NUMBER: 2001:306914 CAPLUS
DOCUMENT NUMBER: 134:293560
TITLE: AGE and AGE-receptors
AUTHOR(S): Ohgami, Nobutaka; Nagai, Ryoji; Nakayama, Hitoshi; Horiuchi, Seikoh
CORPORATE SOURCE: Dep. Siofunctional Chem., Fac. Pharm. Sci., Kumamoto Univ., 5-1, Oe-honmachi, Kumamoto, 862-0973, Japan
SOURCE: Seikagaku (2001), 73(3), 200-204
CODEN: SEIKAQ; ISSN: 0037-1017
PUBLISHER: Nippon Seikagakkai
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
AB A review with 15 refs., on advanced glycation end products (AGE) and its receptors involved in aging-related **diabetic** complications and atherosclerosis, discussing AGE formation and its relevance to aging, class A scavenger receptors involved in AGE clearance, expression and functions of AGE-binding proteins (OST-48, 80K-H, and **galectin-3**), function of RAGE (receptor for AGE), and physiol. significance of a novel AGE receptor, CD36, belonging to the scavenger receptor family.

L36 ANSWER 40 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 23
ACCESSION NUMBER: 2000:116925 CAPLUS
DOCUMENT NUMBER: 132:165131
TITLE: Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
INVENTOR(S): Sasaki, Satoshi; Sumi, Yoshihiko; Hughes, Reginald Colin
PATENT ASSIGNEE(S): Teijin Limited, Japan
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000007624 | A2 | 20000217 | WO 1999-JP4238 | 19990805 |
| WO 2000007624 | A3 | 20000622 | | |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 9950653 | A1 | 20000228 | AU 1999-50653 | 19990805 |
| EP 1104307 | A2 | 20010606 | EP 1999-935073 | 19990805 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2002522398 | T2 | 20020723 | JP 2000-563306 | 19990805 |
| US 2005032675 | A1 | 20050210 | US 2004-928407 | 20040830 |

PRIORITY APPLN. INFO.:
JP 1998-233499 A 19980806
WO 1999-JP4238 W 19990805
US 2001-744328 B1 20010123

AB A pharmaceutical composition having an inhibitory effect on the overprodn. and the accumulation of extracellular matrix, said composition comprising as an active ingredient a compound that inhibits the biol. activity of **galectin-3**, which pharmaceutical composition can serve as a therapeutic or preventive agent for glomerular nephritis, **diabetic**

nephropathy or tissue fibrosis, as well as the use of said compound for the production of pharmaceuticals for the above-mentioned use, and a method for inhibition of the overprodn. and accumulation of the extracellular matrix.

L36 ANSWER 41 OF 59 Elsevier BIOBASE COPYRIGHT 2005 Elsevier Science B.V. on STN

ACCESSION NUMBER: 2000249655 ESBIOBASE
TITLE: Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats
AUTHOR: Tsuchiyama Y.; Wada J.; Zhang H.; Morita Y.; Hiragushi K.; Hida K.; Shikata K.; Yamamura M.; Kanwar Y.S.; Makino H.
CORPORATE SOURCE: Dr. J. Wada, Department of Medicine III, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
E-mail: junwada@meewsI.med.okayama-u.ac.jp
SOURCE: Kidney International, (2000), 58/5 (1941-1952), 38 reference(s)
CODEN: KDYIA5 ISSN: 0085-2538
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Background. Galectins are characterized by specific affinity for β-galactoside sugars, and they play a role in diverse biological processes, including cell adhesion, cell proliferation, and apoptosis. Galectin-1, -3, and -9 have been implicated in modulating the immune response. Methods. Nephrotoxic serum nephritis, which is characterized by crescent formation and glomerular influx of CD8.sup.+ cells into glomerular capillaries, was induced in Wistar Kyoto (WKY) rats by injecting rabbit antiglomerular basement membrane serum. Following induction, the rats were treated either with phosphate-buffered saline or dexamethasone, galectin-1, **galectin-3**, or galectin-9 on alternate days and were sacrificed at day 14. At day 8, splenic lymphocytes were isolated and employed for terminal deoxytransferase-mediated uridine triphosphate nick end-labeling (TUNEL) assay to assess the degree of apoptosis, and the kidneys were utilized to determine the extent of influx of CD4.sup.+ and CD8.sup.+ cells and glomerular damage. Results. Dexamethasone induced a marked apoptosis of splenic CD4.sup.+ and CD8.sup.+ cells, and it inhibited the production of anti-rabbit IgG and the influx of CD8.sup.+ cells and macrophages into the renal glomeruli. Crescent formation and excretion of urinary proteins were also reduced. Galectin-9 failed to induce apoptosis in the CD4.sup.+ cells; however, it induced apoptosis in the CD8.sup.+ cells and inhibited the infiltration of CD8.sup.+ cells. Although galectin-1 and -3 did not induce the apoptosis in the T cells, they inhibited the accumulation of macrophages in the renal glomeruli. Like dexamethasone, the galectins also reduced the crescentic formation, proliferation of glomerular cells, and excretion of urinary proteins. Conclusions. Galectin-9 selectively induces apoptosis of the activated CD8.sup.+ cells, while the macrophage influx into the kidney is modulated by all three galectins. This finding raises an interesting possibility for the utility of galectins in the modulation of macrophages that are involved in immune-mediated glomerular diseases.

L36 ANSWER 42 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 24

ACCESSION NUMBER: 2000:477959 CAPLUS
DOCUMENT NUMBER: 133:191437
TITLE: The **diabetic** milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating **galectin -3** expression
AUTHOR(S): Pugliese, Giuseppe; Pricci, Flavia; Leto, Gaetano; Amadio, Lorena; Iacobini, Carla; Romeo, Giulio; Lenti, Luisa; Sale, Patrizio; Gradini, Roberto; Liu, Fu-Tong; Di Mario, Umberto
CORPORATE SOURCE: Department of Clinical Sciences, La Sapienza University, Rome, Italy
SOURCE: Diabetes (2000), 49(7), 1249-1257

CODEN: DIAEAZ; ISSN: 0012-1797
PUBLISHER: American Diabetes Association
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Nonenzymic glycation has been implicated in the pathogenesis of the dysregulated tissue remodeling that characterizes **diabetic** glomerulopathy, via the formation of advanced glycation end products (AGEs) and their binding to cell surface receptors. Several AGE-binding proteins have been identified so far, including p60, p90, and the adhesive and growth-regulating lectin **galectin-3** (**Gal-3**), the components of the so-called AGE-receptor complex. This study aimed to evaluate the mesangial expression of the AGE-receptor complex and its modulation by the **diabetic** milieu, both in vivo, in non-**diabetic** vs. streptozotocin-induced **diabetic** rats, and in vitro, in mesangial cells exposed to either normal glucose (NG) levels (5.5 mmol/l), as compared with high glucose (HG) levels (30 mmol/l) and iso-osmolar mannitol (M), or to native bovine serum albumin (BSA), as compared with glycated BSA with AGE formation (BSA-AGE) and glycated BSA in which AGE formation was prevented by aminoguanidine (BSA-AM). In vivo, **Gal-3** protein and mRNA were not detectable in glomeruli from nondiabetic rats until 12 mo after initiating the study. On the contrary, in **diabetic** rats, **Gal-3** expression was observed at 2 mo of disease duration, and it increased thereafter. Both p60 and p90 immunoreactivities were observed at the glomerular level with slightly increased expression of p90, but not p60, in **diabetic** vs. nondiabetic animals. In vitro, **Gal-3** was not detectable in mesangial cells cultured in NG (although it became evident after a certain number of passages in culture), whereas **Gal-3** was detectable in cells grown on BSA. Prolonged exposure (2-4 wk) of mesangial cells to HG but not to M, as well as growing cells on BSA-AGE and, to a lesser extent, BSA-AM, induced or significantly increased the expression of **Gal-3**, both protein (up to 2.65-fold) and mRNA (up to 3.10-fold) and its secretion in the medium (by .apprx.50%). Both p60 and p90 were demonstrated in mesangial cells under NG conditions, and the expression of p90, but not p60, was upregulated by .apprx.20% by HG or BSA-AGE. These results indicate that (1) under basal conditions, **Gal-3**, unlike p90 and p60, is not detectable in the mesangium but becomes expressed with aging and (2) the **diabetic** milieu induces or upregulates **Gal-3** production, whereas it increases only slightly the expression of p90, but not p60. **Gal-3** expression or overexpression may modulate the AGE-receptor-mediated events by modifying the function of the AGE-receptor complex. Addnl., it may exert direct effects on tissue remodeling by virtue of its adhesive and growth-regulating properties.
REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 43 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 25
ACCESSION NUMBER: 2000:667186 CAPLUS
DOCUMENT NUMBER: 133:347635
TITLE: Role of galectin-3 as a receptor for advanced glycosylation end products
AUTHOR(S): Pricci, Flavia; Leto, Gaetano; Amadio, Lorena; Iacobini, Carla; Romeo, Giulio; Cordone, Samantha; Gradini, Roberto; Barsotti, Paola; Liu, Fu-Tong; Di Mario, Umberto; Pugliese, Giuseppe
CORPORATE SOURCE: Department of Clinical Sciences, Division of Endocrinology, "La Sapienza" University, Rome, Italy
SOURCE: Kidney International, Supplement (2000), 77, S31-S39
CODEN: KISUDF; ISSN: 0098-6577
PUBLISHER: Blackwell Science, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 90 refs. The advanced glycosylation end product (AGE)-binding proteins identified so far include the components of the AGE-receptor complex p60, p90 and **galectin-3**, receptor for advanced glycosylation end products (RAGE), and the macrophage scavenger receptor types I and II. **Galectin-3**

interacts with β-galactoside residues of several cell surface and matrix glycoproteins through the carbohydrate recognition domain and is also capable of peptide-peptide assocns. mediated by its N-terminus domain. These structural properties enable **galectin-3** to exert multiple functions, including the modulation of cell adhesion, the control of cell cycle, and the mRNA splicing activity. Moreover, in macrophages, astrocytes, and endothelial cells, **galectin-3** has been shown to exhibit a high-affinity binding for AGEs; the lack of a transmembrane anchor sequence or signal peptide suggests that it assocs. with other AGE-receptor components rather than playing an independent role as AGE-receptor. In tissues that are targets of **diabetic** vascular complications, such as the mesangium and the endothelium, **galectin-3** is not expressed or only weakly expressed under basal conditions, at variance with p90 and p60 but becomes detectable with aging and is induced or up-regulated by the **diabetic** milieu, which only slightly affects the expression of p90 or p60. This (over)expression of **galectin-3** may in turn modulate AGE-receptor-mediated events by modifying the function of the AGE-receptor complex, which could play a role in the pathogenesis of target tissue injury. Up-regulated **galectin-3** expression may also exert direct effects on tissue remodeling, independently of AGE ligands, by virtue of its adhesive and growth regulating properties.

REFERENCE COUNT: 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 44 OF 59 Elsevier BIOBASE COPYRIGHT 2005 Elsevier Science B.V. on STN

ACCESSION NUMBER: 2000206492 ESBIOBASE

TITLE: Role of **galectin-3** as a receptor for advanced glycosylation end products

AUTHOR: Pricci F.; Leto G.; Amadio L.; Iacobini C.; Romeo G.; Cordone S.; Gradini R.; Barsotti P.; Liu F.-T.; Di Mario U.; Pugliese G.

CORPORATE SOURCE: Dr. G. Pugliese, Diab., Endocrinology/Metabol. Found., Largo Marchiafava 1, 00161 Rome, Italy. E-mail: demfound@tin.it

SOURCE: Kidney International, Supplement, (2000), 58/77 (S31-S39), 10 reference(s) CODEN: KISUDF ISSN: 0098-6577

DOCUMENT TYPE: Journal; General Review

COUNTRY: United States

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The advanced glycosylation end product (AGE)-binding proteins identified so far include the components of the AGE-receptor complex p60, p90 and **galectin-3**, receptor for advanced glycosylation end products (RAGE), and the macrophage scavenger receptor types I and II. **Galectin-3** interacts with β-galactoside residues of several cell surface and matrix glycoproteins through the carbohydrate recognition domain and is also capable of peptide-peptide associations mediated by its N-terminus domain. These structural properties enable **galectin-3** to exert multiple functions, including the modulation of cell adhesion, the control of cell cycle, and the mRNA splicing activity. Moreover, in macrophages, astrocytes, and endothelial cells, **galectin-3** has been shown to exhibit a high-affinity binding for AGEs; the lack of a transmembrane anchor sequence or signal peptide suggests that it associates with other AGE-receptor components rather than playing an independent role as AGE-receptor. In tissues that are targets of **diabetic** vascular complications, such as the mesangium and the endothelium, **galectin-3** is not expressed or only weakly expressed under basal conditions, at variance with p90 and p60 but becomes detectable with aging and is induced or up-regulated by the **diabetic** milieu, which only slightly affects the expression of p90 or p60. This (over)expression of **galectin-3** may in turn modulate AGE-receptor-mediated events by modifying the function of the AGE-receptor complex, which could play a role in the pathogenesis of target tissue injury. Up-regulated **galectin-3**

expression may also exert direct effects on tissue remodeling, independently of AGE ligands, by virtue of its adhesive and growth regulating properties.

L36 ANSWER 45 OF 59 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2000:674823 SCISEARCH
THE GENUINE ARTICLE: 348PV
TITLE: Role of galectin-3 as a receptor for advanced glycosylation end products
AUTHOR: Pricci F; Leto G; Amadio L; Iacobini C; Romeo G; Cordone S; Gradini R; Barsotti P; Liu F T; Di Mario U; Pugliese G (Reprint)
CORPORATE SOURCE: Diabet Endocrinol & Metab Fdn, Largo Marchiafava 1, I-00161 Rome, Italy (Reprint); Univ Rome La Sapienza, Dept Clin Sci, Div Endocrinol, Rome, Italy; Univ Rome La Sapienza, Dept Expt Med & Pathol, Div Gen Pathol, Rome, Italy; Univ Rome La Sapienza, Dept Expt Med & Pathol, Div Anat Pathol, Rome, Italy; La Jolla Inst Allergy & Immunol, San Diego, CA USA
COUNTRY OF AUTHOR: Italy; USA
SOURCE: KIDNEY INTERNATIONAL, (SEP 2000) Vol. 58, Supp. [77], pp. S31-S39.
ISSN: 0085-2538.
PUBLISHER: BLACKWELL PUBLISHING INC, 350 MAIN ST, MALDEN, MA 02148 USA.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 90
ENTRY DATE: Entered STN: 2000
Last Updated on STN: 2000
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

AB The advanced glycosylation end product (AGE)binding proteins identified so far include the components of the AGE-receptor complex p60, p90 and **galectin**-3, receptor for advanced glycosylation end products (RAGE), and the macrophage scavenger receptor types I and II. **Galectin**-3 interacts with beta-galactoside residues of several cell surface and matrix glycoproteins through the carbohydrate recognition domain and is also capable of peptide-peptide associations mediated by its N-terminus domain. These structural properties enable **galectin**-3 to exert multiple functions, including the modulation of cell adhesion, the control of cell cycle, and the mRNA splicing activity. Moreover, in macrophages, astrocytes, and endothelial cells, **galectin**-3 has been shown to exhibit a high-affinity binding for AGEs; the lack of a transmembrane anchor sequence or signal peptide suggests that it associates with other AGE-receptor components rather than playing an independent role as AGE-receptor. In tissues that are targets of **diabetic** vascular complications, such as the mesangium and the endothelium, **galectin**-3 is not expressed or only weakly expressed under basal conditions, at variance with p90 and p60 but becomes detectable with aging and is induced or upregulated by the **diabetic** milieu, which only slightly affects the expression of p90 or p60. This (over)expression of **galectin**-3 may in turn modulate AGE-receptor-mediated events by modifying the function of the AGE-receptor complex, which could play a role in the pathogenesis of target tissue injury. Up-regulated **galectin**-3 expression may also exert direct effects on tissue remodeling, independently of AGE ligands, by virtue of its adhesive and growth regulating properties.

L36 ANSWER 46 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 26
ACCESSION NUMBER: 2000:442635 BIOSIS
DOCUMENT NUMBER: PREV200000442635
TITLE: Role of galectin-3 as a receptor for advanced glycosylation end products.
AUTHOR(S): Pricci, Flavia; Leto, Gaetano; Amadio, Lorena; Iacobini, Carla; Romeo, Giulio; Cordone, Samantha; Gradini, Roberto;

Barsotti, Paola; Liu, Fu-Tong; Di Mario, Umberto; Pugliese, Giuseppe [Reprint author]
CORPORATE SOURCE: Diabetes, Endocrinology and Metabolism Foundation, Largo Marchiafava 1, 00161, Rome, Italy
SOURCE: Kidney International Supplement, (September, 2000) No. 77, pp. S.31-S.39. print.
CODEN: KISUDF. ISSN: 0098-6577.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 18 Oct 2000
Last Updated on STN: 10 Jan 2002

AB The advanced glycosylation end product (AGE)-binding proteins identified so far include the components of the AGE-receptor complex p60, p90 and **galectin-3**, receptor for advanced glycosylation end products (RAGE), and the macrophage scavenger receptor types I and II. **Galectin-3** interacts with beta-galactoside residues of several cell surface and matrix glycoproteins through the carbohydrate recognition domain and is also capable of peptide-peptide associations mediated by its N-terminus domain. These structural properties enable **galectin-3** to exert multiple functions, including the modulation of cell adhesion, the control of cell cycle, and the mRNA splicing activity. Moreover, in macrophages, astrocytes, and endothelial cells, **galectin-3** has been shown to exhibit a high-affinity binding for AGEs; the lack of a transmembrane anchor sequence or signal peptide suggests that it associates with other AGE-receptor components rather than playing an independent role as AGE-receptor. In tissues that are targets of **diabetic** vascular complications, such as the mesangium and the endothelium, **galectin-3** is not expressed or only weakly expressed under basal conditions, at variance with p90 and p60 but becomes detectable with aging and is induced or up-regulated by the **diabetic** milieu, which only slightly affects the expression of p90 or p60. This (over)expression of **galectin-3** may in turn modulate AGE-receptor-mediated events by modifying the function of the AGE-receptor complex, which could play a role in the pathogenesis of target tissue injury. Up-regulated **galectin-3** expression may also exert direct effects on tissue remodeling, independently of AGE ligands, by virtue of its adhesive and growth regulating properties.

L36 ANSWER 47 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 27
ACCESSION NUMBER: 1999:497633 BIOSIS
DOCUMENT NUMBER: PREV199900497633
TITLE: Promoter sequence studies of the **LGALS3** (**galectin-3**) gene in insulin-dependent **diabetes** mellitus.
AUTHOR(S): Larsen, Z. [Reprint author]; Kristiansen, O. P. [Reprint author]; Johannesen, J. [Reprint author]; Nerup, J. [Reprint author]; Pociot, F. [Reprint author]
CORPORATE SOURCE: Steno Diabetes Center, Gentofte, Denmark
SOURCE: American Journal of Human Genetics, (Oct., 1999) Vol. 65, No. 4, pp. A258. print.
Meeting Info.: 49th Annual Meeting of the American Society of Human Genetics. San Francisco, California, USA. October 19-23, 1999. The American Society of Human Genetics.
CODEN: AJHGAG. ISSN: 0002-9297.
DOCUMENT TYPE: Conference; (Meeting)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 23 Nov 1999
Last Updated on STN: 23 Nov 1999

L36 ANSWER 48 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:324881 CAPLUS
DOCUMENT NUMBER: 129:39786
TITLE: Diabetes-mediating proteins and their therapeutic uses
INVENTOR(S): Mose, Larsen Peter; Fey, Stephen J.; Nerup, Jorn; Karlsen, Allan E.; Bjerre, Christensen Ulla; Pociot, Flemming; Andersen, Henrik U.

PATENT ASSIGNEE(S): Mose Larsen, Peter, Den.; Fey, Stephen J.; Nerup, Jorn; Karlsen, Allan E.; Bjerre Christensen, Ulla; Pociot, Flemming; Andersen, Henrik U.
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9820124 | A2 | 19980514 | WO 1997-IB1627 | 19971024 |
| WO 9820124 | A3 | 19981008 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| WO 9811508 | A1 | 19980319 | WO 1997-IB1114 | 19970916 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC | | | | |
| JP 2001500614 | T2 | 20010116 | JP 1998-513441 | 19970916 |
| CA 2269646 | AA | 19980514 | CA 1997-2269646 | 19971024 |
| AU 9854070 | A1 | 19980529 | AU 1998-54070 | 19971024 |
| EP 934409 | A2 | 19990811 | EP 1997-947839 | 19971024 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2001503860 | T2 | 20010321 | JP 1998-520234 | 19971024 |
| JP 2002504806 | T2 | 20020212 | JP 1998-521182 | 19971024 |
| KR 2000052802 | A | 20000825 | KR 1999-703621 | 19990424 |
| US 6611766 | B1 | 20030826 | US 1999-297034 | 19990621 |
| US 6640000 | B1 | 20031028 | US 1999-254675 | 19990621 |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| US 1996-29324P | P | 19961025 |
| US 1996-30088P | P | 19961105 |
| US 1996-30186P | P | 19961105 |
| US 1997-897098 | A2 | 19970718 |
| US 1996-31291P | P | 19960916 |
| US 1996-29325P | P | 19961025 |
| WO 1997-IB1114 | W | 19970916 |
| WO 1997-IB1337 | W | 19971024 |
| WO 1997-IB1627 | W | 19971024 |

AB Protective and deleterious **diabetes**-mediating proteins involved in the development of **diabetes** or in the prevention of **diabetes** development are identified by differential expression during during development of **diabetes** relative to expression in the absence of **diabetes** development. These proteins are referred to by their position on 10% IEF or NEPHGE 2-dimensional gels. The purified **diabetes**-mediating proteins are characterized by mol. weight, isoelec. point, and mass spectroscopic characteristics. **Galectin**-3 (rat and human) and mortalin (mouse and human), two of the identified proteins from pancreatic islets, were also sequenced. Transgenic animals expressing a **diabetes**-mediating protein, drug screening methods for identifying a test compound capable of altering the expression of a **diabetes**-mediating protein, and methods of preventing or ameliorating **diabetes** by administering a compound capable of altering the expression of a **diabetes** -mediating protein are also provided..

L36 ANSWER 49 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 28
ACCESSION NUMBER: 1998:760707 CAPLUS

DOCUMENT NUMBER: 130:107885
TITLE: Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs
AUTHOR(S): Thornalley, Paul J.
CORPORATE SOURCE: Department of Biological Sciences, University of Essex, Essex, CO4 3SQ, UK
SOURCE: Cellular and Molecular Biology (Paris) (1998), 44(7), 1013-1023
CODEN: CMOBEF; ISSN: 0145-5680
PUBLISHER: C.M.B. Association
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review, with .apprx.72 refs. Proteins modified by advanced glycation end products (AGE) bind to cell surface receptors and other AGE binding proteins. AGE-binding receptors are: scavenger receptors types I and II, the receptor for advanced glycation end products (RAGE), oligosaccharyl transferase-48 (OST-48, AGE-R1), 80K-H phosphoprotein (AGE-R2) and **galectin-3** (AGE-R3). AGE receptors are found in monocytes, macrophages, endothelial cells, pericytes, podocytes, astrocytes and microglia. AGE-modified proteins also bind to lysozyme and lactoferrin. A critical review of the evidence for receptors binding AGE-modified protein binding in vivo is presented. Scavenger receptors have only been shown to bind proteins modified by AGE to a much higher extent than found in vivo. 80K-H phosphoprotein is involved in FGFR3 signal transduction to MAP kinase, and may be involved in AGE-receptor signal transduction. Whether all of these proteins bind AGE-modified proteins in vivo is not yet clear. Cell activation in response to AGE-modified proteins is associated with increased expression of extracellular matrix proteins, vascular adhesion mols., cytokines and growth factors. Depending on the cell type and concurrent signaling, this is associated with chemotaxis, angiogenesis, oxidative stress, cell proliferation or programmed cell death (PCD). Receptor recognition factors for agonism at the AGE receptor have been little studied but to date hydroimidazolones appear to be the most likely candidates. Pharmacol. inhibition of AGE receptor-mediated cell activation with specific antagonists may provide the basis for therapeutic intervention in diseases where AGE accumulation is a suspected etiol. factor vascular complications of **diabetes**, macrovascular disease, renal insufficiency and Alzheimer's disease.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 50 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:19779 BIOSIS
DOCUMENT NUMBER: PREV199900019779
TITLE: **Diabetic** glomerulosclerosis in **galectin -3** knockout mice.
AUTHOR(S): Barsotti, Paola [Reprint author]; Pricci, Flavia; Leto, Gaetano; Liu, Fu-Tong; Di Mario, Umberto; Pugliese, Giuseppe
CORPORATE SOURCE: Univ. Roma "La Sapienza", Roma, Italy
SOURCE: Journal of the American Society of Nephrology, (Sept., 1998) Vol. 9, No. PROGRAM AND ABSTR. ISSUE, pp. 628A. print.
Meeting Info.: 31st Annual Meeting of the American Society of Nephrology. Philadelphia, Pennsylvania, USA. October 25-28, 1998. American Society of Nephrology.
CODEN: JASNEU. ISSN: 1046-6673.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Jan 1999
Last Updated on STN: 20 Jan 1999

L36 ANSWER 51 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 29
ACCESSION NUMBER: 1998:424371 BIOSIS

DOCUMENT NUMBER: PREV199800424371
TITLE: Accelerated **diabetic** glomerulopathy in **galectin**-3/age-receptor-3 knockout mice.
AUTHOR(S): Pugliese, G. [Reprint author]; Pricci, F. [Reprint author]; Leto, G. [Reprint author]; Romeo, G. [Reprint author]; Amadio, L. [Reprint author]; Catalano, S. [Reprint author]; Hsu, D.; Barsotti, P. [Reprint author]; Albanese, E. [Reprint author]; Cordone, S. [Reprint author]; Frigeri, L.; Liu, F.-T.; Dimario, U. [Reprint author]
CORPORATE SOURCE: Univ. Rome "La Sapienza", Rome, Italy
SOURCE: Diabetologia, (Aug., 1998) Vol. 41, No. SUPPL. 1, pp. A27. print.
Meeting Info.: 34th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, Spain. September 11, 1998. European Association for the Study of Diabetes.
CODEN: DBTGAJ. ISSN: 0012-186X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Oct 1998
Last Updated on STN: 2 Oct 1998

L36 ANSWER 52 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 30
ACCESSION NUMBER: 1998:424372 BIOSIS
DOCUMENT NUMBER: PREV199800424372
TITLE: Induction of glomerular/mesangial **galectin**-3/age-receptor-3 expression by the **diabetic** milieu.
AUTHOR(S): Leto, G. [Reprint author]; Pricci, F. [Reprint author]; Romeo, G. [Reprint author]; Catalano, S. [Reprint author]; Amadio, L. [Reprint author]; Diaz-Horta, O. [Reprint author]; Sale, P. [Reprint author]; Gradini, R. [Reprint author]; Lenti, L. [Reprint author]; Barsotti, P. [Reprint author]; Frigeri, L.; Dimario, U. [Reprint author]; Pugliese, G. [Reprint author]
CORPORATE SOURCE: "La Sapienza" Univ., Rome, Italy
SOURCE: Diabetologia, (Aug., 1998) Vol. 41, No. SUPPL. 1, pp. A27. print.
Meeting Info.: 34th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, Spain. September 11, 1998. European Association for the Study of Diabetes.
CODEN: DBTGAJ. ISSN: 0012-186X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Oct 1998
Last Updated on STN: 2 Oct 1998

L36 ANSWER 53 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1998:378688 BIOSIS
DOCUMENT NUMBER: PREV199800378688
TITLE: Combining proteome and genome analysis: Is galectin-3 a candidate gene for IDDM?.
AUTHOR(S): Larsen, Zenia M. [Reprint author]; Karlsen, Allan E. [Reprint author]; Nerup, Jorn [Reprint author]; Fey, Stephen; Larsen, Peter M.; Pociot, Flemming [Reprint author]
CORPORATE SOURCE: Steno Diabetes Cent., Gentofte, Denmark
SOURCE: European Journal of Endocrinology, (April, 1998) Vol. 138, No. SUPPL. 1, pp. 14. print.
Meeting Info.: 33rd Annual Meeting of the Scandinavian Society for the Study of Diabetes. Elsinore, Denmark. April 24-26, 1998. Scandinavian Society for the Study of Diabetes.
ISSN: 0804-4643.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Dec 1998
Last Updated on STN: 22 Dec 1998

L36 ANSWER 54 OF 59 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1997:630226 SCISEARCH
THE GENUINE ARTICLE: XG123
TITLE: Modulation of **galectin-3** /AGE-receptor-3 expression by the **diabetic** milieu in cultured rat mesangial cells
AUTHOR: Pugliese G (Reprint); Pricci F; Romeo G; Leto G; Gradini R; Santangelo C; Lenti L; Cirulli V; Hayek A; Liu F T; Frigeri L; DiMario U
CORPORATE SOURCE: UNIV ROMA LA SAPIENZA, ROME, ITALY; UNIV RC CATANZARO, CATANZARO, ITALY; UCSD, WHITTIER INST, LA JOLLA, CA 92093
COUNTRY OF AUTHOR: ITALY; USA
SOURCE: DIABETOLOGIA, (JUN 1997) Vol. 40, Supp. [1], pp. 1998-1998
.
ISSN: 0012-186X.
PUBLISHER: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010.
DOCUMENT TYPE: Conference; Journal
FILE SEGMENT: LIFE; CLIN
LANGUAGE: English
REFERENCE COUNT: 0
ENTRY DATE: Entered STN: 1997
Last Updated on STN: 1997

L36 ANSWER 55 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1997:372276 BIOSIS
DOCUMENT NUMBER: PREV199799671479
TITLE: Modulation of **Galectin-3**/age-receptor-3 expression by the **diabetic** milieu in cultured rat mesangial cells.
AUTHOR(S): Pugliese, G. [Reprint author]; Pricci, F.; Romeo, G.; Leto, G.; Gradini, R.; Santangelo, C.; Lenti, L.; Cirulli, V.; Hayek, A.; Liu, F. T.; Frigeri, L.; Di Mario, U.
CORPORATE SOURCE: Univ. Rome La Sapienza, Italy
SOURCE: Diabetologia, (1997) Vol. 40, No. SUPPL. 1, pp. A508.
Meeting Info.: 16th International Diabetes Federation Congress. Helsinki, Finland. July 20-25, 1997.
CODEN: DBTGAJ. ISSN: 0012-186X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 4 Sep 1997
Last Updated on STN: 4 Sep 1997

L36 ANSWER 56 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1997:371986 BIOSIS
DOCUMENT NUMBER: PREV199799671189
TITLE: Macrophage scavenger receptor mediates greater part of the endocytic uptake of AGEs.
AUTHOR(S): Horiuchi, S. [Reprint author]; Higashi, T. [Reprint author]; Suzuki, H.; Kodama, T.; Shichiri, M.
CORPORATE SOURCE: Dep. Biochem., Kumamoto Univ. Sch. Med., Kumamoto, Japan
SOURCE: Diabetologia, (1997) Vol. 40, No. SUPPL. 1, pp. A434.
Meeting Info.: 16th International Diabetes Federation Congress. Helsinki, Finland. July 20-25, 1997.
CODEN: DBTGAJ. ISSN: 0012-186X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English

ENTRY DATE: Entered STN: 4 Sep 1997
Last Updated on STN: 4 Sep 1997

L36 ANSWER 57 OF 59 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1997:370419 BIOSIS
DOCUMENT NUMBER: PREV199799669622
TITLE: Galectin-3, a lectin involved in cytokine-mediated beta-cell destruction and IDDM?.
AUTHOR(S): Karlsen, A. E. [Reprint author]; Andersen, H. U. [Reprint author]; Larsen, P. Mose; Fey, S. J.; Larsen, M.; Pociot, F.; Whitmore, T.; Nielsen, K. [Reprint author]; Nerup, J. [Reprint author]
CORPORATE SOURCE: Steno Diabetes Cent., Gentofte, Denmark
SOURCE: Diabetologia, (1997) Vol. 40, No. SUPPL. 1, pp. A35.
Meeting Info.: 16th International Diabetes Federation Congress. Helsinki, Finland. July 20-25, 1997.
CODEN: DBTGAJ. ISSN: 0012-186X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 4 Sep 1997
Last Updated on STN: 4 Sep 1997

L36 ANSWER 58 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 31
ACCESSION NUMBER: 1995:944605 CAPLUS
DOCUMENT NUMBER: 124:83769
TITLE: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex
AUTHOR(S): Vlassara, Helen; Li, Yong Ming; Imani, Farhad; Wojciechowicz, Donald; Yang, Zhi; Liu, Fu-Tong; Cerami, Anthony
CORPORATE SOURCE: Picower Institute for Medical Research, Manhasset, NY, USA
SOURCE: Molecular Medicine (Cambridge, Massachusetts) (1995), 1(6), 634-46
CODEN: MOMEF3; ISSN: 1076-1551
PUBLISHER: Blackwell
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Advanced glycation end products (AGE), the reactive derivs. of nonenzymic glucose-protein condensation reactions, are implicated in the multiorgan complications of **diabetes** and aging. An AGE-specific cellular receptor complex (AGE-R) mediating AGE removal as well as multiple biol. responses has been identified. By screening an expression library using antibody against a previously identified component of the AGE-R complex p90, a known partial cDNA clone was isolated with homol. to **galectin-3**, a protein of diverse identity, and member of the galectin family. To explore this finding, the nature of the interactions between **galectin-3** and AGE was studied using intact macrophage-like RAW 264.7 cells, membrane-associated and recombinant galectin-1 through -4, and model AGE-ligands (AGE-BSA, FFI-BSA). Among the members of this family (galectin-1 through 4), recombinant rat **galectin-3** was found to exhibit high-affinity 125I-AGE-BSA binding with saturable kinetics (kD 3.5+107 M-1) that was fully blocked by excess unlabeled naturally formed AGE-BSA or synthetic FFI-BSA, but only weakly inhibited by several known **galectin-3** ligands, such as lactose. In addition to the p90, immunopptn. with anti-**galectin-3**, followed by 125I-AGE-BSA ligand blot anal. of RAW 264.7 cell exts., revealed **galectin-3** (28 and 32 kDa), as well as **galectin -3**-associated proteins (40 and 50 kDa) with AGE-binding activity. Interaction of **galectin-3** with AGE-BSA or FFI-BSA resulted in formation of SDS-, and β-mercaptoethanol-insol., but hydroxylamine-sensitive high-mol. weight complexes between AGE-ligand, **galectin-3**, and other membrane components. The findings point toward a mechanism by which **galectin-3** may serve in the assembly of AGE-R components and in the efficient cell surface

attachment and endocytosis by macrophages of a heterogeneous pool of AGE moieties with diverse affinities, thus contributing to the elimination of these pathogenic substances.

L36 ANSWER 59 OF 59 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 32
ACCESSION NUMBER: 1996:93551 CAPLUS
DOCUMENT NUMBER: 124:171917
TITLE: Receptors for advanced glycation endproducts: in vivo role and human studies
AUTHOR(S): Vlassara, Helen
CORPORATE SOURCE: Picower Institute Medical Research, Manhasset, NY, 11030, USA
SOURCE: International Congress Series (1995), 1100(Diabetes 1994), 286-91
CODEN: EXMDA4; ISSN: 0531-5131
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 23 refs. Irreversible modification of proteins, lipids, and DNA by advanced glycation is strongly implicated in multiple organ damage in aging and in **diabetes**, including vasculature, kidneys, and nerves. Search for removal mechanisms of these terminal modifications led to the discovery of a macrophage AGE-specific receptor system mediating AGE endocytosis, as well as a wide spectrum of biol. responses potentially critical in normal tissue turnover. Recent evidence points to the association of AGE-receptors to cell activation, cytokine- and growth-promoting events. Two components of the AGE-receptor complex were initially characterized by this group: a 50-60 kDa, and a 90 kDa. Two addnl. AGE-binding proteins were subsequently described including a 35 kDa protein, referred to as RAGE, and a lactoferrin-like 80 kDa protein. Recently a 32 kDa macrophage protein, known as Mac-2 or carbohydrate-binding protein-35 (CBP-35), now called **galectin-3** was identified as an AGE-binding protein. Addnl. studies have yielded the presence of AGE-receptors on a range of cells, including lymphocytes, endothelium, mesangial, smooth muscle, neural cells, and fibroblasts. The role of AGE-receptors in **diabetic** complications can be seen as a chain of events mobilized by increased AGE accumulation and followed by local and inflammatory cell activation, growth and proliferative events, and widespread cellular dysfunction, any of which can contribute to tissue pathol., such as **diabetic** atherosclerosis and nephropathy.